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As you set out for Ithaka 
hope the voyage is a long one, 
full of adventure, full of discovery. 
Laistrygonians and Cyclops, 
angry Poseidon—don’t be afraid of them: 
you’ll never find things like that on your way 
as long as you keep your thoughts raised high, 
as long as a rare excitement 
stirs your spirit and your body. 
Laistrygonians and Cyclops, 
wild Poseidon—you won’t encounter them 
unless you bring them along inside your soul, 
unless your soul sets them up in front of you. 
 
Hope the voyage is a long one. 
May there be many summer mornings when, 
with what pleasure, what joy, 
you come into harbors seen for the first time; 
may you stop at Phoenician trading stations 
to buy fine things, 
mother of pearl and coral, amber and ebony, 
sensual perfume of every kind— 
as many sensual perfumes as you can; 
and may you visit many Egyptian cities 
to gather stores of knowledge from their scholars. 
 
Keep Ithaka always in your mind. 
Arriving there is what you are destined for. 
But do not hurry the journey at all. 
Better if it lasts for years, 
so you are old by the time you reach the island, 
wealthy with all you have gained on the way, 
not expecting Ithaka to make you rich. 
 
Ithaka gave you the marvelous journey. 
Without her you would not have set out. 
She has nothing left to give you now. 
 
And if you find her poor, Ithaka won’t have fooled you. 
Wise as you will have become, so full of experience, 
you will have understood by then what these Ithakas mean. 
 
Ithaka – C.P. Cavafy 










One can easily find the parallelism between the PhD years and Cavafy’s 
interpretation of the trip to Ithaka. We are often too focused on the final 
destination so as to understand that what is truly important is all what happens 
during the journey. Now that I have understood this, I would like to thank all those 
who encouraged me to start the trip and the ones who helped me along the way. 
Thank you Kostas for leaving this very exciting project on my hands, even if 
they were surely not the best prepared for it. It has been a huge jump for me. I have 
learned a lot, I have enjoyed it a lot and, at the times that it was not easy, it always 
helped to feel that you trusted me more than I trusted myself! Thanks as well for 
giving me freedom in the direction of the project, necessary to build my own 
critical thinking, while always being available for discussions that I really enjoyed. 
Thanks for your dedication and for being so motivational.  
Many people have come to and left the Nanomedicine Lab since I first 
arrived as a Master student in 2010. I cannot fit so many names in these lines! But 
my gratitude goes to all of you for the advice and guidance on my early days and 
for the support, understanding, and putting up with my writing-up mood in the last 
few months! Dr Cyrill Bussy and Dr Açelya Yilmazer deserve however a special 
mention because without them this project would have never taken off. Cyrill, you 
have now raised a few generations of Nanomediciners, always leaving aside your 
own things to rescue our experiments, and I am grateful to be one on the list. 
Acelya, you taught me so much and took so much care of me at the beginning and I 
really value that you did this even in your most stressful time. And I am glad that 
after four years I can still have your support. We always made a good team. I would 
also like to thank the master and PhD students that during their training and under 
my supervision have had an input in this project: Sarah, for the Southern Blot 
experiments; Yein and Faziela, without you I would not have had enough hands to 
handle so many stainings. I hope I have managed to teach you something as well! 
Some of the studies in this thesis would not have been possible without our 
collaborators. I would like to thank the staff at the Genome Centre (Queen Mary 
University of London) for microarray experiments, Dr Neil Humphreys and Ms. Maj 
Simonsen Jackson (Transgenic Facility, University of Manchester) for chimerism 
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experiments, Dr Adam Reid (Centre for Tissue Injury and Repair, University of 
Manchester) for advice and training on surgical procedures and Dr Hans Degens 
(Manchester Metropolitan University) for advice, training and equipment for 
muscle myography. I would like to especially thank Prof. Giulio Cossu (Centre for 
Tissue Injury and Repair, University of Manchester) and the members of his lab for 
sharing their expertise and giving their advice on my observations. I would also 
like to ackownledge Obra Social LaCaixa and UCL for a jointly funded PhD 
Scholarship.  
To the UCL School of Pharmacy I owe not only the experience gained during 
the first two years of my PhD, but also getting to know many special people that, 
although did not have an input in the science behind this thesis, merit equal 
acknowledgement for their help outside the lab. Giulia, you are missed in the lab 
and outside. Thanks for being “my only normal friend” in this cloud of craziness. 
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for sharing your complaints with me and for complaining together! Francisco and 
Katrien, thanks for making the office an awful place to get work done, but a great 
place to be. Álvaro, the School of Pharmacy became a better place from the 
moment you arrived. Thanks for calling each Sunday, making me be rational when 
I am not and helping me overcome my fear to heights…I want to be like you when I 
grow up! Nicola, we have been through this PhD together…think how many things 
we have done and experienced since that first Christmas ice-skating! Thanks for 
being there throughout this trip…I hope we keep it this way. 
Thanks as well to my non-scientist friends for understanding that 
sometimes I had to prioritise my cells or mice and for bringing me back to the 
outside world when it got too much. Mayte, you helped so much when things went 
rough and I would not have made it without you! You have also set the best 
example that anything can be achieved, just with a lot of effort. Miguel, who would 
have told us that summer in Santander 6 years from now that we would end up as 
we are now… I am glad that destiny decided to send us to the same island. Dessi, 
Mike and Jess, the times in Ampton St were the best, I wish we could go back. Artal, 
you have gained a place in heaven by sharing a flat with me the last few crazy 
months, thanks for your patience…I guess it will be my turn soon! Thanks to my 
friends from home Elena (the person who understands me better for the last 15 
years), Jesús, Iván, Jose, Marta, Noemí, Carmen, María, Irene, Lorena, Jessica, 
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spite the distance. You are the definition of home. Gloria, Diego, Jordi, Julian, Mufi, 
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Artificially induced changes of cell identity are increasingly attracting 
attention as potential strategies to regenerate diseased or injured tissues, but still 
rely heavily on ex vivo culture with the exception of a small number of in vivo 
transdifferentiation studies. The reprogramming of somatic cells to pluripotency in 
vivo is even less explored, partly due to fears of teratoma formation. In this thesis, 
we hypothesised that such twist in cell fate can be safely achieved in vivo provided 
that sufficient but transient levels of reprogramming factors are locally expressed. 
We also speculated that transiently pluripotent cells can be generated in different 
tissues, thanks to the universality of the Yamanaka reprogramming factors, and 
that they may contribute to replenish the injured site after an insult. In vivo 
induction of pluripotency was first described in the liver and later in the skeletal 
muscle of wild-type mice. In both scenarios, the fast but transient upregulation of 
pluripotency markers and downregulation of tissue-specific genes did not progress 
to teratoma formation. The in vivo reprogrammed hepatocytes were established as 
a cell line in vitro, the so-called in vivo induced pluripotent stem (i2PS) cells, and 
their pluripotency was confirmed at the molecular and functional levels. Clusters 
of in vivo reprogrammed cells within the skeletal muscle tissue were found to 
express pluripotency and myogenic progenitor markers and to re-integrate in the 
normal tissue architecture after a transient proliferative stage recapitulating 
events of normal postnatal myogenesis. Finally, in vivo reprogramming to 
pluripotency resulted in a modest enhancement of regeneration and functional 
rehabilitation in a model of skeletal muscle injury. In conclusion, this work not 
only provides proof-of-concept of safe in vivo cell reprogramming to pluripotency 
but also presents a thorough characterisation of the in vivo reprogrammed cells 
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1.1. Regenerative medicine and cell replacement: 
tackling disease at its roots.  
The Western world has witnessed a remarkable increase in life expectancy 
in the last decades. According to the UK’s Office for National Statistics (ONS), 
average life expectancy is 77.9 years for males and 82.0 years for females (2007-
2009 data). However, healthy life expectancy is estimated in 63.0 and 65.0 years, 
respectively [1]. We now live longer lives, but we also live with disease for longer, 
and treatment of many conditions remains challenging to manage with the 
currently available small molecule therapeutics and surgical interventions. These 
strategies often target the symptoms but do not tackle the genuine cause of the 
disease [2]. Such is the case in the treatment of Parkinson’s disease (PD), one of the 
most prevalent degenerative ailments of our time,  in which the administration of 
L-DOPA alleviates motor symptoms but does not restore death of dopaminergic 
neurons in the substantia nigra, the major origin of the disease [3]. Eventually, the 
“wearing off” effect of the drug over time results in the reappearance of motor 
impairment [4]. Treatment limitations are not only encountered by degenerative 
diseases. For example, in the event of a severe muscle injury, clinically-available 
conservative treatment - based on rest, ice, compression and elevation (RICE) - 
does not replace lost myofibers, failing to fully recover muscle force [5].  
In such scenario, there is an urgent need to explore new therapeutic 
approaches that replenish and restore the damaged or degenerated tissues rather 
than simply compensate their impaired or lost function. This is precisely the 
uttermost aim of regenerative medicine and more in particular of cell replacement 
strategies [6] that, following on the examples above, attempt permanent 
replacement of lost neurons to alleviate PD [7] and of damaged muscle fibers to 
recover muscle force upon injury [8]. Indeed, the treatment of conditions in which 
a particular cell type is damaged or degenerated could be simplified if a stock of 
healthy replacement cells was readily available. However, the challenge to find an 
optimal source to generate such a stock is daunting and has not yet been entirely 
resolved. 
 Despite the initial success of studies involving transplantation of fetal 
tissue [9], the limited availability of this material together with ethical 
considerations have narrowed its potential as convenient source for cell 
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replacement [10]. Primary human cells isolated from unused or rejected organs for 
transplantation suffer from similar limitations [11]. Autologous grafts from 
different tissues of the same individual were at first seen as a better alternative 
[12]. However, the expectations of this approach have not been fulfilled in the long 
term, partly due to the invasive techniques that are frequently required for their 
sourcing, but mainly due to excessive variability in the results, inherent to the use 
of a non-standardised starting material [13, 14].  
1.1.1.  Stem cells in regenerative medicine: sources, promises and 
challenges. A realistic view on panacea. 
In view that scarcity of the starting material is one of the main limitations in 
the search for an optimal cell source, stem cells stand out as promising candidates 
since they self-renew (divide unlimitedly into identical undifferentiated daughter 
cells) and can differentiate into representatives of one or various developmental 
lineages (potency), as represented in Figure 1.1.  Several types of cells that fall 
into such definition can be found during human development and are classified 
according to the developmental stage at which they occur and to their 
differentiation potential (Figure 1.2) [15]. 
 
Figure 1. 1. Stem cell properties. Stem cells are able to self-renew (divide unlimitedly remaining 
undifferentiated) and also to differentiate into cells from one or various developmental lineages. 
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Totipotent cells are only found in the zygote and up to the 8-cell embryo. In 
a later stage, the blastocyst, embryonic stem (ES) cells can no longer generate 
extraembryonic tissues. However, they are regarded as one of the most promising 
sources for cell replacement strategies because they can differentiate into 
representatives of all three lineages (endoderm, mesoderm and ectoderm, hence 
termed “pluripotent”) and, more importantly, because they can retain pluripotency 
and self-renew in culture when exposed to the right conditions. This was 
manifested thanks to Evans and Martin’s first ES cell isolation from the inner cell 
mass (ICM) of mouse blastocysts in  1981 [16, 17] and to the identification of 
Leukemia inhibitory factor (LIF) as key to maintain pluripotency in vitro [18]. ES 
cells were finally established as the gold standard of pluripotency in 1990, when 




Figure 1. 2. Sources of stem cells classified according to their developmental origin and 
differentiation potential.  
Further excitement was led by Thomson’s first-ever isolation of human ES cells 
almost a decade later [20] that, probably too prematurely, suggested that the 
perfect source for human cell-based therapeutics could have been found. However, 
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this enthusiasm has been overshadowed by ethical constraints derived from the 
necessary destruction of human blastocysts. Such debate has spread beyond the 
scientific community and has resulted in governmental policies that limit research 
on human ES cells. From 2011 no process or technique involving blastocyst 
destruction can be patent-protected in the European Union, which might affect 
investor motivation for research in this area [21]. The situation has improved 
slightly in the US, where the ban on the use of federal funding for human ES cell 
research was abolished in 2009. However, such funds can still only be allocated to 
research on approved human ES cell lines and not for the derivation of new ones 
[22]. Leaving ethical and legal considerations aside, there is not a definite answer 
to whether the transplantation of ES cell-derived differentiated cells, which will 
necessarily be allogenic, will trigger an immune response and graft rejection. This 
may be another factor limiting the potential of such cells [23-25]. 
 Later in development, fetal (obtained from aborted fetuses) and perinatal 
stem cells (harvested from placenta, umbilical cord blood and amniotic fluid) can 
be relatively easily accessed and their isolation does not involve the destruction of 
the embryo.  However, their differentiation potential is restricted to certain 
lineages (i.e. they are not pluripotent but multipotent) and they cannot be 
maintained in culture for long periods of time without being coerced [26]. A lot of 
hope has been placed in the therapeutic application of umbilical cord blood (UCB) 
stem cells and numerous private and public “umbilical cord banks” have been 
created to preserve this tissue. However, the extremely restricted cell numbers 
encountered in some umbilical cords directly impede their therapeutic utilisation. 
Even with the most populated specimens, the amount of cells obtained from a 
single umbilical cord after ex vivo expansion is only sufficient to treat an infant up 
to 5 or 7 years old. In spite of the promising results of some preclinical and clinical 
studies, the limitations of this source must be taken into account and false hopes 
should be avoided [27].   
Stem cells are not restricted to developmental stages prior to birth, but are also 
present in the adult organism, generally known as adult stem cells (ASCs). 
Multipotent mesenchymal stem (MS) cells are found in bone marrow and in the 
connective tissue of various organs [28]. Tissue-specific stem cells reside also in 
several organs including epidermis, liver, skin and skeletal muscle. Their role is to 
28 
 
maintain cellular homeostasis in the particular tissue and therefore their 
differentiation potential is very limited (oligo- or unipotent). In addition, they are 
not always sufficiently accessible to be isolated for their use in cell-based 
therapies. Bone marrow and adipose tissue are currently the most accessible 
sources ASCs [29]. 
In summary, different types of stem cells naturally occurring at various 
developmental stages offer different opportunities as sources of replacement cells. 
These are evidenced by the numerous clinical trials currently exploring their safety 
and therapeutic potential [30]. However, each and every of these sources is also 
accompanied by limitations and there is little consensus on which of them will 
perform better.  Overall, this landscape confirms that a source that meets all 
requirements of abundance, accessibility, versatile differentiation potential, 
capacity to grow in culture without potency loss or coercion, immune compatibility 
and lack of ethical constraints has not yet been identified.  
1.2. Induced cell fate changes as a therapeutic option: 
reprogramming meets regeneration. 
1.2.1. New notions on differentiation, fate and plasticity of cell identity. 
A series of findings initiated in the 1950s have shifted our views on cell 
differentiation from its definition as an irreversible process, to the realisation that 
cell identity is stable in the adult organism yet sufficiently plastic to be reset or 
altered when the right mechanisms are activated. Such observations have unveiled 
the concepts of cell reprogramming to pluripotency and transdifferentiation 
(direct reprogramming between two differentiated cell types) [31, 32]. 
The major contributions that led to this change in paradigm for 
developmental biology are chronologically summarized in Figure 1.3. Briggs and 
King’s technical development of Somatic Cell Nuclear Transfer (SCNT), more 
commonly known as cloning, set the basis for John Gurdon’s work on nuclear 
reprogramming. The initial studies introduced nuclei isolated from Rana pipiens 
frog blastula [33] and gastrula differentiating cells [34] into enucleated oocytes 
from the same species, and were able to generate new embryos. Gurdon’s 
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experiments went one step further and, using the same technique, generated adult 
frogs from the nucleus of Xenopus endoderm differentiating cells [35], fully 
differentiated tadpole epithelial cells [36] and even fully differentiated keratinized 
adult frog skin cells [37].  
 
 
Figure 1. 3. Timeline of the studies in cell plasticity and reprogramming. Blue: advances in 
SCNT. Orange: somatic and pluripotent cell fusion studies. Green: reports on transcription factor-
mediated transdifferentiation. Pink: studies on transcription factor-mediated induced pluripotency 
(iPS cells).  
These findings initiated a genuine revolution in the field as they confirmed 
that, throughout the process of differentiation and even at the end of it, cells retain 
the same genetic information. They can therefore, under defined conditions, 
reverse differentiation – what has now been termed “reprogramming to 
pluripotency” – and support the generation of a new organism. Thanks to the 
advances in molecular biology we currently know that the process of 
differentiation is governed by reversible epigenetic changes rather than 
irreversible changes to the DNA sequence [32]. The same observation has been 
confirmed in mammalian organisms, although it took four decades until Dolly 
became famous world-wide for being the first-ever cloned mammal, generated via 
SCNT from the nucleus of an adult, fully differentiated, sheep mammary gland cell 
[38]. The births of Dolly and her offspring revolutionized thinking among the 
scientific community and public opinion and even triggered alarming reactions by 
those foreseeing the imminent misuse of human cloning [39, 40]. Such predictions 
were however very “optimistic”. Almost two more decades were needed to reverse 
human cells to the pluripotent state via SCNT and such conversion is still 
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nowadays not fully optimised [41-43]. Thus, utilisation of this technique for 
therapeutic purposes is not predicted to take place in the near future.  
Whilst SCNT protocols were adapted to mammalian organisms, Miller and 
Ruddle relied on the fusion of somatic and pluripotent cells as an alternative 
technique to confirm that differentiated cells could be reverted to pluripotency 
[44, 45]. The hybrids resulting from the fusion of thymocytes and embryonic 
carcinoma cells (ECCs, pluripotent cells isolated from germ cell tumours [46]) 
acquired biochemical and molecular characteristics of the latter while somatic cell 
features were lost. In conclusion, the pluripotent phenotype predominated over 
that of full differentiation. Currently available strategies to reprogram somatic cells 
to pluripotency, including SCNT and cell fusion, are illustrated in Figure 1.4. 
 
 
Figure 1. 4. Cell reprogramming to pluripotency strategies. Three different approaches have been 
reported to reprogram somatic cells back to a pluripotent state. (a) Somatic Cell Nuclear Transfer: 
generation of pluripotent stem cells via injection of a somatic nucleus into an enucleated oocyte. (b) 
Cell fusion of somatic and pluripotent cells (ECCs), which produces hybrids that preserve the features 
of the stem cells.  (c) Transcription factor based reprogramming: via forced expression of Yamanaka 
or OKSM factors.  
While the precise agents that drive the pluripotent conversion were still 
unidentified, research on transcription factors and the regulation of gene 
expression in the 1980s also contributed to the understanding of cell fate. Davies 
demonstrated fibroblast-to-myoblast conversion via retroviral overexpression of 
MyoD, a transcription factor with a relevant role in myogenesis [47]. Weintraub 
later confirmed the expression of  muscle-related genes, albeit not complete 
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myoblast conversion, when the study was repeated on other cell lines [48]. These 
studies highlighted the capacity of lineage-specific transcription factors to induce 
fate changes between two differentiated cell types, which was later termed 
“transdifferentiation” or “direct reprogramming”. Interestingly, Zhou and 
colleagues, followed by many others, confirmed that transdifferentiation is not 
restricted to the in vitro scenario and can also be induced in living tissues [49]. 
The conclusions reached from SCNT [33-38], cell fusion [44-46] and 
transcription factor-mediated transdifferentiation studies [47, 48, 50], led 
Yamanaka and Takahashi to hypothetise that transcription factors present in the 
oocyte and pluripotent cells could be responsible for the pluripotent conversion 
observed upon SCNT and cell fusion studies. With the aim to isolate those 
“pluripotency factors”, a pool of 24 candidates was selected based on their 
enriched presence in oocytes and ES cells and on their previously known roles in 
pluripotency and its maintenance. After systematic screening of all possible 
combinations, a retroviral cocktail containing Oct3/4, Sox2, Klf4 and c-Myc, 
nowadays known as OKSM or Yamanaka factors, was able to reprogram mouse 
embryonic and adult fibroblasts to the pluripotent state [51]. The ectopic 
expression of these factors in somatic cells constitutes the most novel strategy to 
reverse differentiation, joining SCNT and cell fusion in the reprogramming (to 
pluripotency) toolbox (Figure 1.4). The resulting pluripotent cells are termed 
induced pluripotent stem (iPS) cells and brought Yamanaka the Nobel Prize in 
Medicine and Physiology in 2012, jointly awarded with Sir John Gurdon for his 
contributions to nuclear reprogramming.  
1.2.2.  Opportunities offered by cell reprogramming in regenerative 
medicine. 
The reprogramming technologies discussed above are gradually becoming 
more than techniques to study the mechanisms and mediators of cell plasticity, 
differentiation and de-differentiation. They have not only already provided 
invaluable research tools for disease modelling and drug screening among other 
applications but might also be able to offer novel alternative sources for cell 
replacement therapies [52]. In this respect, although at a very early stage, they 
have already contributed at the pre-clinical level by the:  
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1. Generation of iPS cells for cell replacement interventions: with the aim 
to establish a self-renewing stock of undifferentiated pluripotent cells in 
culture, derived from readily-available and non-ethically-controverted 
sources, which can generate customised differentiated cells to meet specific 
therapeutic needs.   
2. Induction of transdifferentiation in vivo: as a means to directly 
manipulate cell fate in the living organism to reprogram a readily-available 
resident cell type into the phenotype required to alleviate a particular 
disease.  
The achievements and limitations of these approaches are discussed in the 
next sections of this Chapter. 
1.3. iPS cells in regenerative medicine 
1.3.1. iPS cell promises: the alternative to ES cells. 
The excitement brought by iPS cells to the future directions of cell-based 
therapies lays not only on the relative simplicity of their generation, but mainly on 
their similarities with ES cells. Like them, iPS cells have large nucleus, reduced 
cytoplasmic space and form domed-shaped compact colonies with refractive edges 
in culture. They express pluripotency genes at the mRNA and protein levels, 
including Nanog, Ecat1 and Rex1 among many others and, more importantly, grow 
indefinitely in culture maintaining their pluripotent properties intact under the 
appropriate conditions [51]. Mouse iPS cells are confirmed functionally pluripotent 
since they contribute to the adult tissues of chimeric mice obtained by blastocyst 
injection, including the germline [53]. Very importantly, iPS cells have also been 
generated from human fibroblasts by expression of human OCT3/4, SOX2, KLF4 
and c-MYC [54], replacing c-MYC and KLF4 by NANOG and LIN28 [55] and even 
avoiding the tumourigenic  c-MYC [56].  
Commonly, iPS cells are presented not just as equivalent to ES cells but as 
superior alternatives that may overcome some of their associated limitations [52]. 
The main differences involved in the predicted use of ES and iPS cells in 




Figure 1. 5. Proposed utilisation of ES and iPS cells in regenerative medicine. (a) ES cell-based 
therapy strategies involve discontinuation of the blastocyst development and rely on transplantation 
of allogeneic differentiated cells. (b) iPS cell technology allows the generation of patient-specific 
replacement cells for autologous transplantation, derived from easily accessible sources that do not 
involve handling of embryonic material.  
The first obvious benefit is the fact that iPS cell generation does not involve 
blastocyst destruction and therefore does not suffer from the same ethical 
constraints surrounding ES cell derivation. However, this is not the most relevant 
opportunity emerged from the way iPS cells are produced.  They can be generated 
from a wide range of somatic cell types from all three lineages with little or no 
variation in the reprogramming cocktail [51, 57-65]. Dermal fibroblasts are a 
convenient source for iPS cell generation since they can be harvested by simple 
skin biopsy [62], while equally accessible mononuclear peripheral blood cells are 
less dependent on in vitro expansion to achieve sufficient cell numbers. They might 
also be a safer option since they are not directly exposed to environmental insults 
(e.g. mutations provoked by UV radiation) [57, 63, 64]. UCB cells share these 
advantages, however they require cord collection and banking at birth [65]. 
Overall, the use of these sources ensures that the procedure is minimally invasive 
for the donor and that they can potentially be generated from the same patient in 
need of the transplant. The use of patient-specific cells is predicted to minimise the 
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risk of immune graft rejection compared to that associated to ES cell derivatives 
and other cell-based therapies [23-25].  
In conclusion, the envisioned application of iPS cell technology in 
regenerative medicine would involve harvesting easily accessible cells from a 
specific patient, followed by ex vivo induction into iPS cells, re-differentiation into 
the progenitor or mature phenotype required to alleviate the disease and eventual 
transplantation into the same patient. This sequence is illustrated in Figure 1.5b. 
In addition, it is precisely the capacity to generate patient-specific pluripotent and 
mature cells carrying a particular disease what makes iPS cells so valuable as tools 
in disease modelling and drug discovery, as discussed above. The advances in such 
areas fall out of the scope of this thesis but have been extensively reviewed by 
others [52, 66]. 
1.3.2. iPS cells: pre-clinical studies. 
The first transplantation of iPS cell derivatives for therapeutic purposes 
was carried out in a murine model of sickle cell anemia only one year after the 
original Takahashi and Yamanaka article [67]. Since then, several other examples 
have highlighted the potential of iPS cell technology in regenerative medicine at 
the preclinical level. Table 1.1 summarises the most relevant of these reports. The 
tissues and conditions targeted vary, but PD [68-70] and ischemic stroke [71-75] 
have attracted most interest. The interventions that aimed to alleviate genetic 
disorders required gene correction ex vivo in addition to iPS cell derivation and re-
differentiation prior to transplantation [67, 76, 77]. Non-genetic diseases only 
involved the generation of iPS cells and their re-differentiation to the appropriate 
precursor or mature cell type in the culture dish before implantation. Only two 
studies have implanted undifferentiated iPS cells to date, one of which resulted in 
uncontrolled tumourigenesis [71], whereas the other showed absolute absence of 
tumours [78]. These discrepancies have not been further investigated. The 
therapeutic outcomes achieved have also varied among studies. In some reports, 
successful engraftment of the iPS cell derivatives did not result in functional 
recovery [75], while in others the alleviation of the disease was not clearly linked 
to the transplanted cells and may have been due to paracrine effects [72, 73]. 
Various reports have however shown more positive outcomes, proving not only 
the successful engraftment and survival of the transplanted cells but also their 
35 
 
functionality once integrated in the host’s tissue [79, 80]. Overall, the results of 
these studies seem promising but there are many limitations that need to be 
overcome, which are discussed in Section 1.3.4 of this Chapter.   
1.3.3. iPS cells in humans: first clinical study. 
Considering their brief history, iPS cells are rapidly making their way 
towards clinical development. The first human clinical study using iPS cell 
derivatives started recruiting patients in August 2013 and transplantation to the 
first patient was announced in September 2014 [81]. The cells to be transplanted 
are sheets of retinal pigmented epithelium grown in the laboratory and derived 
from the patient’s own iPS cells. They are intended to repair the epithelium 
affected by age-related macular degeneration, however, the primary goal of this 
study is to assess the safety of such intervention [82]. The rapid progress of this 
technology towards clinical investigation has been received with mixed reactions 
among the scientific community. While some experts express excitement of the 
opportunities, others show concerns about the immaturity of the field and these 
trials [83]. Dr. Takahashi and her team at the RIKEN Center for Developmental 
Biology in Japan, where the sheets of retinal pigmented epithelium have been 
developed, have however highlighted the reproducibility of their protocol for sheet 
generation [84]. More importantly, they have confirmed that such cells are 
functional upon transplantation in diseased mice retina [80] and that they elicit no 
tumourigenicity or graft rejection when implanted in mice [85]  and non-human 
primates [86]. 
Two other groups have also declared themselves ready to seek clinical trial 
authorisation in the very near future. Provided their goals are accomplished, a 
group in Kyoto University will implant iPS cell-derived dopaminergic neurons for 
PD treatment, supported by encouraging results in non-human primates [87]. The 
US-based biotechnology company Advanced Cell Technology will explore the 
potential benefits of iPS cell-derived platelets in blood clotting disorders. In theory, 






Disease model iPS cell derivatives Restorative effect Ref. 
Sickle cell anaemia Hematopoietic precursors 
(genetic defect corrected by 
gene therapy) 
 
Normal erythrocyte phenotype restored. [67] 
Parkinson’s disease Midbrain dopaminergic 
neurons 
Improvement of PD symptoms in 
behavioural tests. Positive engraftment 








(genetic defect corrected by 
gene therapy) 
Restoration of α-sarcoglycan expression 
and of depleted muscle progenitors. 





Myogenic progenitors (genetic 
defect corrected by gene 
therapy) 
 
Restoration of utrophin, replenishment 
of satellite cells and improvement of 
muscle force. 
[76] 
Spinal cord injury 
 
Neurospheres Enhanced recovery of motor function. [79] 






















Neuroepithelial-like stem cells 
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Neuro-epithelial-like stem cells 
Generation of neuroblasts and mature 
neurons but uncontrolled 
tumourigenesis. 
 
Improved functional recovery of stroke-
damaged brain. 
 
Improvement of somatosensory and 
motor symptoms. 
 
Graft survival and differentiation to 
neuronal phenotypes but no restorative 
effect. 
 

























Mesenchymal stem cells 
Revascularization of the ischemic limb 






























Tumour free regeneration of infarcted 
tissue and improvement of contractile 
performance. 
 
Neovascularization, reduction of fibrosis 















Retinal pigmented epithelial 
cells 
Improved visual function. [93] 
Age-related macular 
degeneration  








1.3.4. Barriers to the applications of iPS cells in regenerative medicine. 
 In spite of the encouraging results shown in pre-clinical studies and their 
rapid progress towards clinical research, the use of iPS cells is not completely 
devoid of limitations.  
Regarding the reprogramming methods employed, there has been a trend 
to first avoid the use of integrating vectors to deliver the reprogramming factors, 
due to the inherent risk of insertional mutagenesis, and further to completely 
abolish the use of DNA, which can be replaced by mRNA [94], microRNA (miRNA) 
[95], proteins [96] or small chemical compounds [97]. Excisable methods have also 
been utilised, however not all of them guarantee a 100% efficiency in transgene 
removal [98-101]. Unfortunately, many of the strategies considered as “safe”, fail 
to achieve the same efficiency as the initially used integrating technology [51].  In 
some cases, a single technology was not enough to induce iPS cell derivation. Such 
was the case in the use of human artificial chromosomes, which had to be co-
administered with miRNAs [102]. In Table 1.2, the reprogramming technologies 
available today for iPS cell generation are classified according to their 
safety/efficiency balance. We determined ‘safety’ based on the occurrence of 
genomic integration and immune complications and ‘efficiency’ according to the 
reported percentage of starting cells successfully converted into iPS cell colonies.  




Retrovirus - ++ [51] 
Lentivirus - ++ [103] 
Inducible lentivirus - ++ [104] 
Excisable Excisable lentivirus ++ ++ [98] 
Non-integrating Adenovirus ++ - [105] 
DNA free Sendai virus ++ ++ [106] 
Naked DNA 
pDNA + - [107, 108] 
Episomal pDNA ++ +++ [109, 110] 
Mini circle pDNA ++ +++ [111] 
PiggyBac transposon ++ + [100] 
Sleeping Beauty transposon + + [101] 
Human artificial chromosome ++ - [102] 
DNA free 
mRNA +++ +++ [94] 
microRNA +++ + [95] 
Protein +++ - [96] 
Small molecules +++ - [97] 
Table 1. 2. Reprogramming technologies available for iPS cell generation. (+++) denotes very 
safe/efficient, (-) denotes not safe/not efficient. 
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The transcription factors utilised to induce reprogramming might also 
compromise the safety of this technology. The use of Klf4 and, especially, c-Myc 
remains controversial due to their involvement in oncogenic pathways [53]. While 
initial efforts to exclude c-Myc from the reprogramming cocktail resulted in a 
decrease of the efficiency of the pluripotent conversion [56], it should be noted 
that the combination of factors required to induce pluripotency may also critically 
depend on the differentiation status and nature of the starting cells. For example, 
neural stem cells can be reprogrammed to pluripotency upon expression of Oct4 
alone [61]. Hence, it is difficult to establish fair comparisons and make general 
statements. 
Although in the early phases of iPS cell research, patient-specific iPS cell 
derivatives were thought to elude immune recognition, the reality is that almost 
ten years later there is still little consensus on the immunogenicity of such cells. 
Immune responses have been reported upon transplantation of undifferentiated 
iPS cells and subsequent generation of teratomas [112]. However, this was not 
observed when fully differentiated iPS cell derivatives were implanted, which 
suggests that the immune response may be a product of tumourigenesis rather 
than due to the iPS cells per se [113, 114]. It has also been proposed that 
differences among  iPS  cell lines generated by different protocols could be behind  
the discrepancies observed across studies [115]. Overall, more systematic studies 
are required to determine whether iPS cells may trigger immune complications.  
The heterogeneity among iPS cell clones (depending on starting cell type, 
protocol utilised for pluripotent conversion and other factors, as reviewed 
elsewhere [116]) is  also a matter of concern for the reproducibility of iPS cell 
therapies. Whether they should be considered identical to ES cells in terms of 
epigenetic status, genomic stability, mutational load and differentiation potential 
remains to be determined. Genome-wide analyses have found differences in gene 
expression profiles suggesting that epigenetic signatures from the tissue of origin 
could remain in iPS cells, which might restrict their differentiation potential [117, 
118]. In addition, some studies have reported incomplete reprogramming to a 
pseudo-iPS cell intermediate state that, albeit similar to bona fide iPS cells in 




The capacity of pluripotent cells to generate teratomas in vivo has also 
raised some concerns on the safety of the approach. It should however be 
highlighted that this problem has only been encountered when undifferentiated 
iPS cells were transplanted [71], which is not the intended use of iPS cells in 
regenerative medicine, or when incomplete silencing of the reprogramming 
transgenes was suspected [70]. Appropriate quality control mechanisms that 
ensure absolute absence of undifferentiated cells among iPS cell derivatives 
intended for transplantation should therefore abolish this concern [120]. 
The use of iPS cells also suffers from limitations inherent to cell 
replacement therapies. Efforts have been made to simplify the long and complex 
culturing protocols necessary to generate iPS cell colonies, that may trigger 
karyotypic aberrations on the cells, and to avoid the use of xeno-biotics during this 
process, in order to fulfill Good Manufacturing Practices (GMP) and clinical-grade 
requirements [121-123]. However the subsequent differentiation protocols still 
rely heavily on the use of growth factors and other substances. Safety of the 
exposure to these molecular cues will have to be thoroughly investigated prior to 
any clinical application [124, 125]. Finally, and in addition to the challenges of cell 
delivery and transplantation, poor engraftment is often the leading cause of the 
absence of restorative effect at the pre-clinical level [92].  
The economic resources and time-frame needed to derive iPS cells and re-
differentiate them to the appropriate cell type become even more relevant if they 
are to be generated from specific patients. With the technologies available today, 
approximately 3 months are necessary to complete this process. Adding the 
necessary safety and quality control tests, up to six months could be required, 
which compromises the clinical relevance of iPS cell therapies when prompt 
treatment is mandatory [126]. A proposition to circumvent this problem relies in 
the establishment of banks of allogeneic iPS cell lines. Although at first glance this 
would act in detriment of the notion of personalized iPS cell therapy, it has been 
calculated that a stock of 75 iPS cell lines derived from homozygous human 
leukocyte antigen (HLA) donors would be enough to match 80% of the population 
in Japan without triggering any immune response [110, 127]. Similarly, it has been 
estimated that a pool of 150 cell lines from defined HLA donors would match 93% 
of the UK population [128]. This initiative is becoming a reality after the 
authorisation of an ambitious scheme, known as the “iPS cell Stock Project”, which 
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aims to generate iPS cells from samples stored in various Japanese cord blood 
banks [83]. 
In this scenario, there is still no unanimous voice in the scientific 
community that confirms whether iPS cells are truly a superior alternative to ES 
cells, or simply have different advantages to offer. What transpires from the 
studies presented here is that the possibility to reverse a patient’s own cells back 
to the very plastic pluripotent state may allow new revolutionary ways of 
treatment, however several barriers need to be overcome before they become a 
reality in the clinical practice.  
1.4. Transdifferentiation in regenerative medicine. 
1.4.1.  In vivo transdifferentiation: looking at Nature and escaping the dish. 
Direct conversion of cells resident in a diseased or injured tissue into the 
replacement phenotypes needed to alleviate the particular condition would be an 
optimal strategy to regenerate the affected tissue. In fact, transdifferentiation 
occurs spontaneously after injury in certain organisms with striking capacity to 
regenerate. It is a substantial mechanism underlying liver [129] and heart [130] 
regeneration in zebrafish as well as lens regeneration in axolotls [131]. However, 
this ability has been lost in mammals, with the exception of very few examples 
restricted to neonatal stages and definitely not sufficient to restore significant 
damage [132]. On the contrary, spontaneous transdifferentiation in mammalian 
organisms is rare and mainly linked to the onset of disease. This is the case of 
Barret’s metaplasia, whereby Cdx2-mediated transdifferentiation of stratified 
squamous into columnar epithelium predisposes to oesophagus carcinoma [133, 
134]. Similarly, transdifferentiation of different starting cell types into 
myofibroblasts after injury or chronic damage to various tissues, including kidney 
[135], liver [136] and muscle [137], triggers the establishment of a fibrotic scar.   
Based on the paradigm of those organisms with better capacities to 
regenerate and thanks to the increasing knowledge of the specific developmental 
regulators - mainly transcription factors - that govern each cell type, 
transdifferentiation has been proposed as a therapeutic strategy in different 
mammalian tissues and disease models. As discussed previously, Davis and 
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Weintraub’s MyoD studies set the bases for this proposition, since they confirmed 
that transdifferentiation can be intentionally induced by the ectopic expression of 
such regulators [47, 48]. Their studies have been followed by others attempting to 
induce cell-to-cell changes in vivo to tackle specific conditions (Figure 1.6). Most 
efforts have been dedicated to explore therapeutic strategies against diabetes, 
heart disease and, to a lesser extent, injuries and degenerative diseases affecting 
the central nervous system (CNS). Specific details of these studies are compiled in 
Table S1, Table S2 and Table S3, respectively.  
 
 
Figure 1. 6. In vivo transdifferentiation studies. In vivo transdifferentiation studies have been so 
far focused on: liver and pancreas, for the treatment of diabetic disease; heart, to regenerate the tissue 
after myocardial infarction or to establish a biological pacemaker that corrects bradycardia; and CNS, 
to alleviate both neurodegenerative and traumatic conditions.  
1.4.2. In vivo transdifferentiation: pre-clinical studies.   
1.4.2.1. In vivo transdifferentiation in pancreas and liver. 
Efforts to alleviate diabetic disease via in vivo transdifferentiation have 
followed two different strategies: the generation of new β-cells in the pancreas 
[49] and the induction of insulin-secreting cells in an organ with a very similar 
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developmental origin, the liver [138-144]. Interestingly, the same combination of 
transcription factors – Pdx1, Ngn3 and MafA - has proven the most effective 
reprogramming cocktail in both strategies. In the pancreas, induced β-cells 
resembled their endogenous counterparts very closely [49], whereas in the liver 
unique insulin-secreting ducts were formed [144]. Both studies achieved long-
term amelioration of hyperglycaemia in diabetic mice. 
1.4.2.2. In vivo transdifferentiation in heart. 
The heart is perhaps the organ most intensively investigated for in vivo 
transdifferentiation, motivated by the high prevalence and mortality rate 
associated with cardiovascular disease [145]. The studies reported to date aim to 
generate new cardiomyocytes (CMs) after myocardial infarction (MI) or to correct 
bradycardia by the generation of a biological pacemaker in situ.  
Regeneration of infarcted hearts 
In the event of MI, CMs die in the infarcted area and cardiac fibroblasts 
migrate to the site and proliferate actively to replenish the tissue. Thanks to their 
abundance, cardiac fibroblasts have been considered as an advantageous starting 
cell type for cell fate conversions. Leaving aside a 1996 study that attempted to 
generate skeletal myofibers to regenerate the myocardium via forced expression of 
MyoD, with not much success [146], the increasing knowledge of the factors 
involved in CM development allows now to replenish the injured heart with 
induced CMs (iCMs). 
The combinations Gata4, Mef2c and Tbx5 (GMT) [147, 148], Gata4, Mef2c, 
Hand2 and Tbx5 (GMHT) [149] and the micro-RNAs 1, 133,208 and 499 [150, 151] 
have all confirmed generation of iCMs in mouse models of MI, however with 
different outcomes in the improvement of cardiac function and reduction of scar 
tissue.  
Generation of a biological pacemaker in situ 
The generation of a biological pacemaker via transdifferentiation has 
exploited the role of Tbx18 in the embryonic development of the sinoatrial node 
(SAN), a small group of approximately 10,000 cells responsible for initiating the 
heartbeat. Transdifferentiation of ventricular CMs into induced SAN (iSAN) cells, 
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able to beat spontaneously and alleviate bradycardia, has been achieved in guinea 
pig [152] and porcine [153] models of complete heart block.  
 
1.4.2.3. In vivo transdifferentiation in the CNS. 
Intense efforts are also made to change cell identity in situ in the brain and 
CNS. However, the literature is more scattered in terms of starting and induced cell 
types, reprogramming factors used, disease models investigated and restorative 
effect achieved. 
Various studies have explored the feasibility to reprogram astrocytes into 
neurons or neuron precursors (neuroblasts). Proof-of-principle of such conversion 
was achieved with a combination of Ascl1, Brn2a and Myt1l [154] and later 
confirmed via forced expression of Sox2 alone [155, 156] and NeuroD1 alone [157]. 
Importantly, NeuroD1-mediated astrocyte-to-neuron conversion was more 
extensive in an aged 5xFAD transgenic mouse model of Alzheimer’s disease 
compared to young transgenics and wild-types (WT). This finding was attributed 
to the enriched astrocyte population triggered by neurodegeneration and 
highlighted the opportunities to tackle this type of conditions via in vivo 
transdifferentiation. Similarly, Sox2-mediated astrocyte-to-neuroblast conversion 
took advantage of astrocyte migration to the injury site in a model of spinal cord 
injury. Induced neuroblasts matured into neurons that formed synapses with 
resident brain cells, however functional recovery remained unexplored [158]. 
Fate changes between different types of neurons have also been explored, 
however they have proven more challenging due to the post-mitotic status of the 
cells. Fezf2 induced transdifferentiation between different types of post-mitotic 
neurons in two different studies, however in both cases the conversion was only 
possible in a specific time window (from embryonic to early post-natal stages) and 





1.4.3. Opportunities and limitations of in vivo transdifferentiation. 
Although in vivo transdifferentiation studies are still scarce and 
preliminary, they have already generated valuable knowledge regarding the 
plasticity of various mature cell types within their native microenvironment. They 
have also produced encouraging results in disease models at the early-stage pre-
clinical level and are progressively unveiling the opportunities and limitations of 
this approach.  
In vivo transdifferentiation takes advantage of the crucial role of the native 
microenvironment in the survival and maturation of the induced cells. Direct 
comparison of in vitro and in vivo transdifferentiated cells evidenced that those 
switched to a different phenotype within living tissue better resembled their 
endogenous counterparts in terms of morphology, function, degree of 
differentiation and interaction with neighbouring cells [49, 147]. In addition, the 
fact that the conversion takes place in vivo eliminates the challenges associated to 
in vitro culture and cell delivery or transplantation [92, 121-123]. Altogether, these 
facts place in vivo transdifferentiation in an advantageous position over traditional 
cell therapy. 
Direct generation of the desired mature phenotype, avoiding pluripotent 
intermediates, is considered beneficial by many [31]. However, in some of the 
studies discussed above, the induced cells were in fact precursors that required co-
administration of epigenetic regulators or other signalling molecules to fully 
mature [155, 158]. In addition, direct conversion requires the identification of 
specific reprogramming factors for each particular cell-to-cell conversion, contrary 
to the versatility of the Yamanaka factors that are able to induce pluripotency in 
several starting cell types [51, 57-65] .  
Beyond the extra efforts in the search for specific reprogramming cues, 
poor conversion efficiency acted as limiting factor in most of the studies and can 
compromise the therapeutic outcomes of the strategy [148]. Such obstacle is 
sometimes exacerbated by immune clearance of viral vectors and virally 
transduced cells [148, 153].  Indeed, in vivo transdifferentiation has so far relied 
heavily on the use of viral vectors for the delivery and expression of 
reprogramming factors, which also complicates to a certain extent the cruise 
towards the clinic. Various studies have used retrovirus in order to exclusively 
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restrict the infection to dividing cells [147-149]. However, engineering safer non-
viral vectors that can more sophisticatedly target specific cell types is desirable.  
Finally, in those studies with therapeutic aims, there is a need to investigate 
the effects and outcomes of in vivo transdifferentiation when reprogramming 
factors are administered at different time points after the onset of injury. All the 
studies published to date, with the exception of Murry et al. [146], induced the cell 
fate conversion at the time of injury. Such experimental design not only questions 
clinical relevance; it might also underestimate the therapeutic potential of those 
strategies that rely on the injury-triggered proliferation of particular cell types (e.g. 
cardiac fibroblasts, astrocytes) to be available for transdifferentiation.  
Overall, in vivo transdifferentiation has the potential to become a very 
powerful tool in tissue repair and regeneration but the results of the studies 
presented here should be considered with caution before overenthusiastic 
promises are conveyed. 
1.5. The third way: generating pluripotent cells in situ.  
1.5.1. In vivo reprogramming to pluripotency: proof-of-concept. 
Recent studies have suggested that induced reprogramming of 
differentiated cells to pluripotency could also be feasible within the living 
organism [161-163]. Should these initial findings be fully confirmed, they could 
constitute a third therapeutic alternative by which cell reprogramming could 
contribute to tissue regeneration (i.e. in addition to in vitro iPS cell generation and 
transplantation and in vivo transdifferentiation).  
 In 2012, Vivien et al. were first to report in vivo somatic cell 
reprogramming to pluripotency in a non-mammalian model. Their work was 
conducted on pre-metamorphic tadpoles, therefore not fully developed organisms. 
However, that study offered an important contribution to the field, by confirming 
that ectopic expression of Yamanaka factors (excluding c-Myc) induces 
pluripotency against the pro-differentiation signals present in the in vivo 
microenvironment. Forced expression of OKS factors in the tadpole tail muscle 
triggered the expression of pluripotency genes, silenced at such developmental 
stage under normal circumstances. In addition, cell clusters expressing such 
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markers were found within the muscle tissue, which were able to differentiate in 
vitro towards all three lineages when exposed to different conditions [161]. 
  Our laboratory performed simultaneously studies with mammalian models 
(BALB/c mouse) that were reported by Yilmazer et al. This initial work evidenced 
that the adult mouse liver microenvironment is also permissive to OKSM-mediated 
induction of pluripotency. Forced expression of OKSM factors in mouse 
hepatocytes resulted in rapid and transient upregulation of pluripotency markers 
at the mRNA level and downregulation of hepatocyte-specific genes. Protein 
expression also suggested a shift of the differentiated status of the cells towards 
pluripotency, but no confirmation was provided of the generation of fully 
functionally pluripotent cells within the liver tissue [162, 163]. 
1.5.2. Hypotheses, promises and challenges of in vivo reprogramming to 
pluripotency. 
Importantly, the studies by Vivien et al. and Yilmazer et al. did not report 
complications associated to teratoma formation or other aberrations in the tissue. 
In addition, the pluripotent conversion was not sustained for extended periods of 
time [161-163]. These observations suggest that in vivo reprogramming to 
pluripotency might also have a space in the regenerative medicine toolbox. Given 
that the cell fate conversion takes place in vivo but making use of the very versatile 
Yamanaka factors, in vivo reprogramming to pluripotency might even overcome 
some of the limitations associated to in vitro iPS cell generation and in vivo 
transdifferentiation. However, at the time of initiation of this thesis there was only 
one report of this kind in mammalian (mouse) organisms, confirmation of 
complete reprogramming to functional pluripotency was yet to be obtained and, 
more importantly, the potential of this strategy to contribute to regeneration had 
not yet been challenged in disease models. Therefore, the early stage of this 
technology makes it challenging to predict the specific opportunities and 
limitations that will be involved. In this thesis, we aimed to fill some of such gaps in 
order to better understand the possible role of in vivo reprogramming to 
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The capacity to induce changes in cell fate that generate patient-specific, 
customised, replacement cells for the tissue where they are needed – via in vitro 
iPS cell generation or in vivo transdifferentiation - suggests new and exciting ways 
to tackle disease and may develop into a very powerful tool in regenerative 
medicine [164]. The first clinical study using iPS cell derivatives is currently taking 
place in Japan [165, 166] and, although still at their infancy, these strategies have 
the chance to become a clinical reality in the near future. However, they are not 
devoid of limitations. The generation of iPS cells suffers from the risks associated 
with long in vitro culture protocols and the challenges of cell delivery and 
transplantation [120].  Although transdifferentiation to specific cell types can be 
directly achieved in vivo, this strategy is complicated by the need to identify 
specific reprogramming factors for each particular cell fate conversion and its poor 
efficiency [144, 148, 155]. 
In vivo cell reprogramming to pluripotency could combine the opportunities 
offered by in vitro iPS cell generation and in vivo transdifferentiation, as well as 
circumvent some of the limitations faced by each of such approaches. However, it 
is yet largely unexplored. The overall aim of this thesis was to explore in vivo cell 
reprogramming to pluripotency as a novel strategy to enhance regeneration of 
injured tissues. 
Based on Yilmazer et al.’s first-ever report suggesting in vivo 
reprogramming towards pluripotency in a mammalian tissue [162], we 
hypothetised that adult, fully differentiated cells from different tissues could be 
reversed in vivo to a functionally pluripotent state via ectopic expression of 
Yamanaka factors. We speculate that reprogrammed cells would only exist 
transiently in the pluripotent state in such scenario, given the pro-differentiation 
cues present in the tissue microenvironment; and that such signals would assist 
the re-differentiation of the pluripotent intermediates towards the appropriate 
phenotype. This hypothesis is represented in Figure 2.1 using the mouse liver as 
an illustrative example. Thus, the generation of transiently pluripotent cells in situ 







Figure 2. 1. Hypothesis: in vivo induced reprogramming to pluripotency and re-differentiation 
within the native microenvironment. 
In order to prove the hypotheses above, the particular aims of this thesis were: 
 To further investigate the induction of pluripotency in mouse liver, 
reassuring the safety of the approach and exploring modifications to the 
Yilmazer et al.’s protocol. 
 To determine the differentiation potential of in vivo reprogrammed cells.  
In vivo reprogrammed cells could share the differentiation potential of iPS and 
ES cells. However, it is known that incomplete reprogramming can lead to an 
intermediate state that shares morphological and molecular similarities with 
pluripotent stem cells [119] but is not functionally pluripotent (i.e. fails to 
differentiate into representatives of all three lineages). In order to confirm the 
pluripotency of in vivo reprogrammed cells, we aimed to isolate them from the 
tissue and establish them as a stable cell line in vitro for comparison to a 




 To challenge the capacity of Yamanaka factors to induce pluripotency in 
tissues of different developmental origin. One of the anticipated benefits of 
in vivo reprogramming to pluripotency over in vivo transdifferentiation relies 
on the versatility of the Yamanaka cocktail. This combination of transcription 
factors has proven able to reverse a variety of differentiated cell types to 
pluripotency in vitro and therefore is considered a universal tool to induce 
such fate switch [164]. It was thus among our objectives to verify that such 
observation holds in the in vivo scenario by attempting the induction of 
pluripotency with such cocktail in tissues of different developmental origin.  
 To follow the fate of the in vivo reprogrammed cells in the tissue. In vivo 
reprogrammed cells were expected to proliferate, based on the fact that active 
cell division has been identified as a mandatory step in the pluripotent 
conversion [167]. Hence, we aimed to confirm the occurrence of cell 
proliferation and intended to confirm the re-integration of the in vivo 
reprogrammed cells into the tissue after such phase. 
 To investigate whether the generation of pluripotent cells in vivo would 
enhance regeneration and functional recovery of injured tissue. The 
ultimate aim of this thesis was to explore the therapeutic potential of in vivo 
reprogramming to pluripotency in the event of tissue injury. For this, we 
aimed to establish a reproducible injury model and subsequently test different 
therapeutic interventions involving the administration of reprogramming 
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3.1. Scope of Chapter III. 
Reprogramming of somatic cells to pluripotency via forced expression of 
transcription factors in vitro has been intensively explored for the last 9 years. 
However, very little has been reported about the possibility to induce this 
particular cell fate conversion in vivo. The first account of in vivo cell 
reprogramming to pluripotency dates to 2012, when Vivien and colleagues 
induced the generation of pluripotent cells within tadpole tail muscle tissue [161]. 
A recent report by Yilmazer et al. suggested that a similar effect could be achieved 
in an adult, fully differentiated, mammalian tissue - the mouse liver. In this work, a 
shift towards pluripotency in gene and protein expression of liver cells was 
evidenced, but a definite proof of the generation of bona fide pluripotent cells 
within the tissue remained to be obtained [162, 163].  
In this Chapter, we sought to further explore the induction of pluripotency 
in mouse liver following on Yilmazer’s studies but, more importantly, we aimed to 
characterise the resulting in vivo reprogrammed cells and their differentiation 
potential in order to confirm, or not, functional pluripotency. 
3.2. Introduction. 
Although the forced expression of reprogramming factors is not free of 
impediments when it is performed in the culture dish [120], even more challenging 
is to deliver such factors and induce the pluripotent conversion in vivo. Specificity 
for a particular cell population (to avoid off-target effects or widespread 
reprogramming), efficiency and safety are requirements of particular relevance. In 
Yilmazer’s report, hydrodynamic tail vein (HTV) injection was the administration 
method of choice to specifically and efficiently transfect mouse hepatocytes with 
naked pDNA and avoid the risks inherent to the use of viral delivery vectors [162, 
163]. HTV injection is a well-established technique for the expression of foreign 
genes in vivo via systemic administration of naked pDNA, first described by Liu et 
al. [168] in the late 1990s. It results in high levels of gene expression in the liver, 
especially in hepatocytes, whereas transgene expression is minor in other organs. 
Importantly, this approach has not only achieved satisfactory results in small 
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rodents, but has also been escalated to larger animal models such as rabbits [169] 
and pigs [170-172] and translated into human clinical trials [172]. 
The procedure involves the injection of a large volume of pDNA solution (8-
12% of the total body weight) in a short time interval (no more than 5 s for a 20 g 
mouse) via the tail vein, being these the two most crucial parameters to achieve 
high expression of the exogenous genes [168, 173]. A single mechanism has not yet 
been identified to explain the preferential uptake of pDNA by hepatocytes after 
HTV injection and it may be possible that different processes contribute to this 
end-effect. The rapid injection of such a large volume exceeds cardiac output, 
increasing the pressure in the inferior vena cava and driving the injected solution 
to backfill the liver circulation. In addition, the rise in hydrostatic pressure in the 
liver opens the sinusoids fenestrae, thus assisting the extravasation of pDNA 
solution, and may lead to pore formation in the hepatocyte membrane [174]. The 
rapid entrance of pDNA in the hepatocytes acts as a protective mechanism against 
its degradation by nucleases present in the blood stream, contributing as well to 
high levels of transgene expression [168]. Finally, some studies have suggested 
contribution of a receptor-mediated mechanism [175].  
Following this strategy to express Yamanaka factors in mouse hepatocytes, 
Yilmazer and collaborators reported a rapid and transient upregulation of 
pluripotency markers and downregulation of hepatocyte-specific genes in the 
BALB/c mouse liver, which was interpreted as the de-differentiation of a subset of 
cells towards pluripotency in the tissue. Hepatocytes are parenchymal cells that 
derive from the anterior portion of the endoderm, one of the three germ layers 
formed in the embryo during gastrulation. This process has been extensively 
reviewed by others [176, 177], which has allowed the identification of key 
hepatocyte-lineage marker genes. Such markers have been classified in four 
groups according to the stage in hepatocyte development in which their role is 
more relevant. Endodermal markers such as Afp and Foxa2 are expressed from the 
establishment of the endoderm layer, while genes whose role commences at later 
developmental stages include Alb (fetal hepatocyte marker), G6pc and Tat 
(perinatal expression) and Cyp3a, Pc1k, Tdo, Aat and Trf (characteristic of mature 
hepatocytes only) [178]. The knowledge built around these markers has been used 
by Yilmazer et al. and in this Chapter to assess the potential loss of hepatocyte 
identity upon in vivo reprogramming. 
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In Yilmazer’s report, the induction of pluripotency happened faster (as early 
as 2 days after HTV injection) and was more efficient (estimated in 5 to 15% of the 
total hepatocyte population) than the vast majority of in vitro reprogramming 
protocols described to date. In addition, such effect was not sustained over time. 
Hepatocyte gene expression returned to baseline levels after 8 days and cells 
expressing pluripotency markers at the protein level were only found within the 
liver tissue until day 4 after HTV injection [162, 163]. Equally encouraging was the 
fact that no teratoma formation or other abnormalities were detected in the tissues 
after the procedure. However, no further information regarding the nature of such 
in vivo reprogrammed cells was gathered and hence complete reprogramming to 
functional pluripotency could not be confirmed.  
In this chapter we used different reprogramming pDNA and administration 
schemes, based on those utilised by Yilmazer et al., to further investigate in vivo 
reprogramming to pluripotency in mouse liver. We also isolated the in vivo 
reprogrammed cells from the tissue and cultured them as a stable cell line in vitro 
in order to investigate their molecular signature and differentiation potential in 
comparison to a standard pluripotent stem cell line.  
3.3. Materials and Methods. 
3.3.1. Materials used in Chapter III. 
3.3.1.1. pDNA vectors.  
Three different reprogramming pDNA were used in this work. pLenti-III-EF1α-
mYamanaka (referred to as OKSM) encodes the reprogramming factors Oct3/4, 
Klf4, Sox2 and c-Myc and the reporter eGFP under the control of the EF1α 
promoter. pCX-OKS-2A (referred to as OKS) encodes Oct3/4, Klf4 and Sox2 and 
pCX-c-Myc (referred to as M) encodes c-Myc, both under the control of the CAG 
promoter. OKS and M have been used in previous publications for iPS cell 
generation [107, 108]. When these two pDNA were administered together, we 
referred to the combination as OKS+M. 
OKS and M were obtained from Addgene (USA) and OKSM was purchased from 
Applied Biological Materials (USA), in all cases as bacterial stabs.  pDNA 
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production was performed  by Plasmid Factory (Germany). Relevant pDNA maps 
are represented in Figure S1. 
3.3.1.2. Mouse strains.  
Female mice were used in this work that entered the procedures at 7 weeks of age, 
unless otherwise specified. BALB/c mice were purchased from Harlan, UK. E12.5-
14.5 pregnant CD1 mice for MEF isolation, CD1 nude mice for teratoma studies and 
C57BL/6 and BDF1 mice for chimerism experiments were obtained from Charles-
River, UK. BDF1 mice (B6D2F1) are a cross between female C57BL/6 and male 
DBA/2. 
All experiments were performed with previous approval from the UK Home Office 
under a project license PPL 70/7763 and after allowing the mice to acclimatise to 
the facilities for one week. 
3.3.1.3. Cell lines.  
E14TG2a, a mouse ES (mES) cell line isolated from 129/Ola mice blastocysts, was 
purchased from the American Type Culture Collection (ATCC). Cells were 
maintained in an incubator at 37°C and 5% CO2 pressure. Culture medium was 
changed daily and cells were passaged every other day. 
The composition of the various cell culture media used in different studies in this 
chapter are listed in Table S4. 
3.3.2. Methodology involved in Chapter III. 
3.3.2.1. Hydrodynamic tail vein (HTV) injection of pDNA.  
BALB/c mice (n=3) were warmed at 37°C in a heating chamber, anesthetised with 
isoflurane and administered 1.5 ml of pDNA solution prepared in 0.9% saline via 
the tail vein. Injection time was fixed to 5 s. For the different groups, the pDNA 
solution included: 75 µg OKS and 75 µg M, 75 µg OKS alone or 150 µg OKSM. 
Control groups were administered the same volume of 0.9% saline alone. Mice 
were culled at different time points specified for each study, including 2, 4, 8, 12 
and 24 days after HTV injection, and livers were processed for investigation. 
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3.3.2.2. Repeated HTV injection of pDNA.  
BALB/c mice (n=3) were HTV injected with 75 µg OKS and 75µg M in 1.5 ml 0.9% 
saline, as described before. The control group was administered the same volume 
of 0.9% saline alone. 3 days after the injection, animals were either culled or 
administered a second dose of the corresponding treatment. Animals that received 
two doses of pDNA or saline solution were sacrificed at days 4 and 8 after the first 
administration (1 and 5 days after the second HTV injection, respectively). Livers 
were processed for gene expression studies. 
3.3.2.3. Characterisation of in vivo reprogrammed liver tissue. 
Isolation of hepatocyte population. Mouse livers were perfused and digested as 
previously described [179] with some modifications. In brief, under terminal 
anaesthesia, mice were first perfused from the inferior cava vein with 10 ml of Ca2+ 
and Mg2+ free Hank’s Buffered Salt Solution (HBSS, Sigma-Aldrich, UK), pre-
warmed at 37°C, for approximately 3 min, until the liver whitened. Perfusion was 
then continued with Liver Digest Medium containing collagenase (LDG, Gibco, UK), 
pre-warmed also at 37°C, and at a flow rate of 0.6 ml/min for 10-15 min, until the 
liver became swollen and loose. Digested livers were washed with Hepatocyte 
Wash Medium (HWM, Gibco, UK) at 4°C and disrupted through a 100 μm cell 
strainer (BD Biosciences, UK) to obtain a cell suspension.  5 min centrifugation at 
50 g was used to separate parenchymal cells (including hepatocytes), which were 
collected in the pellet, and non-parenchymal cells (including Kupffer cells and 
epithelial cells), which stayed in the supernatant. The cell pellet was re-suspended 
in HWM and the hepatocyte fraction was collected after 4 repeats of the 
centrifugation procedure.  
RNA isolation and real-time Reverse Transcription-quantitative Polymerase 
Chain Reaction (real-time RT-qPCR) analysis.  Nucleospin RNA II kit (Macherey-
Nagel, UK) was used to extract total RNA from isolated hepatocytes. RNA 
concentration and quality were analysed by UV spectrophotometry 
(BioPhotometer, Eppendorf, UK). cDNA synthesis was performed from 1 µg RNA 
sample with iScript cDNA synthesis kit (Bio-Rad, UK)  according to manufacturer’s 
instructions. The protocol for reverse transcription was as follows: 25°C for 5 min, 
42°C for 30 min, 85°C for 5 min and 4°C for 5 min. 2 µl of cDNA sample were used 
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for each real-time qPCR reaction performed with iQ SYBR Green Supermix (Bio-
Rad, UK). Experimental duplicates of each sample were run on CFX-96 Real Time 
System (Bio-Rad, UK) with the following protocol: 95°C for 3 min, 1 cycle; 95°C for 
10 s, 60°C for 30 s, – repeated for 40 cycles. Melt curve analysis was conducted at 
the end of the protocol to confirm amplification of a single product. β-actin was 
used as housekeeping gene and gene expression levels were normalised to saline-
injected control groups, unless otherwise specified. Livak’s method was followed 
to analyse the data and dCt values were utilized for statistical analysis. The primer 
sequences used are listed in Table S5. 
Immunohistochemistry (IHC) of mouse livers. Livers were perfused with 10 ml 
HBSS, as described before, but then immediately immersed in isopentane, pre-
cooled in liquid nitrogen, for fixation. Frozen livers (n=3) were stored at -80°C 
until further processing. 14 µm thick sections were prepared on a cryostat (Leica 
Microsystems, CM3050S) and air-dried for 1 h at room temperature (RT) before 
storage at -20°C. Before staining, liver sections were post-fixed with methanol, pre-
cooled at -20°C, for 10 min and then air-dried for 15 min and washed twice with 
Phosphate Buffered Saline (PBS, 5 min each, RT). 1 h incubation in blocking buffer 
(5% goat serum-0.1% Triton in PBS, pH 7.3) at RT was followed by two washing 
steps with washing buffer (1 %BSA- 0.1% Triton in PBS, pH 7.3). Tissue sections 
were incubated overnight at 4°C with the corresponding primary antibody: rabbit 
pAb anti-OCT4 (ab19857, 3 µg/ml, Abcam, UK), rabbit pAb anti-SOX2 (ab97959, 1 
µg/ml, Abcam, UK), rabbit pAb anti-NANOG (ab80892, 1 µg/ml, Abcam, UK) or 
mouse mAb anti-SSEA1 (ab16285, 20 µg/ml, Abcam,UK). The next day, 3 washing 
steps (5 min each) with washing buffer were followed by 1.5 h incubation at RT 
with the corresponding secondary antibody: goat pAb anti-rabbit IgG labeled with 
Cy3, 1/250 or goat pAb anti-mouse IgG labeled with Cy3, 1/250, both purchased 
from Jackson ImmunoResearch Laboratories, UK. Finally, sections were washed 
with PBS and mounted with DAPI and antifade containing medium (Vectashield, 
Vector Laboratories, UK). Slides were visualised under an epi-fluorescence 
microscope (Zeiss Axio Observer). 40X images were obtained with Axiovision 





3.3.2.4. Generation and in vitro culture of i2PS cell colonies. 
Isolation of primary mouse embryonic fibroblasts (MEFs). Mouse embryonic 
fibroblasts (MEFs) were isolated as previously described [180], with some 
modifications. In brief, an E12.5-14.5 pregnant CD1 mouse was sacrificed by CO2 
suffocation and the developing embryos were released from the uterine horns. 
After removal of the placenta and surrounding membranes, internal organs 
including heart, liver and brain were excised. The remaining material of each 
embryo was finely minced, suspended in 2 ml of 0.25% trypsin solution with 100 
µl DNAse and incubated at 37˚C for 30 min with frequent homogenization. After 
incubation, 6 ml of fresh MEF medium (Table S4) were added and vigorous 
pipetting was used to enhance tissue dissociation. Big pieces of tissue were let to 
settle down to the bottom of the tube for a few minutes and the supernatant was 
then centrifuged at 200g for 5 min. The cell pellet was re-suspended in 8 ml of pre-
warmed MEF medium and then plated at a density of 1 embryo/T75 tissue culture 
vessel, which constituted passage 0 of the primary MEF culture. The cells were 
maintained at 37ºC and 5% CO2 pressure and MEF medium was changed daily 
until the cells became confluent and were either split of frozen. A maximum of 3 
passages were done before the cells were mitotically arrested to be used as feeder 
layers. 
Mitotic inactivation and preparation of MEF feeder layers. Primary MEFs were 
treated as described in a previous report [180], with some modifications, to 
prepare feeder layers for the culture of pluripotent stem cells. MEF medium was 
removed from a confluent T75 tissue culture vessel and 10 ml of inactivation 
medium (containing 10 µg/ml mitomycin C, Table S4) were added. Cells were 
incubated at 37˚C and 5% CO2 pressure for 3 h.  Following 3 washes with PBS, the 
cells were trypsinised and plated in new tissue culture vessels with fresh MEF 
medium. A density from 1.0 to 1.5 x 105 inactivated MEFs/cm2 was appropriate to 
produce feeder layers. Inactivated MEFs were ready to be used as feeder layers or 
frozen as inactivated stocks one day after the treatment with mitomycin C.  
Generation of i2PS cell colonies. BALB/c mice (n=3) were HTV injected with 75 
µg OKS and 75µg M in 1.5 ml of 0.9% saline or 1.5 ml of 0.9% saline alone (control) 
and the hepatocyte fraction was isolated 2 days after injection as described above. 
2 x 106 cells were seeded on each well of a 6-well plate where MEF feeder layers 
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had been previously prepared. Cultures were maintained in DMEM/LIF medium 
(Table S4), which was changed daily. Cells were passaged 1:2 on fresh MEF 
feeders after 10 days in culture and 2 days later compact cell colonies started to 
appear in the cultures from OKS+M group. No colonies were formed from saline-
injected control mice. i2PS cell colonies were established as a stable cell line in 
vitro, culture medium was changed daily and cells were passaged every other day. 
Specific culture conditions are indicated for each particular study. 
3.3.2.5. Pluripotency assays at the molecular level. 
Real-time RT-qPCR gene expression analysis of E14TG2a and i2PS cells. 
E14TG2a and i2PS cells (n=3) were cultured on 0.1% gelatin coated tissue culture 
vessels and DMEM/LIF conditions for 3 passages until complete removal of feeder 
cells was achieved. Total RNA was extracted from 2 x 106 cells with Nucleospin 
RNA II kit (Macherey-Nagel, UK) and used for real-time RT-qPCR analysis as 
described in Section 3.3.2.3. The expression of pluripotency and early 
differentiation markers in i2PS cells was normalised to that in E14TG2a cells. 
Livak’s method was followed to analyse the data and dCt values were utilized for 
statistical analysis. Primer sequences are listed in Table S5.  
Whole-genome expression profiling by DNA Microarray. 1 µg RNA extracted 
from feeder-free E14TG2a and i2PS cells (n=3) as described above was used for 
DNA microarray analysis. Mouse WG-6 v2.0 Expression BeadChip array (Illumina) 
was used, which allowed the profiling of 45,200 transcripts. The array was 
performed by the staff at the Genome Centre, Queen Mary University of London 
(UK), which also assisted in data analysis.  GenomeStudio software and the 
National Center for Biotechnology Information (NCBI) database were used to 
interpret the results by gene clustering and pathway analysis. The data obtained 
from this study is deposited in the NCBI Gene Expression Omnibus (GEO), with 
accession number: GSE55996.  
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55996 
Response to 2i conditions. E14TG2a and i2PS cells (n=3) were cultured on 0.1% 
gelatin-coated vessels and maintained under standard ES conditions (DMEM/LIF 
medium) or on a dual-inhibition medium (KODMEM/LIF/2i), described elsewhere 
[119]. The detailed composition is listed in Table S4. In both conditions, medium 
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was changed daily and cells were passaged every other day. The effects of culture 
conditions on the expression of the pluripotency genes Nanog and Rex1 were 
studied by real-time RT-qPCR for up to 40 days after the start of the culture. 
Primer sequences are listed in Table S5. 
Immunocytochemistry (ICC) of i2PS cell colonies.  i2PS cell colonies  cultured on 
MEF feeder layers and DMEM/LIF conditions were fixed with methanol, pre-cooled 
at -20°C, for 10 min and processed for ICC using the same antibodies and protocol 
described in Section 3.3.2.3.  
CDy1 live staining. The compound of designation yellow 1(CDy1) that selectively 
stains live ES and iPS cells [181] was kindly provided by Dr. Young-Tae Chang 
(National University of Singapore and A*STAR Singapore), and used according to 
instructions provided. Briefly, i2PS cell colonies were cultured on MEF feeder 
layers and DMEM/LIF conditions. CDy1 dye was diluted to 0.1µM in the culture 
medium and the cells were incubated at 37°C and 5% CO2 for 1 h. After 3 washes 
and 2 h incubation (37°C, 5% CO2) with full medium free of the compound, live 
imaging was perfomed with an epi-fluorescence microscope (Zeiss Axio Observer). 
3.3.2.6. Pluripotency assays at the functional level. 
Generation and differentiation of embryoid bodies (EBs). Feeder-free i2PS 
cultures (DMEM/LIF conditions) were used to generate embryoid bodies (EBs) 
following a previous report [182]. In brief, i2PS cells were detached from the tissue 
culture vessel with 0.05% trypsin-EDTA and dissociated into a single cell 
suspension in EB medium (Table S4). 10,000 cells were seeded in each well of a 
1% agar-coated 96-well plate, maintained in EB medium culture conditions, which 
is free from LIF, and left to form EBs. After 3 days, the cell aggregates were 
transferred to 0.1% gelatin-coated culture dishes and left to differentiate 
spontaneously for 7 or 15 days when they were used for ICC and gene expression 
analysis, respectively. 
ICC of cells differentiated from EBs. After 7 days of spontaneous differentiation 
from EBs, cell cultures were processed for ICC following the protocol described in 
Section 3.3.2.3. As primary antibodies, rabbit pAb anti-beta-III-tubulin (ab76287, 
1/200, Abcam, UK), rabbit pAb anti-alpha 1-fetoprotein (N1501, ready to use, 
DAKO, UK) and mouse mAb anti-alpha smooth muscle actin (N1584, ready to use, 
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DAKO, UK)] were used.  As secondary antibodies, goat pAb anti-rabbit IgG labeled 
with Cy3 and goat pAb anti-mouse IgG labeled with Cy3 (1/250, Jackson 
ImmunoResearch Laboratories) were used.  
Real-time RT-qPCR gene expression analysis of cells differentiated from EBs. 
Total RNA was extracted from cultures left to differentiate for 15 days from the 
EBs (n=3). The starting i2PS cells used to generate the EBs and MEFs we included 
in the study as controls of pluripotent and differentiated cells, respectively.  Real-
time RT-qPCR was performed as described in Section 3.3.2.3 and the expression 
of pluripotency (Oct3/4, Nanog) and early differentiation markers (Afp, Fgf-5, T) 
was normalised to that of the starting of i2PS cells. Primer sequences are listed in 
Table S5. 
Teratoma assay.  Primary hepatocytes were isolated 2 days after HTV injection 
with 75 µg OKS and 75 µg M in 1.5 ml 0.9% saline or 1.5 ml 0.9% saline alone, as 
previously described. Feeder-free i2PS and E14TG2a cultures (DMEM/LIF 
conditions) were obtained as described before.  Female CD1 nude mice (n=5) were 
anaesthetised with isoflurane and implanted with 2 x 106 cells of the groups above 
suspended in DMEM medium. Primary hepatocytes were obtained from 3 mice and 
pooled prior to implantation. When i2PS or E14TG2a cells were implanted, a single 
independent line of each type was tested. The administration was subcutaneous 
(sc) in the dorsal flank and was done bifocally.  Tumours were left to develop for 5 
weeks and then dissected and fixed in 4% paraformaldehyde (PFA). Paraffin-
embedded tumour sections were stained with H&E and images were captured by 
light microscopy (10X). 
Chimera generation and genotyping. i2PS cells were cultured on MEF feeder 
layers and DMEM/LIF medium, or on 0.1% gelatin and KO-DMEM/2i/LIF 
conditions. At passage 13 (P13), i2PS cells were microinjected in embryos that 
were then surgically transferred to synchronized pseudopregnant CD1 surrogate 
mothers. 3.5 days post coitum (dpc) blastocysts from C57BL/6 background, 2.5 
dpc morulas from the same origin and 2.5 dpc morulas from BDF1 hybrids were 
used for different studies. The detailed conditions of each study including the 
number of i2PS cells injected per embryo and number of embryos injected are 
compiled in Table 3.1. Genotyping for the Major Histocompatibility Complex 
(MHC) Class I antigen was performed to assess the contribution of each 
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background when C57BL/6 embryos were used.  Primer sequences were designed 
to differentiate between H2-Kb (C57BL/6) and H2-Kd (BALB/c). When BDF1 
morulas were used, chimerism assessment relied on the differences in D19Mit59 
satellite DNA. Relevant primer sequences are listed in Table S5 and PCR 
conditions were as follows: 94°C for 3 min, 1 cycle; 94°C for 30sec, 58°C for 30sec,  
72°C  for 30sec– repeated for 32 cycles, 72°C  for 10 min. To visualize the 
differences in amplicon size, PCR products were resolved by agarose gel 
electrophoresis (1.2% agarose, 1X TBE, 70V). 
3.3.2.7. Investigation of transgene integration. 
PCR-based screening for genomic integration. Potential transgene integration 
in the i2PS cell genome was studied by a PCR-based method, modified from 
previous studies [107, 108]. In brief, genomic DNA (gDNA) was isolated from 2 x 
106 feeder-free i2PS (n=4) or E14TG2a cells (n=2), cultured in DMEM/LIF 
conditions, with PureLink Genomic DNA Kit (Life Technologies, UK). 0.2 µg gDNA 
were used for each PCR reaction. 11 sets of primers were used to amplify specific 
regions of OKS and M pDNA used to generate i2PS cells. Relevant sequences are 
listed in Table S6.  Samples were run on CFX-96 Real Time System (Bio-Rad, UK) 
with the following protocol: 92°C for 2 min- 1 cycle; 92°C for 20 s, 64°C for 20 s, 
72ºC for 40 s– repeated for 40 cycles, 72ºC for 3 min – 1 cycle. The PCR products 
were separated by agarose gel electrophoresis (0.7% agarose, 1X TBE, 90 V). OKS 
and M pDNA were included as positive controls for the presence of the transgenes 
and E14TG2a cells were used as positive control for the endogenous locus and 
negative for the transgene.  
Southern-blot based assessment of transgene integration. A Southern Blot 
protocol, modified from a previous study [183], was used to detect integration of 
OKS and M pDNA in the genome of i2PS cells. All Southern Blot related reagents 
were purchased from Roche, UK. Digoxigenin (DIG)-labelled probes against Oct4, 
Sox2, Klf4 and c-Myc were synthesized using PCR DIG Probe Synthesis Kit, by which 
DIG-11-dUTP was incorporated every 10–20 nucleotides. gDNA was obtained as 
described above and from the same samples (i2PS cells,  n=4; E14TG2a, n=2). 15µg 
gDNA were digested using EcoRI and BamHl restriction enzymes (2 h, 37°C), 
followed by deactivation of the restriction enzyme at 60°C for 15 min. Digested 
gDNA was separated in 0.8% agarose gel (1X TBE, 30V, 4 h), depurinated and 
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denatured prior to overnight transfer to a positively charged nylon membrane in 
high salt concentration solution (20X SSC). After transfer, gDNA bands were fixed 
to the membrane by UV light exposure for 3 min. The blot was pre-hybridised in 
DIG Easy Hyb buffer at 40°C for 30 min. The same buffer, pre-warmed at 40°C, was 
also used to prepare the hybridization solution containing 50 μl of DIG-labelled 
denatured probe in 25 ml buffer. After 12 h hybridisation at 40°C with continuous 
shaking, the membrane was washed first with low stringency buffer at RT, 
followed by high stringency buffer at 65°C. Finally, hybridised probes were 
detected via incubation with an anti-Digoxigenin-AP antibody (1 h, RT) and a 
colour substrate solution (NBT/BCIP in 1X detection buffer), overnight with 
shaking.  
3.3.3. Statistical analysis. 
N numbers were specified for each particular study. Statistical analysis was 
performed first by Levene’s test to assess homogeneity of variance. When no 
significant differences were found in the variances of the different groups, 
statistical analysis was continued by one-way ANOVA and Tukey's post-hoc test. 
When variances were unequal, the analysis was followed with Welch ANOVA and 
Games-Howell’s post-hoc test. Probability values <0.05 were regarded as 









3.3.1. In vivo reprogramming to pluripotency in mouse liver with different 
reprogramming pDNA vectors. 
Yilmazer et al. demonstrated rapid and transient induction of pluripotency 
and downregulation of hepatocyte-specific genes in BALB/c mouse liver via HTV 
administration of a combination of two reprogramming pDNA, OKS (encoding 
Oct3/4, Sox2, and Klf4) and M (encoding c-Myc) [162, 163]. Here, we aimed to 
confirm whether the same effect would be achieved with a different pDNA vector 
encoding all such factors in a single cassette. We also investigated if the exclusion 
of c-Myc from the reprogramming cocktail or the repeated administration of 
reprogramming pDNA would affect the changes observed in the tissue. Relevant 
pDNA maps are represented in Figure S1. 
3.3.1.1. Gene expression in mouse liver after HTV administration of different 
reprogramming pDNA. 
We first tested a polycistronic pLenti-III-EF1α-mYamanaka vector, referred 
to as OKSM, which encoded the four Yamanaka factors (Oct3/4, Sox2, Klf4 and c-
Myc) and a reporter eGFP under the control of the EF1α promoter. Transgenes 
were separated by 2A peptides to allow the expression of multiple products from a 
single cassette. We selected this pDNA because the presence of the eGFP reporter 
could facilitate the identification and isolation of the transfected cells. In addition, 
the use of a single cassette could reduce the chances of insertional mutagenesis in 
the host genome, since equivalent copy numbers of the transgenes are delivered in 
half the number of pDNA constructs. A dose escalation study in Yilmazer’s work  
identified the combination of 75 µg OKS and 75 µg M (equivalent to 8.17x1012 and 
1.14x1013 copies of each pDNA, respectively) as the lowest pDNA dose that 
triggered the highest reprogramming effect before a plateau was reached [162]. 
We compared the performance of an OKSM dose equivalent to the above OKS+M 
combination in transgene copies (150 μg OKSM, 9.58x1012 pDNA copies). BALB/c 
mice were injected with 75 µg OKS and 75 µg M, 150 μg OKSM or 0.9% saline 
alone as control. Injection volume was adjusted to 1.5 ml (10% of the body weight, 
approximately) and administered in 5 s in all the studies involving HTV injection, 
in order to achieve optimal transgene expression.  
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Real-time RT-qPCR data of the isolated hepatocyte fraction evidenced that 
the administration of similar transgene copy numbers, delivered in OKS+M or 
OKSM pDNA cassettes, resulted in similar expression of reprogramming factors. 
Such observation was made both 2 and 4 days after injection (Figure 3.1a) and a 
similar finding was obtained when comparing the expression of endogenous 
pluripotency genes (Figure 3.1b). Administration of the different cassettes led to 
very similar Nanog and Rex1 expression levels. 
In order to elucidate the longer-term changes in gene expression triggered 
by a single HTV administration of 150 μg OKSM, BALB/c mice were culled 2, 4, 8, 
12 and 24 days after injection. The expression of reprogramming, reporter, 
pluripotency and hepatocyte-specific genes was studied by real-time RT-qPCR in 
the isolated hepatocyte population. In agreement with the findings by Yilmazer et 
al. [162], the expression of reprogramming factors was at its highest 2 days after 
HTV injection and decreased over time. Sox2 and c-Myc levels were very low by day 
8 after injection when compared to saline-injected controls and c-Myc expression 
decreased to baseline levels by day 24, both when saline-injected or uninjected 
mice were included as control group  (Figure 3.2a). The reporter eGFP followed a 
similar trend, with a peak on day 2 that rapidly plummeted by day 4 and negligible 
expression 12 days after HTV injection (Figure 3.2b). Regarding the expression of 
endogenous pluripotency markers, Nanog and Rex1 were upregulated compared to 
the saline-injected group as early as 2 days after in vivo transfection (Figure 3.2c, 
top panel), indicating the fast kinetics of the pluripotent conversion. Notably, such 
upregulation was even more prominent when gene expression levels were 
compared to those of uninjected animals (Figure 3.2c, bottom panel). Finally, the 
study of hepatocyte-specific genes indicated a transient downregulation in the 
pDNA-injected group compared to saline-injected control on days 2 and 4 after 
injection, which was not observed at later time points (Figure 3.2d).   
Next, we investigated whether the exclusion of c-Myc from the 
reprogramming cocktail would affect the induction of pluripotency. c-Myc is a 
known oncogene and therefore its use in vivo may question the safety of this 
approach. Although reprogramming to pluripotency with Oct3/4, Sox2 and Klf4 
and without c-Myc has been achieved in vitro, decreased reprogramming 
efficiencies have been reported in the absence of this factor [56].  BALB/c mice 
were HTV injected with 75 μg OKS and 75 μg M, 75 μg OKS alone or 0.9% saline as 
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control. At day 4 after injection, the c-Myc-free reprogramming cocktail failed to 
achieve the same levels of Nanog and Rex1 upregulation triggered by the four-
factor combination (Figure 3.3b). The downregulation of hepatocyte-specific 
genes was only clearly achieved when all four factors were present. In the absence 
of c-Myc, only Aat showed minor downregulation 4 days after the injection, 
however significantly less prominent compared to the result in the OKS+M group. 
(Figure 3.3c).  
 
 
Figure 3. 1. Gene expression in mouse liver upon HTV administration of different 
reprogramming pDNA. BALB/c mice were HTV injected with 150 µg OKSM or 75 µg OKS and 75 µg 
M in 0.9% saline. A control group was injected with 0.9% saline alone. Primary hepatocytes were 
isolated on days 2 and 4 after injection and real-time RT-qPCR was conducted to determine the 
relative gene expression of (a) transfected reprogramming factors and (b) endogenous pluripotency 
genes. Gene expression was normalised to the saline-injected group. No statistically significant 
differences in gene expression were found between the groups injected with different reprogramming 





Figure 3. 2. Long-term gene expression changes in mouse liver after HTV administration of 
OKSM reprogramming pDNA. BALB/c mice were HTV injected with 0.9% saline alone,150 µg OKSM 
in 0.9% saline or left uninjected. Primary hepatocytes were isolated on days 2, 4, 8, 12 and 24 after 
injection and real-time RT-qPCR was performed to determine the relative gene expression of (a) 
transfected reprogramming factors, (b) eGFP reporter, (c) endogenous pluripotency genes and (d) 
hepatocyte-specific markers. Gene expression levels were normalised to the saline-injected group (top 
panels) or the uninjected control (bottom panels) with the exception of eGFP values, which were 
normalised to the expression 2 days after injection in the pDNA-injected group. *p<0.05 and 
***p<0.001 indicate statistically significant difference in eGFP expression compared to that of day 2 
after administration, assessed by one-way ANOVA and Tukey’s test. *p<0.05 and **p<0.01 indicate 
statistically significant differences in the upregulation of pluripotency markers and downregulation of 
hepatocyte-specific genes among treatment groups and time points, assessed by Welch ANOVA and 




Figure 3. 3. Contribution of the reprogramming factor c-Myc to the induction of pluripotency. 
BALB/c mice were HTV injected with 75 µg OKS and 75 µg M or 75 µg OKS alone in 0.9% saline. A 
control group was injected with 0.9% saline alone. Primary hepatocytes were isolated on days 2 and 4 
after injection and real-time RT-qPCR was performed to investigate the relative gene expression of (a) 
the transfected reprogramming factors, (b) endogenous pluripotency genes and (c) hepatocyte 
markers. Gene expression levels were normalised to the saline-injected group. *p<0.05 indicates 
statistically significant differences in the expression of pluripotency and hepatocyte markers in the 
presence or absence of c-Myc, assessed by one-way ANOVA. Data are presented as mean ± SD, n=3. 
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3.3.1.2. Protein expression in mouse liver upon HTV administration of 
different reprogramming pDNA. 
The expression of markers characteristic of the pluripotent state after HTV 
injection with different combinations of reprogramming pDNA, including OKSM, 
OKS+M, and OKS alone, was further investigated at the protein level. 
Immunostaining for different pluripotency markers (NANOG, SOX2, OCT4) and an 
ES cell-specific surface antigen (SSEA1) was performed on liver tissue sections 
collected 2 days after HTV injection. All markers investigated were reproducibly 
observed in several tissue sections from all pDNA-injected groups, indicating the 
presence of cells expressing proteins characteristic of the pluripotent state 
throughout the liver tissue (Figure 3.4). No immunoreactivity was detected in the 
saline-injected group. and no statistically significant differences in the number of 
positive cells were observed among the groups HTV-administered with different 
reprogramming pDNA 
Overall, these results showed that cells expressing pluripotency markers at 
the protein level appeared within the liver tissue when the single cassette OKSM, 
the combination OKS+M and even OKS alone were administered, without 
significant differences among the groups. However, since gene expression results 
were optimal when c-Myc was administered, we decided not to exclude this factor 





Figure 3. 4. Protein expression of pluripotency markers in mouse liver tissue upon HTV 
administration of different reprogramming pDNA. BALB/c mice (n=3) were HTV injected with 150 
µg OKSM, 75 µg OKS and 75 µg M or 75 µg OKS pDNA alone in 0.9% saline. A control group was 
administered with 0.9% saline alone. (a) Livers were collected 2 days after injection and 14 µm thick 
frozen tissue sections were stained with anti-NANOG, anti-SOX2, anti-OCT4 and anti-SSEA1 antibodies. 
The pattern was faithfully recapitulated in pDNA-injected mice compared to saline controls. 
Representative images were images were captured with an epi-fluorescence microscope (40X). Scale 
bar represents 50 μm. (b) Quantification of positive cells for each marker under investigation. No 
statistically significant differences in the number of positive cells were found across groups HTV-
administered with different reprogramming pDNA (one-way ANOVA, n=3 mice per condition, at least 
3 random fields/mouse). Data are presented as mean ± SD. 
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3.3.1.4. Repeated HTV administration of reprogramming pDNA: effects on the 
expression of reprogramming, pluripotency and hepatocyte-specific genes. 
The expression of the transfected reprogramming factors was consistently 
found at its highest levels on day 2 after HTV injection, regardless of the 
combination of pDNA used, to gradually decrease over time after this time point. 
Repeated HTV injection of pDNA has been shown to restore transgene expression 
back to peak levels in a previous study [168]. We investigated how repeated HTV 
administration of reprogramming pDNA would affect not only the expression of 
reprogramming factors but also the up- and downregulation of pluripotency and 
hepatocyte-specific markers, respectively. BALB/c mice were HTV injected with 75 
µg OKS and 75 µg M or 0.9% saline as control.  A cohort of animals from each 
group was culled 3 days after injection while the rest were administered a second 
dose of the same treatment and sacrificed 1 or 5 days after the second 
administration (i.e. 4 or 8 days after the first injection, respectively).  A diagram 
representing such administration schemes is provided in Figure 3.5a. 
One day after the second dose, the expression of the administered 
reprogramming factors experienced a significant rise (ca. 10-fold increase 
compared to the levels observed on day 3, just before the second injection). On day 
5 after the second administration (i.e. day 8 after the first dose) the expression 
levels decreased. However, they were still comparable to those reported on day 3 
after the first injection (Figure 3.5b). This confirmed that a second dose was able 
to restore transgene expression levels momentarily, however it failed to increase 
the expression of pluripotency markers (Figure 3.5c). In addition, no significant 
differences in the expression of hepatocyte-specific genes were observed 
throughout the course of the study (Figure 3.5d). These data suggested that no 
enhancement of the in vivo reprogramming outcomes at the mRNA level was 




Figure 3. 5. Gene expression in mouse liver after repeated HTV administration of 
reprogramming pDNA. (a) BALB/c mice were HTV injected with 75 µg OKS and 75µg M in 0.9% 
saline. A control group was injected with 0.9% saline alone. A cohort of animals from each group was 
culled on day 3 after injection while the remaining were administered a second dose of the 
corresponding treatment and culled 1 or 5 days after the second injection (4 or 8 days after the first 
dose). Real-time RT-qPCR analysis was performed to determine the relative gene expression of (b) 
transfected reprogramming factors, (c) endogenous pluripotency genes and (d) hepatocyte markers. 
Gene expression was normalised to the saline-injected group. *p<0.05 designates statistically 
significant differences in the expression of reprogramming factors between the first and second 
injection assessed by one-way ANOVA and Tukey’s test. Data are presented as mean ± SD, n=3. 
3.3.1.5. Effects of liver damage on the expression of reprogramming, 
pluripotency and hepatocyte-specific genes. 
Certain pluripotency-related genes are also involved in the process of 
hepatocyte regeneration, thus any liver insult can alter their expression [184]. 
Yilmazer et al. reported minor liver damage as a consequence of the HTV injection 
procedure, albeit only detected at the earliest time point (day 2) after injection and 
resolved immediately after [162]. We evaluated the effect of this transient damage 
in the expression of genes of interest for our study. These included the 
administered reprogramming factors (Oct3/4, Sox2 and c-Myc), since the 
corresponding endogenous loci are involved in pluripotency pathways, other 
pluripotency-related genes (Nanog, Ecat1, Rex1) and hepatocyte-specific genes 
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(Alb, Aat and Trf). BALB/c mice were HTV administered with 0.9% saline, without 
reprogramming pDNA. 2 days after injection, gene expression in the hepatocyte 
fraction was compared to that of uninjected animals.  
All pluripotency-related genes investigated were upregulated in the group 
that received the injection. For Oct3/4, Sox2, c-Myc, Nanog and Rex1 the differences 
were statistically significant. On the other hand, hepatocyte-specific genes such as 
Alb, Aat and Trf were significantly upregulated in the saline-injected group (Figure 
3.6). These changes in the gene expression profile of the hepatocytes are 
attributed to the minor damage inherent to HTV administration and the 
subsequent regeneration and proliferation of the liver cells and should be taken 
into account when interpreting the gene expression data in this study. 
 
Figure 3. 6. Effects of HTV injection on the expression of pluripotency and hepatocyte-specific 
genes. BALB/c mice were HTV injected with 0.9% saline and hepatocytes were isolated 2 days after 
injection. Real-time RT-qPCR was performed to determine the relative gene expression of (a) 
endogenous pluripotency genes that are also encoded in the reprogramming pDNA used in this study, 
(b) endogenous pluripotency genes not encoded in reprogramming pDNA and (c) hepatocyte-specific 
markers. Gene expression was normalised to a control uninjected group. *p<0.05 and **p<0.01 
indicate statistically significant differences in the expression of pluripotency and hepatocyte-specific 
genes between the injected and uninjected groups, assessed by one-way ANOVA. Data are presented as 
mean ± SD, n=3. 
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3.3.2. In vitro culture of in vivo reprogrammed liver cells: generation of i2PS 
cells, confirmation of pluripotency and study of genomic integrity. 
Once the changes in gene and protein expression in mouse liver were 
reproduced with various combinations of reprogramming pDNA, it was of our 
interest to confirm whether the cells enduring those changes were fully 
reprogrammed and functionally pluripotent. For this, we aimed to establish them 
as a stable cell line in vitro and used a mES cell line, E14TG2a, as benchmark of 
pluripotency for comparison.  
3.3.2.1. Generation of in vivo induced pluripotent stem (i2PS) cell colonies. 
Mouse embryonic fibroblasts (MEFs) secrete factors that help to maintain 
the pluripotency and undifferentiated state of stem cells. For this reason, 
mitotically inactivated MEFs are commonly used as feeder layers to support the 
growth of a variety of pluripotent stem cells, including ES and iPS cells  [180]. Here, 
MEFs were isolated from E12.5-14.5 CD1 embryos, mitotically inactivated with 
mitomycin C after three passages (Figure S2a), and used as feeder layers for the 
culture of E14TG2a cells and for the generation and culture of pluripotent cell 
colonies from in vivo reprogrammed cells. Figure S2b shows the characteristic 
morphology of E14TG2a cells when cultured on feeder layers, i.e. domed-shaped 
colonies with well-defined and refractive edges. Conversely, colonies of the same 
cell line cultured on 0.1% gelatin-coated culture vessels without the support of 
feeder cells exhibited a flatter shape, together with less clearly defined edges and 
the differentiation of some cells from their margins (Figure S2c). 
We took advantage of the eGFP reporter in the OKSM cassette to endeavour 
the sorting of cells transfected with reprogramming pDNA, candidate in vivo 
reprogrammed cells, by Fluorescence Activated Cell Sorting (FACS). However, due 
to the low cell numbers recovered from the sorting and the detrimental impact of 
the procedure in their viability, we were not able to maintain such cells in culture 
(data not shown). We next decided to culture the whole hepatocyte extract, which 
contains the in vivo reprogrammed cells, in an attempt to generate pluripotent 
stem cell colonies in vitro. 
Figure 3.7 illustrates the timeline for the generation of i2PS cell colonies 
from in vivo reprogrammed liver cells. BALB/c mice were HTV injected with 75 μg 
OKS and 75 μg M or 0.9% saline as control. 2 days later, the hepatocyte fraction 
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was isolated as previously described, seeded on MEF feeder layers and cultured 
under standard mES cell conditions (DMEM/LIF medium). Cells were passaged 1:2 
on fresh feeders after 10 days in culture and 2 days later colonies began to form 
that shared morphological features with mES cells (i.e. large nucleus and reduced 
cytoplasmic space, domed shape and refractive edges). Such colonies, which were 
only found in cultures originated from pDNA-injected mice but not from the saline 
control, were named in vivo induced pluripotent stem (i2PS) cells in reference to 
their origin [185]. Nonetheless, complete reprogramming to functional 
pluripotency had to be confirmed with further studies. In addition, the derivation 
of i2PS cells from in vivo reprogrammed livers proved very challenging. Only one 
out of approximately 20 pDNA-injected livers, processed in different experiments, 
gave rise to i2PS cell colonies when cultured under these conditions. 
 
Figure 3. 7. Generation of i2PS cell colonies from in vivo reprogrammed liver cells. BALB/c mice 
were HTV administered with 75 μg OKS and 75 μg M pDNA in 0.9% saline. Mice in the control group 
were injected with 0.9% saline alone. The hepatocyte fraction was isolated 2 days after injection, 
seeded on MEF feeder layers and cultured in DMEM/LIF medium. Cells were passaged (1:2) 10 days 
after the start of the culture and i2PS cell colonies were visible 2 days after passaging. Images of the 
cultures were taken with an optical microscope. Scale bars represent 100 µm (left picture, 10X) and 25 
µm (40X, right). This experiment was performed by Dr. Cyrill Bussy. 
3.3.2.2. Assessment of pluripotency at the molecular level. 
When a new iPS cell line is generated, pluripotency cannot be confirmed by 
their ES-like morphological appearance but has to be verified through exhaustive 
examination [119, 186].  Such confirmation was of special relevance in the case of 
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i2PS cells, being the first-ever reported iPS cell line generated in vivo. Our initial 
objective was to challenge the pluripotency of i2PS cells at the molecular level.  
Gene expression profile of i2PS cells in comparison to a standard mES cell 
line 
The gene expression signature of i2PS cells was compared to that of 
E14TG2a cells. Prior to RNA extraction, both cell lines were passaged 3 times on 
0.1% gelatin-coated tissue culture vessels in order to remove any remaining feeder 
cells that could interfere in the results (Figures 3.8a and b).   
Real-time RT-qPCR data evidenced the upregulation of a series of 
pluripotency genes in i2PS cells, compared to E14TG2a cells. For Nanog, Ecat1, 
Rex1, Cripto, endo-Sox2 and endo-Klf4 the difference was significant (Figure 3.8c) 
although in none of the cases was it higher than a 3-fold increase. Regarding the 
expression of early differentiation markers, Afp (endoderm) was 10-fold 
upregulated in i2PS cells, while Fgf-5 (ectoderm) and T (mesoderm) were 
downregulated compared to E14TG2a cells (Figure 3.8d).  
 
Figure 3. 8. Gene expression of key pluripotency and early differentiation markers in i2PS cells 
and a standard mES cell line. (a) E14TG2a mES and (b) i2PS cells were cultured on gelatin-coated 
tissue culture vessels (scale bars represent 100 μm). Total RNA was extracted from 2 x 106 cells and 
real-time RT-qPCR was performed to determine the relative gene expression of (c) pluripotency 
markers and (d) an early differentiation marker representing each of the three germ layers. Gene 
expression in i2PS cells was normalised to that of E14TG2a cells. *p<0.05, **p<0.01 and ***p<0.001 
indicate statistically significant differences in the expression of pluripotency and differentiation 
markers between both cell lines, assessed by one-way ANOVA. Data are presented as mean ± SD, n=3. 
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In order to further confirm the results obtained by real-time RT-qPCR and 
to build a whole-genome expression profile of the generated i2PS cells, a DNA 
microarray study was conducted. Out of the 45,200 probes analysed in the array, 
2,327 were differently expressed in i2PS compared to E14TG2a cells, however the 
expression of key genes related to pluripotency such as Nanog, Ecat1 and Rex1 was 
very similar in both cell lines (Figure 3.9a). In agreement with these observations, 
hierarchical clustering analysis of the different cell samples showed that i2PS and 
E14TG2a cells clustered relatively close to each other when the whole 
transcriptome was considered (Figure 3.9b).  
 
Figure 3. 9. Whole-genome expression profile of i2PS and E14TG2a mES cells. 1 μg RNA was 
extracted from feeder-free i2PS and E14TG2a cell cultures (n=3) and the global gene expression 
profiles of both cell types were compared by DNA microarray. Biological replicates of each cell type 
are numbered 1-3. (a) The scatter plot represents the expression of 45,200 probes in i2PS (Y axis) and 
E14TG2a cells (X axis). Each dot represents the logarithm of the average signal intensity of a probe. 
(b) Dendrogram representing the hierarchical clustering of the different cell samples. (c) Heatmap 
comparing the expression of 274 genes involved in the induction, maintenance, amelioration or loss of 
pluripotency. The array was performed by the staff at the Genome Centre, Queen Mary University of 
London (UK), who also assisted with the analysis of the data.  
Microarray data can be accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55996. 
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Once the global gene expression profile of both cell lines was compared, the 
focus of the study shifted to different sets of genes involved in specific pathways 
and developmental processes. In a comprehensive study, Som et al. unveiled a 
network of 574 molecular interactions, including activations and inhibitions, which 
are involved in the pluripotency pathway in the mouse. 274 genes were found to 
participate in the induction, maintenance, amelioration or loss of pluripotency 
[187]. The expression of these genes was found to be very similar in i2PS and 
E14TG2a cells, as illustrated in Figure 3.9c. 
Next, in order to identify whether the differentiation potential of i2PS cells 
was favoured towards a particular lineage, the expression of genes related to the 
early development of the endoderm (Figure 3.10a), mesoderm (Figure 3.10b) 
and ectoderm (Figure 3.10c) was investigated. These genes were clustered using 
the NCBI Biosystems Database and no remarkable differences in their expression 
were observed between cell lines.   
 
Figure 3. 10. Expression of genes involved in the early differentiation of the three germ layers. 
The expression of early differentiation markers was investigated in i2PS and E14TG2a mES cells (n=3) 
by DNA microarray. Biological replicates of each cell type are numbered 1-3. Heatmaps show clusters 
of (a) 123 genes involved in endoderm development, (b) 228 genes participating in mesoderm 
development and (c) 60 genes related to the ectoderm lineage. The array was performed by the staff 
at the Genome Centre, Queen Mary University of London (UK), who also assisted with the analysis of 
the data.  
Microarray data can be accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55996. 
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Finally, the possibility that a gene expression signature characteristic to the 
tissue of origin remained in i2PS cells was investigated. A set of 10 genes highly 
expressed at different stages of hepatocyte differentiation within the endoderm 
lineage were analysed. Afp and Foxa2 were selected as representatives of early 
endoderm, Alb and Cyp3a16 for fetal hepatocytes, Tat and G6pc for perinatal 
hepatocytes and Cyp3a11, Cyp3a25, Pck1 and Tdo2 for postnatal hepatocytes, as 
described in a previous work [178]. As shown in Figure 3.11, none of those genes 
were highly expressed in the E14TG2a control, nor in i2PS cells. 
 
Figure 3. 11. Expression of genes upregulated at different stages during hepatocyte 
differentiation. The heatmap represents the expression of markers characteristic of early endoderm 
development (Afp, Foxa2); fetal hepatocyte (Alb, Cyp3a16); perinatal hepatocyte (Tat, G6pc) and 
postnatal hepatocyte (Cyp3a11, Cyp3a25, Pck1, Tdo2) in E14TG2a mES and i2PS cells (n=3), analysed 
via DNA microarray. Biological replicates of each cell type are numbered 1-3. The array was 
performed by the staff at the Genome Centre, Queen Mary University of London (UK), who also assisted 
with the analysis of the data.   
(Microarray data can be accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55996) 
Overall, the results of the array suggested that the gene expression program 
of the reprogrammed hepatocytes had been shifted to recapitulate very closely 
that of pluripotent cells. However, the remaining of particular signatures of the 
tissue of origin upon reprogramming cannot be completely ruled out in the 
absence of ad hoc epigenetic studies and taking into account the 10-fold 
upregulation of Afp found via RT-qPCR (Figure 3.8). 
80 
 
Response of i2PS and mES cells to dual inhibition (2i) conditions 
The behaviour of reprogrammed cells upon exposure to defined molecular 
conditions present in the embryonic stages in natural development has been 
previously studied. The inhibitors GSK3 and Mek1/2 are known to neutralise 
differentiation signals and maintain the pluripotency and self-renewal capacity of 
ES cells. The presence of such molecules in the culture medium (known as dual 
inhibition or 2i conditions) can induce partially reprogrammed cells (i.e. not fully 
pluripotent) to a state of ground pluripotency. Upon exposure to 2i conditions, 
mRNA levels of key pluripotency genes such as Nanog and Rex1, barely detectable 
in the starting partially reprogrammed cells, were comparable to those of ES cells 
[119]. 
We aimed to explore the response of i2PS cells to 2i conditions compared to 
that of E14TG2a cells and to elucidate whether the expression of pluripotency 
markers had reached a plateau or could be upregulated any further. The cells were 
maintained on 0.1% gelatin-coated culture vessels and either standard mES cell 
culture conditions (DMEM/LIF) or 2i supplemented medium (KODMEM/2i/LIF). 
Nanog and Rex1 expression at different time points post-culture (pc) was 
compared to that of the starting cells by real-time RT-qPCR.   
Figure 3.12a shows the evolution of Nanog and Rex1 mRNA levels over 
time in i2PS cells cultured under DMEM/LIF conditions. 3 days after the start of the 
culture, a slight decrease in Nanog - but not Rex1- expression was detected 
compared to the starting cells. The expression of both genes increased significantly 
with the increased passaging of the cells, reaching baseline levels for Nanog and an 
approximate 10-fold upregulation over the starting cells’ levels for Rex1 by day 30 
pc. When i2PS cells were maintained under KODMEM/2i/LIF conditions (Figure 
3.12b) Nanog and Rex1 were upregulated from the earliest time point after the 
start of the culture (day 3). By the end of the culture (day 40) the upregulation of 
both genes did not surpass the 10-fold increase. 
No difficulties were found in maintaining the initial expression levels of 
pluripotency markers in E14TG2a cells, even at the earliest time points in 
DMEM/LIF cultures (Figure 3.12c). In fact, Nanog and Rex1 were significantly 
upregulated from day 5 pc, compared to the starting cells. Similarly to the response 
of i2PS cells in this medium, the expression of pluripotency markers increased with 
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passaging, showing significant differences between day 5 and day 10 pc. When 
exposed to 2i conditions, a remarkable 10-fold upregulation - for both Nanog and 
Rex1 -was found in E14TG2a cells as early as 2 days after the start of the cultures 
(Figure 3.12d). Once again, gene expression of the pluripotency markers continue 
to increase with increased passaging, this time reaching almost a 100-fold 
upregulation. Overall, these results indicated minor problems to maintain the 
expression of Nanog in i2PS cells cultured in DMEM/LIF, which were resolved with 
extended passaging. These data suggested as well that the expression of 
pluripotency markers could be further upregulated in both cell lines not only with 
increased passaging but also soon after the start of the cultures when exposed to 
2i. The pluripotency upregulation triggered by 2i exposure was more apparent in 
E14TG2a cells, which might be explained by the slightly but significantly lower 
expression of pluripotency genes in such cells compared to i2PS cells (Figure 
3.8c).  
 
Figure 3. 12. Response of i2PS and E14TG2a cells to 2i culture conditions. i2PS and E14TG2a cell 
colonies were cultured in DMEM/LIF or KODMEM/2i/LIF medium and the expression of pluripotency-
related genes was analysed by real-time RT-qPCR to evaluate the changes triggered by dual inhibition. 
(a) i2PS cells in DMEM/LIF, (b) i2PS cells in KODMEM/2i/LIF, (c) E14TG2a cells in DMEM/LIF, (d) 
E14TG2a cells in KODMEM/2i/LIF. Gene expression levels were normalised to those at the start of the 
culture (day 0). *p<0.05, **p<0.01 and ***p<0.001 indicate statistically significant differences in 
Nanog and Rex1 mRNA levels among the different time points, assessed by one-way ANOVA and 




Next, we investigated whether i2PS cell colonies expressed pluripotency 
markers at the protein level. Live staining with a pluripotency-specific dye, CDy1, 
was positive in colonies that also exhibited high AP activity (Figure 3.13a). 
Immunoreactivity for the pluripotency markers OCT3/4, SOX2 and NANOG and the 
ES cell marker SSEA1 was also observed (Figure 3.13b). Identical results were 
obtained in the stainings of E14TG2a cell colonies [185].  
 
Figure 3. 13. Expression of pluripotency markers at the protein level in i2PS cell colonies. (a) 
Live i2PS cell colonies cultured on MEFs feeder layers were stained with the pluripotency-specific 
fluorescent dye CDy1 and later fixed and stained with the BCIP/NBT substrate to detect AP activity. 
(b) Fixed i2PS cell colonies were stained with anti-OCT4, anti-SOX2, anti-NANOG and anti-
SSEA1antibodies. Images were acquired with optical (AP) and epi-fluorescence (CDy1, IHC) 




3.3.2.3. Assessment of pluripotency at the functional level. 
Once we confirmed that i2PS cells showed a gene and protein expression 
profile characteristic of the pluripotent state, there was a need to prove that such 
cells were functionally pluripotent and thus able to differentiate into cells from all 
three germ layers (endoderm, mesoderm and ectoderm). The differentiation 
potential of i2PS cells was tested in vitro and in vivo. 
In vitro study of functional pluripotency: embryoid bodies (EBs) 
When cultured on non-adherent surfaces, pluripotent cells form spherical 
aggregates in which cells start to differentiate. Given the resemblance with the 
gastrulating embryo, they are known as embryoid bodies (EBs). The presence in 
these aggregates of representatives of all three germ layers is considered an in 
vitro proof of functional pluripotency [182, 188, 189].  
Feeder-free i2PS cells cultured on DMEM/LIF conditions were dissociated 
and seeded on non-adherent surfaces (agar-coated 96-well plates). LIF was 
removed from the culture medium to allow the cells to differentiate spontaneously 
and form EBs. Loose aggregates formed as early as 1 day after seeding (Figure 
3.14a) and evolved into more compact spheroids after 3 days. The floating EBs 
were then transferred and left to attach onto gelatin-coated dishes in order to 
culture the cells differentiating and spreading out from their outer layers (Figure 
3.14b).   
 
Figure 3. 5.  Generation of EBs from i2PS cells and spontaneous differentiation in vitro. (a) i2PS 
cells formed compact EBs after 3 days culture on agar–coated surfaces and in the absence of LIF. (b) 
The aggregates were transferred to 0.1% gelatin-coated tissue culture dishes where cells 




mRNA levels of pluripotency and early differentiation markers were 
assessed by real-time RT-qPCR in cells left to differentiate for 15 days on the 
gelatin support. The levels were compared to that of the starting i2PS cells used to 
generate the EBs. Fibroblasts (MEFs) were also included in the study as a control 
for fully differentiated cells (ectoderm lineage). Figure 3.15a shows the 
expression levels of Afp (endoderm), T (mesoderm) and Fgf-5 (ectoderm). As 
expected, the ectodermal marker Fgf-5 was 100-fold upregulated in the control 
fibroblast compared to i2PS cells, whereas Afp and T were downregulated. The 
three markers were significantly upregulated in the cells originated from EBs, 
suggesting their differentiation towards all three lineages. Regarding the 
expression of two key pluripotency genes, MEFs showed a remarkable 
downregulation in both Nanog (104-fold) and Oct3/4 (ca. 106-fold), as predicted for 
terminally differentiated cells (Figure 3.15b). These markers were also 
significantly downregulated in the cells differentiated from EBs when compared to 
the starting i2PS cells; however the difference in gene expression was not as 
prominent (10-fold downregulation). This result was expected given that EBs 
consist of cells in the early stages of differentiation together with cells that still 
retain some degree of pluripotency. These findings were supported by findings in 
protein expression. IHC for early differentiation markers confirmed the presence 
among the cells originated from EBs, of representatives of endoderm (AFP), 
mesoderm (α-SMA) and ectoderm (β-III TUBULIN) lineages (Figure 3.15c).  All 
together, these results confirmed that i2PS cells behaved as pluripotent cells in the 




Figure 3. 15. In vitro assessment of pluripotency. mRNA levels of (a) early differentiation markers 
and (b) pluripotency genes were assessed by real-time RT-qPCR in cells left to differentiate 
spontaneously for 15 days from the EBs and in MEFs. Gene expression was normalised to the starting 
i2PS cells used to generate the EBs. **p<0.01 and ***p<0.001 indicate statistically significant 
differences in gene expression between the starting i2PS cells and the cells differentiated from EBs or 
the control fibroblasts (MEFs), assessed by one-way ANOVA. Data are presented as mean ± SD, n=3. (c) 
AFP (endoderm), α-SMA (mesoderm) and β-III TUBULIN (ectoderm) immunostaining on cells 
differentiated from EBs. Images were obtained with an epi-fluorescence microscope. Scale bar 
represents 50 μm. 
In vivo study of functional pluripotency: teratoma assay 
When subcutaneously (s.c.) injected in immunodeficient mice, fully 
pluripotent cells form teratomas containing tissues from all developmental origins. 
This is often used to validate the differentiation potential of candidate pluripotent 
cells in the in vivo scenario [186, 190]. 2x106 feeder-free i2PS cells were s.c. 
injected in the dorsal flank of CD1 nude mice. Equal numbers of E14TG2a cells 
were administered following the same procedure, as positive control for the 
generation of teratomas. Primary hepatocytes isolated 2 days after HTV injection 
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with 75 μg OKS and 75 μg M were also included in the study. This was aimed to 
test the differentiation potential held by the in vivo reprogrammed cells prior to 
any culturing procedure. 
Finally, hepatocytes isolated 2 days after HTV injection with 0.9% saline alone 
were included as negative control. After 5 weeks, all the animals (n=5) injected 
with i2PS or E14TG2a cells developed teratomas with the presence of tissues from 
all three germ layers (Figure 3.16). Most importantly, teratomas were also 
generated with a 100% efficiency upon implantation of primary cells directly 
extracted from mice administered with OKS+M (without any culturing), although 
their growth was generally slower than that of the i2PS and E14TG2a groups and 
the various tissue types present did not seem as differentiated. Primary 
hepatocytes from saline-injected animals failed to form tumours.  This result not 
only reaffirmed the functional pluripotency of the i2PS cell line but also 
demonstrated that the conversion to such state took place in the mouse liver and 
not as a result of the culture conditions, favourable to maintain pluripotent cells 
that were used to generate i2PS cell colonies.  
 
Figure 3. 16. In vivo assessment of pluripotency via teratoma formation in nude mice. 2 x 106 
hepatocytes extracted from n=3 mice 2 days after HTV injection with 0.9% saline or 75 μg OKS and 75 
μg M were pooled together and s.c. implanted in CD1 nude mice (n=5) to investigate their 
differentiation potential in vivo. The same number of i2PS and E14TG2a mES cells (from a single 
independent cell line of each type) were also injected following the same procedure. Tumours were 
dissected 5 weeks after injection and the presence of different tissue types was observed in H&E 
stained sections. All animals (n=5) injected with primary hepatocytes extracted upon pDNA 
administration, i2PS or E14TG2a cells developed tumours. No teratomas were formed in the animals 
injected with hepatocytes from saline-injected mice, but the site of implantation was also sectioned 
and analysed. Representative images were obtained with an optical microscope (10X). n=5  mice per 
condition. M, G, N, C, E and A indicate muscle, gland, neural, cartilage, epidermis and adipose tissue 
respectively. This experiment was performed with Dr. Acelya Yilmazer. 
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In vivo study of functional pluripotency: chimerism experiment 
Contribution to the adult tissues of chimeric mice is considered as one of 
the most stringent requisites for the confirmation of functional pluripotency [191]. 
Passage 13 (P13) i2PS cells were selected for embryo injections since we 
previously observed a significant increase in the upregulation of pluripotency 
markers with increased passaging, regardless of the culture conditions (Figure 
3.12). This agreed with previous studies in which extended passaging was 
reported to erase epigenetic memory and improve the overall differentiation 
potential of iPS cells [192]. 
We first attempted to generate chimeric mice with i2PS cell contribution by 
injecting these cells - originated from BALB/c liver cells - in 3.5 dpc blastocysts 
from C57BL/6 background. i2PS cells were either cultured on MEF feeder layers 
and DMEM/LIF conditions or on 0.1% gelatin-coated tissue culture vessels under 
2i conditions (KODMEM/2i/LIF) (Figure 3.17a). Upon fibroblast removal if 
required, i2PS cells were microinjected in C57BL/6 blastocysts, which were then 
surgically transferred to synchronized pseudopregnant CD1 surrogate mothers. 
Figure 3.17b illustrates the sequence of i2PS cell inoculation into the embryos 
with a microinjector.   
Blastocyst injection of i2PS cells cultured under 2i conditions failed to 
generate viable offspring. In contrast, 11 viable mice were obtained from i2PS cells 
cultured in DMEM/LIF-MEFs, although i2PS cell contribution could not be 
confirmed by the fur coat colour – as evidenced from the lack of white patches 
(Figure 3.17d). We then took advantage of the differences in the Major 
Histocompatibility Complex (MHC) Class I haplotype between mice strains (H2-Kb 
for C57BL/6 and H2-Kd for BALB/c mice) to genotype the adult offspring.  Two of 
the mice – identified as no. 7 and 8 - were positive for both haplotypes, which 
confirmed the co-existence of C57BL/6 and BALB/c derived cells (Figure 3.17c). 
Next, i2PS cell contribution to various tissues of different developmental origin was 
investigated (Figure 3.17e). As expected, no i2PS cell contribution was observed in 
mice no. 5 and 6, which had shown pure C57BL/6 genotype in the previous study. 
Interestingly, chimerism was widespread in all tissues examined in mice no. 7 and 
8. Very importantly, these mice reached adulthood, were sacrificed at 6 months of 
age and no teratomas were observed in any of the organs upon necropsy. 
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The next step was to test the contribution of i2PS cells to the germline. Mice 
no. 7 and 8 were mated with pure BALB/c background partners. Although we had 
confirmed i2PS cell contribution to the gonads (Figure 3.17e), no pure BALB/c 
genotypes were obtained in the first generation (F1, data not shown) and thus 
germline transmission remained to be demonstrated. 
Driven by the low chimera generation efficiency achieved via blastocyst 
injection, we repeated the experiment injecting i2PS cells in embryos at the morula 
stage (2.5 dpc). Given the lower number of host’s cells present in the morula as 
compared to the blastocyst, we hypothesised that i2PS cell contribution to the adult 
organism would be favoured. In spite of the larger number of surrogate mothers 
implanted (Table 3.1), a first round of injections of i2PS cells (DMEM/LIF-MEFs) in 
C57BL/6 morulas yielded only 2 viable mice. None of them showed H2-Kd 
genotype that confirmed i2PS cell contribution (Figure 3.18a). The same 
procedure was repeated with i2PS cells (KODMEM/2i/LIF-gelatin) in BDF1 
morulas. Genotyping for the MHC Class I antigen could not be used since this strain 
shares the H2-Kd haplotype with BALB/c mice. The satellite DNA D19Mit59 was 
therefore selected given its different size in the two strains [193]. As in the 
previous attempt, the viable offspring was very limited in numbers and the 





Figure 3. 17. i2PS cell contribution to adult tissues of mice generated via blastocyst injection. 
(a) i2PS cell colonies were cultured under DMEM/LIF-MEFs or KODMEM/2i/LIF-gelatin conditions. 
Scale bar represents 50 μm. (b) i2PS cells were microinjected in C57BL/6 embryos at the blastocyst 
stage (3.5 dpc). (c) Genotype of the MHC Class I antigen in mice  generated from the injection of i2PS 
cells cultured under DMEM/LIF-MEFs conditions (H2-Kb – C57BL/6 and H2-Kd – BALB/c). (d) Images 
of mouse 7 and 8, which showed i2PS cell contribution as indicated by the presence of the H2-Kd gene, 
but not evidenced in the fur coat colour. (e) Contribution of i2PS cells to adult tissues of different 
developmental origins investigated by MHC Class I haplotype genotyping. Embryo injections and 





Figure 3. 18. i2PS cell contribution in adult mice obtained via morula injection. (a) i2PS cells 
cultured under DMEM/LIF-MEFs conditions were microinjected in C57BL/6 morulas (2.5 dpc) and 
transplanted to surrogate mothers. i2PS contribution to the offspring was assessed via MHC Class I 
antigen genotype. (b) i2PS cells cultured under KODMEM/2i/LIF-gelatin conditions were 
microinjected in BDF1 morulas (2.5 dpc) and transplanted to surrogate mothers. i2PS contribution to 
the offspring was assessed via  D19Mit59  satellite DNA genotype. Embryo injections and surrogate 
mother implantation were performed by the staff at the Transgenic Facility, University of Manchester 
(UK). 
A summary of the conditions and results obtained in the various chimerism 
experiments described here can be found on Table 3.1.  In spite of the low 
efficiency and poor offspring viability in the generation of chimeras, this study 
proved that i2PS cells are fully functionally pluripotent in the in vivo scenario that 
















DMEM/LIF MEFs P13 5-8  22 
(blastocyst) 
C57BL/6 
2 11 2 
KODMEM/2i/LIF 
Gelatin 
P13 15-20 46 
(blastocyst) 
C57BL/6 
3 0 0 
DMEM/LIF MEFs P13 5-8 65 (morula) 
C57BL/6 
4 2 0 
KODMEM/2i/LIF 
Gelatin 
P13 5-8 135 (morula) 
BDF1 
7 4 0 




3.3.2.4. Investigation of transgene integration. 
Transgene integration in the genome is one of the main concerns 
surrounding the generation of iPS cells, since disruptions in the host’s genome 
(insertional mutagenesis) or the permanent integration of oncogenic 
reprogramming factors can trigger tumourigenesis [194]. The use of naked pDNA 
does not involve as high a risk of genomic integration as other reprogramming 
technologies, one of the most problematic being the use of retroviral vectors [120]. 
However, occasional integration of the pDNA cassette or regions of it may still 
occur and has indeed been reported by others [107, 108, 183].  It was therefore 
our aim to investigate the integrity of the genome of i2PS cells with a focus on 
pDNA integration.  
PCR-based study of genomic integration 
Genomic DNA (gDNA) was extracted from i2PS cells and a set of specific 
primers was used to amplify 11 distinct regions of the reprogramming pDNA used 
in their generation (OKS+M). The location of such regions in the pDNA cassettes is 
shown in Figure 3.19a. A mixture of OKS+M pDNA was included as positive 
control to detect the presence of the transgenes, while gDNA extracted from 
E14TG2a cells was used as positive control for the amplification of the endogenous 
loci and negative control for the transgenes. PCR products were run in an agarose 
gel and differences in size were used to discern between transgenes and 
endogenous loci, when these existed. Signs of genomic integration were only found 
for c-Myc transgene in one out of four i2PS samples screened, as deduced from the 
appearance of a band the same size as that of the pDNA control (Figure 3.19b). 
Integration of other pDNA regions investigated in this study was not suggested 




Figure 3. 19. PCR screening of pDNA integration in the genome.  (a) Location of the 11 regions 
amplified in OKS and M pDNA cassettes to assess their integration in the genome; (b) A mixture of 
OKS+M was included as positive control for the presence of the transgenes, while gDNA from E14TG2a 
mES cells (n=2) was included as negative control for the transgene and positive for the endogenous 
loci.  i2PS cell gDNA (n=4) was amplified in independent PCR reactions for the specified regions and the 
products were separated by agarose gel electrophoresis.  When primers amplified both the 
endogenous locus and the transgene, open arrowheads indicate bands corresponding to the 
endogenous locus while closed arrowheads indicate bands derived from the transgene. Biological 
replicates are numbered 1-2 for E14TG2a and 1-4 for i2PS cells. 
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Southern Blot study of genomic integration 
To confirm the above observations, gDNA from i2PS cells was analysed by 
Southern Blot using digoxigenin (DIG)-labelled probes against Oct3/4, Sox2, Klf4 
and c-Myc. As in the previous study, gDNA from E14TG2a cells was used to identify 
the hybridisation with the endogenous genes while a mixture of OKS+M pDNA 
served to detect the bands corresponding to the transgenes.  As expected, 
endogenous genes were detected in all i2PS cell clones screened. No signs of 
integration were detected when Oct3/4 and Sox2 probes were investigated 
(Figure 3.20a and b), but bands corresponding to the Klf4 transgene were found 
in 2 of the samples tested (Figure 3.20c). In agreement with the PCR study, one of 
the i2PS cell samples suggested c-Myc integration (Figure 3.20d). 
 
Figure 3. 20. Southern blot investigation of pDNA integration. gDNA extracted from E14TG2a 
(n=2) and i2PS (n=4) cells was digested with EcoRI and BamHI restriction enzymes. A mixture of OKS 
and M pDNA was used as control. (a) Location of probes and restriction sites in the pDNA cassettes. (E, 
EcoRI; B, BamHI). DIG-labelled probes were used to detect the integration of (b) Oct3/4, (c) Sox2, (d) 
Klf4 and (e) c-Myc. Closed arrowheads indicate bands derived from the transgenes, while open 
arrowheads indicate bands corresponding to the endogenous genes. Arrows indicate non-specific 





In spite of the numerous laboratories now dedicated to the cell 
reprogramming field, the vast majority of research has focused on reprogramming 
cells in the culture dish. It was not until 2012 that the first report of somatic cells 
reprogrammed to pluripotency in vivo was published by Vivien et al. using an 
amphibian model (pre-metamorphic tadpoles) [161]. The only report to date of in 
vivo reprogramming to pluripotency in an adult, mammalian, non-genetically 
modified organism (WT BALB/c mice) was published by Yilmazer et al. one year 
later [162, 163]. These two studies utilised the same reprogramming technology 
(naked pDNA) and, even if in very different organisms, obtained very similar 
findings. These included the efficient expression of reprogramming factors in the 
tissue upon administration of the reprogramming pDNA, which decreased over 
time, and the upregulation of otherwise repressed pluripotency genes while in the 
absence of teratoma formation. The greatest significance of both reports lays not 
only in the demonstration that somatic cells can be reprogrammed to pluripotency 
within live tissues - in spite of the pro-differentiation signals present in the in vivo 
microenvironment -  but also in the fact that the pluripotent conversion was 
transient. These very relevant observations were confirmed in the present chapter.  
In Yilmazer’s work, liver cell reprogramming towards pluripotency was not 
only evidenced by the upregulation of pluripotency-related genes but also by the 
downregulation of hepatocyte-specific markers. Both changes occurred fast and 
transiently after injection and were induced via HTV administration of a 
combination of two reprogramming pDNA, OKS+M, encoding all four Yamanaka 
factors but with c-Myc in a separate cassette. We demonstrated here that the same 
gene expression changes were induced by the administration of similar transgene 
copy numbers in a single polycystronic vector encoding all factors in the same 
cassette, OKSM (Figure 3.1). A 24-day long gene expression study following HTV 
administration of this pDNA confirmed Yilmazer’s previous observations that the 
shift of the gene expression profile towards pluripotency was sustained for less 
than a week after injection (Figure 3.2). The observations at the mRNA level 
agreed with the expression of the protein. Cells expressing pluripotency markers 
were detected within the liver tissue 2 days after injection, regardless of the pDNA 
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vector used (Figure 3.4), but could not be observed any later than day 4 (data not 
shown). 
In fact, all the studies presented in this chapter, involving different 
combinations of reprogramming pDNA and administration schemes, came to 
reaffirm the fast kinetics and short duration of the pluripotency induction (Figures 
3.2, 3.4 and 3.5). We attribute this finding to the non-sustained expression of 
reprogramming factors provided by the use of a minimally integrative vector 
(pDNA) (Figures 3.2, 3.19 and 3.20) and the fact that the reprogrammed cells 
reside within the liver microenvironment, where they are exposed to pro-
differentiation signals. We also propose that the transient duration of the 
pluripotency induction together with the fact that only a small percentage of cells 
are reprogrammed to pluripotency (5-15% of the total hepatocyte population 
[162]), account for the absence of tumourigenesis in the reprogrammed tissues in 
both Vivien’s and Yilmazer’s reports [161, 162]. Although we did not perform here 
a systematic histological study to assess the appearance of teratomas, none of the 
mice included in the long term study in this chapter (Figure 3.2) showed signs of 
disease or weight loss, nor did we find any visible tumour mass or dysplastic lesion 
when the liver tissues were dissected and processed for the different studies. We 
recorded no deaths prior to the conclusion of the study. 
Two more recent reports by Abad et al. [195] and Ohnishi et al. [196] have 
not only confirmed the feasibility to reprogram cells to pluripotency in vivo, but 
also reinforced the hypotheses above. Unlike Vivien’s, and Yilmazer’s studies (and 
its continuation, presented here), which relied on a single administration of naked 
pDNA targeted to a particular tissue, Abad and Ohnishi used a genetically modified 
(GM) “reprogrammable” mouse strain in which the Yamanaka factors were 
inserted in the genome and their expression was induced upon the administration 
of doxycycline [195, 196]. While the use of naked pDNA that minimally integrated 
in the genome (Figures 3.19 and 3.20) resulted in expression of reprogramming 
factors that decreased over time (Figures 3.2 and 3.5), this GM model allowed to 
sustain the expression of Yamanaka factors for as long as the drug was 
administered. In addition, the expression of such factors was widespread in the 
organism of the mice, due to the ubiquitous presence of the genetic modification. 
Like ours, both studies using the reprogrammable mouse confirmed the 
correlation of the expression of pluripotency markers with the loss of cell-type 
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specific markers in the reprogrammed tissues. However, this event resulted, in 
their studies, in the emergence of teratomas. Prolonged administration of 
doxycycline triggered widespread tumourigenesis and high mortality among in 
vivo reprogrammed mice in both reports. Importantly, Abad et al observed that 
higher doses of the drug administered for shorter periods of time generated 
significantly less teratomas than the administration of lower doses for longer 
periods, indicating that the duration of the OKSM expression might be more 
relevant for the fate of the reprogrammed cells than the expression levels 
themselves [195]. In agreement with this observation, Ohnishi et al reported that 
when the expression of reprogramming factors was switched off via doxycycline 
withdrawal after 5 days, no dysplastic lesions were observed in many of the mice. 
When doxycycline was withdrawn at even slightly later time points (day 7), the 
dysplastic lesions reverted to normal phenotype - the cells entered proliferation 
but did not progress to carcinogenesis – and were integrated in the tissue 
preserving their normal function [196].  
The most relevant conclusion inferred from all in vivo reprogramming to 
pluripotency studies reported so far is thus the correlation between the duration 
of the expression of reprogramming factors (and hence the pluripotent 
conversion) with the appearance of teratomas [161, 162, 195, 196]. We have 
proposed that opposite de-differentiation signals (from the expression of 
reprogramming factors) and pro-differentiation signals (provided by the 
microenvironment) coexist in vivo. When the expression of reprogramming factors 
is not sustained over time, the tissue microenvironment might rapidly drive the re-
differentiation of the pluripotent intermediates preventing teratoma formation 
[164]. Whatever the mechanisms behind, the above observations position the 
transient pluripotent conversion achieved by administration of naked 
reprogramming pDNA in a favoured position to progress towards clinical 
translation.  
We have provided here other valuable information regarding the induction 
of pluripotency in mouse liver via HTV administration of reprogramming pDNA. 
The capacity to induce such cell fate conversion without the oncogenic c-Myc could 
facilitate its clinical translation [53]. Previous in vitro studies reported slower and 
less efficient iPS cell generation when c-Myc was not present [56]. In agreement 
with those reports, our results showed that lower expression of pluripotency 
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markers (Figure 3.3b) and higher mRNA levels of hepatocyte-specific genes were 
obtained when reprogramming was induced in the absence of c-Myc (Figure 3.3c). 
However, this did not prevent the expression of proteins characteristic of the 
pluripotent state in cells within the liver tissue (Figure 3.4). Especially because we 
lacked a quantitative study of protein expression, we preferred to maintain all 
factors in the reprogramming cocktail for the rest of the studies, based on the 
better gene expression results and to ensure maximum reprogramming effect. 
Nevertheless, the induction of pluripotency in vivo without c-Myc should be 
explored further as this technology advances towards the clinical scenario. 
Repeated HTV administration of reprogramming pDNA was also tested to confirm 
whether a higher upregulation of pluripotency markers and downregulation of 
tissue specific genes could be achieved in the mouse liver. As anticipated from a 
previous study [168], a second HTV administration of pDNA was able to restore 
the decreasing expression of reprogramming factors (Figure 3.5a). However, this 
did not trigger any differences in the expression of pluripotency and hepatocyte-
specific genes compared to the single injection protocol (Figures 3.5b and 3.5c). 
We decided to administer the second pDNA dose 3 days after the first injection, 
since at this point the liver has started to recover from the damage derived from 
the first administration (according to the observations by Yilmazer et al. [162] and 
others [168]) and transgene expression has started to decrease but not yet 
plummeted. Considering our lack of success in enhancing the reprogramming 
effect with this protocol, other time frames for the second HTV injection could be 
considered in the future.  
We noticed that the mRNA values of the pluripotency markers Nanog and 
Rex1 were - in some, but not all experiments - relatively elevated in the saline-
injected controls when analysed 2 days after injection. This masked the 
upregulation of such genes in the pDNA-injected groups after normalisation (for 
examples of this see, Figure 3.1b, day 2 data). Nanog and Rex1 were in fact 
significantly upregulated when we compared hepatocyte gene expression in saline-
injected animals to uninjected controls (Figure 3.6b). Other pluripotency-related 
genes, including those encoded in the reprogramming pDNA, were also 
upregulated (Figure 3.6a). However, the mRNA values detected in the saline 
group were not as high as those of Nanog and Rex1, which can explain why their 
expression in pDNA-injected groups was never masked. We attributed these effects 
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to the mild liver damage inherent to HTV administration, which is known to peak 
on day 2 after injection, precisely the time point when we found expression of 
pluripotency-related genes in the controls, and is resolved rapidly afterwards [162, 
168]. In fact, increased expression of several pluripotency markers, including 
Nanog and Rex1, as a result of liver insult had been reported by others and 
attributed to their roles in hepatocyte proliferation and regeneration after injury 
[184]. On the other hand, we found no downregulation of hepatocyte-specific 
markers – a characteristic finding reproducibly observed upon in vivo 
reprogramming to pluripotency - as a consequence of the injection (Figure 3.6c). 
Aat and Trf were in fact significantly upregulated compared to the uninjected 
controls, which might be a consequence of the hepatocyte proliferation after the 
mild injury. Importantly, these results confirmed that the expression of 
pluripotency genes triggered by the HTV injection procedure is most likely linked 
to regeneration mechanisms and definitely not to genuine reprogramming, and did 
not lead to de-differentiation of the cells. The variability in the expression of 
pluripotency genes in the saline controls in different experiments might be due to 
technical differences in the execution of the HTV injection, even though volume 
and time of injection were kept constant precisely to minimise such problem. 
These results were very relevant to confirm that the reprogramming effect 
observed in the tissue upon HTV administration of reprogramming pDNA was 
genuinely credited to the transfected Yamanaka factors.   
Changes in the gene expression profile of the tissue, together with the 
identification of cells expressing pluripotency markers (Figure 3.4), suggested the 
presence of in vivo reprogrammed cells within the liver tissue in the pDNA-injected 
groups. However, those findings were not enough to proof whether such cells had 
been fully reprogrammed into bona fide pluripotent cells. We demonstrated here 
that in vivo reprogrammed cells are functionally pluripotent and able to 
differentiate into representatives of all three lineages in different scenarios.  
The pluripotency of i2PS cells, generated from the culture of whole 
hepatocyte extracts from OKS+M-injected mice, was anticipated by their capacity 
to self-renew and proliferate in colonies morphologically very similar to those of 
E14TG2a mES cells (Figures 3.8a and 3.8b). Importantly, we have provided here 
several pieces of evidence, generated in different studies, which prove that such 
cells originated from genuine reprogramming and not as a result of cross-
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contamination with the mES cells handled in our laboratory (E14TG2A). First, their 
genome-wide gene expression profile was clearly distinguishable when 
hierarchical cluster analysis was performed (Figure 3.9b). Secondly, the BALB/c 
origin of i2PS cells was confirmed by the presence of the H2-Kd haplotype in the 
chimeric mice obtained via blastocyst injection (Figure 3.17), which differed from 
that of E14TG2A cells (129/Ola mice background, H2-Kb haplotype). Finally, the 
fact that Klf4 and c-Myc transgenes were integrated in some of the i2PS cell 
samples analysed also confirmed their reprogrammed cell origin (Figures 3.19 
and 3.20). In addition, since such colonies did not appear in the cultures from 
saline-injected mice, their generation was attributed to the presence of in vivo 
reprogrammed cells in the hepatocyte extract of the pDNA-injected animals and 
not to the effects of the in vitro culture conditions (i.e. presence of LIF to sustain 
pluripotency) (Figure 3.7). It was also confirmed that i2PS cells share numerous 
similarities at the molecular level with other pluripotent cells. Similar expression 
of pluripotency markers to that of E14TG2a cells was evidenced at the mRNA level 
by real-time RT-qPCR (Figure 3.8) and DNA microarray (Figure 3.9c), and at the 
protein level by IHC (Figure 3.13).  Even the whole transcriptome of the two cell 
lines was considerably similar (Figure 3.9a-b), in spite of their very different 
origin:  i2PS cells were generated from in vivo reprogrammed BALB/c mice 
hepatocytes, whereas E14TG12a cells were derived from the ICM of 129/Ola 
mouse blastocysts. Microarray analysis of the expression of 123 genes involved in 
endoderm development and 10 genes specific to hepatocyte differentiation did not 
suggest any significant differences between the two cell lines (Figures 3.10 and 
3.11), although real-time RT-qPCR analysis did determined a 10-fold upregulation 
of the endoderm-specific marker Afp in i2PS compared to E14TG2a cells (Figure 
3.8d). These findings suggested that in parallel with the acquisition of a gene 
expression profile characteristic of the undifferentiated pluripotent state, the gene 
expression signature of the hepatocyte had been lost to a certain extent. Together 
with the fact that genes involved in ectoderm and mesoderm development showed 
also very similar expression to that found E14TG2a cells (Figure 3.10), these 
observations suggested that i2PS cells would have the potential to differentiate 
towards any of the three developmental lineages. However, whether such cells still 
retain epigenetic memory from the tissue of origin which could drive preferential 
differentiation towards endoderm lineages remains to be determined. 
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Nevertheless, the tri-lineage potential of i2PS cells was confirmed at the functional 
level when such cells were left to differentiate spontaneously- without the aid of 
any growth factor – and generated cells and tissues from all three germ layers. 
Such finding held both in the in vitro – embryoid bodies assay (Figure 3.15) - and 
in vivo setting – teratoma assay (Figure 3.16) and generation of chimeras (Figure 
3.17). 
Of particular relevance was the observation that in vivo reprogrammed cells 
generated teratomas containing tissues from all three germ layers, not only when 
cultured as i2PS cells but also when directly isolated from the liver and without 
undergoing any in vitro culturing. On the one hand, this ruled out the possibility 
that the cells had been partially reprogrammed in vivo but only acquired functional 
pluripotency features thanks to the components of the culture medium, which 
were tailored to support pluripotency (i.e. presence of LIF). In addition, the fact 
that in vivo reprogrammed cells were able to form teratomas when transplanted to 
a different host contrasted with Yilmazer’s findings related to the absence of 
tumourigenesis when such cells were left to reside in their native 
microenvironment (i.e. liver), even for prolonged periods of time (120 days). This 
different behaviour might be explained by the pro-differentiation signals in the 
tissue microenvironment that, as we have hypothetised before [164], would be 
able to drive the re-differentiation of the cells to an appropriate phenotype. More 
studies will however be necessary to further elucidate the prevailing mechanisms, 
interactions and cues present in the in vivo microenvironment that might govern 
this process. In addition, it should be noted that nude mice were used for the 
teratoma assay. Future work will have to address the role of the immune system 
towards the in vivo reprogrammed cells. 
The modest results in the generation of chimeric mice from BALB/c i2PS 
cells (Table 3.1) agreed with previous studies reporting the many challenges to 
first derive mES cells from BALB/c blastocysts and then generate chimeric mice 
with them. The efficiency of chimera generation achieved with this background 
was significantly lower as compared to that from other mice strains and BALB/c 
contribution to the fur coat and germline of such chimeras was also very poor 
[197-199]. Many factors other than the genetic background of the mice can also 
dramatically influence the generation of chimeras and might have posed an effect 
in our experiments. Among them, technical aspects of the microinjection [200], 
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culturing conditions[201], chromosomal abnormalities [202, 203], length of the 
telomeres [204] and epigenetic signatures present in the injected cells [199] play a 
crucial role and should be thoroughly investigated for i2PS cells if higher efficiency 
and BALB/c contribution were sought. Nevertheless, and although transmission to 
the germline remains to be demonstrated, the widespread contribution of  i2PS 
cells to numerous tissues of diverse developmental origin in the adult chimeric 
mice (Figure 3.17e) further proved the functional pluripotency of i2PS cells and 
the lack of predisposition to differentiate into a particular lineage in detriment of 
the others.  
Further relevant observations related to the full pluripotent character of 
i2PS cells were that (a) they did not need to be exposed to 2i conditions in order to 
generate chimeras and (b) the expression of pluripotency genes such as Nanog and 
Rex1 was comparable – even slightly upregulated – to that of mES cells and did not 
increase dramatically upon exposure to such dual inhibition (Figures 3.8c and 
3.15-a-b). In the opposite scenario, other reports have shown that partially 
reprogrammed cells expressed very low mRNA levels of Nanog and Rex1 and had 
to be exposed to 2i conditions for at least 10 days before the expression of such 
genes reached levels comparable to mES and the cells acquired the differentiation 
potential required to participate in the adult tissues of murine chimeras [119]. In 
spite of this very positive indications, more specific studies such as the 
investigation of the re-activation of the X-chromosome and the mono- or bi-allelic 
expression of Nanog should be carried out to fully confirm that i2PS cells have 
reach what has been denominated as “ground-state pluripotency” [205], which 
falls beyond the scope of this thesis. 
None of the two chimeric mice or their progeny obtained in this study 
suffered from the development of tumours, as opposed to what has been described 
by others and attributed to the occurrence of insertional mutagenesis or the 
reactivation of c-Myc [53]. This outcome was therefore interpreted as a sign that 
not major genomic integration of the transgenes occurred in i2PS cells. However, 
and especially taking into account the very limited number of chimeric mice 
obtained, this was not enough proof of the genomic integrity of i2PS cells. 
Transfection with pDNA does not present as high a risk of insertional mutagenesis 
as other technologies such as the use of retroviral vectors, but there is still a 
possibility of genomic integration of the transgenes or regions of the pDNA 
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cassettes and hence we planned specific experiments to investigate this possibility 
[206]. We confirmed minor integration of two of the transgenes (Klf4 and c-Myc) 
by two different techniques (PCR and Southern Blot) (Figures 3.19 and 3.20), 
although 2 out of 4 i2PS cell samples screened were absolutely free from 
transgenes. Other studies employing the same pDNA cassettes to reprogram 
somatic cells in vitro have however shown a much higher degree of integration. 
Okita et al reported variable occurrence of such event depending on the 
transfection protocol used [107], the most efficient providing only 3 out of 15 
integration-free clones. Remarkably, this protocol relied in the repeated 
transfection (4 times) of somatic cells with reprogramming pDNA [108]. Another 
study involving liposomal magnetofection with the same pDNA vectors accelerated 
and increased the efficiency of the pluripotent conversion, even reducing the 
number of transfection rounds required (2 transfections). However, only 2 out of 
the 7 iPS cell lines investigated were integration-free [183]. The lower degree of 
pDNA integration reported in our study might be due to the fact that a single in 
vivo transfection was needed to generate i2PS cells. Although, this data should still 
be taken into consideration and non-integrating vectors should be designed if 
therapeutic interventions based in this approach are to be sought, it is also to 
mention that the culture protocol used to generate i2PS cell might have selected 
and expanded the in vivo reprogrammed bearing higher degrees of integration. We 
have not investigated the genomic integrity of in vivo reprogrammed cells directly 
extracted from the tissue, mainly due to the challenges to sort this population from 
the rest of the cells in the liver. However, it could be possible that the proportion of 
cells showing integration of the pDNA in their genome was lower than among i2PS 
cells. Yilmazer’s observations regarding the absence of teratoma formation in the 
liver upon in vivo reprogramming [162] and our findings in the decrease of the 
expression of reprogramming factors over time after injection (Figure 3.2) 
support the hypothesis that the integration of the transgenes in vivo was marginal.  
Overall, the studies presented in this Chapter confirmed that somatic cells 
can be reprogrammed to functional pluripotency in vivo, in spite of the pro-
differentiation signals present in the tissue, and that transient expression of 
reprogramming factors is crucial to prevent the pluripotent conversion from 
generating teratomas. Functional pluripotency was acquired in vivo, and not as a 
result of favourable culture conditions. Finally, the establishment of the in vivo 
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reprogrammed cells as a cell line in vitro allowed their direct comparison to a 
standard mES cell line, hence providing further information on their molecular 
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4.1. Scope of Chapter IV. 
In the previous Chapter, we explored the reprogramming of mouse liver 
cells to pluripotency in vivo via forced expression of Yamanaka factors. Following 
from a previous work [162], we confirmed that the pluripotent conversion 
happened rapidly and  transiently - which precluded the generation of teratomas – 
and was manifested in the tissue by the upregulation of pluripotency markers and 
downregulation of tissue-specific genes. We confirmed that the reprogrammed 
cells formed colonies of self-renewing pluripotent cells (i2PS cells) when cultured 
in vitro although, more importantly, functional pluripotency was already acquired 
in the in vivo microenvironment.  
The combination of the four Yamanaka factors has been postulated as a 
virtually universal reprogramming cocktail, able to return a diverse range of 
differentiated cell types to the pluripotent state when transfected in vitro [60, 62, 
207]. In this Chapter, we first sought to confirm whether such findings also hold 
when the pluripotent conversion takes place in vivo. With this aim, we tried to 
reproduce in vivo reprogramming to pluripotency in a tissue originated from a 
developmental lineage (mesoderm) entirely different from that of liver 
(endoderm), and in which pDNA can be efficiently expressed, such as the skeletal 
muscle. Secondly, we aimed to further investigate the fate of the reprogrammed 
cells in vivo in order to understand whether they would be able to reintegrate into 
the tissue or on the contrary, would not survive in a microenvironment which is 
not designed to support pluripotent cells.  
4.2. Introduction. 
We have previously hypothesised that reprogramming any somatic cell to 
pluripotency in vivo might be achievable provided that we are able to efficiently 
deliver the Yamanaka reprograming factors to the target tissue and cells [164]. The 
myofibers populating the skeletal muscle constitute a convenient target for gene 
delivery and its applications for a number of reasons. First, myofibers have been 
shown to spontaneously uptake naked pDNA [208]. In this particular tissue, such 
process has proven more efficient than the use of viral vectors to deliver nucleic 
acid cargos, with the added benefit of a significantly safer profile [209].  The exact 
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mechanism by which naked pDNA can enter myofibers has not yet been fully 
disclosed, however suggested hypotheses include an active uptake mechanism 
[210] and the use of the T tubule system [211]. Whatever the mechanism of 
uptake, the work led by John Wolff and colleagues in the early 90s showed that 
moderately high - albeit variable - levels of foreign gene expression can be 
achieved in muscle cells after intramuscular (i.m.) administration of pDNA [208]. 
In addition, the post-mitotic status of the myofibers provides a platform for stable 
transgene expression, even when a minimally integrating method such as naked 
pDNA is employed [212]. This has prompted the i.m. administration of pDNA in 
gene therapy strategies against muscle-related ailments and in DNA vaccinations. 
Overall, such tissue peculiarities make the skeletal muscle a favorable target to be 
transfected with reprogramming pDNA in vivo. 
On the other hand and from the developmental and architectural point of 
view, the skeletal muscle is a very distinct tissue in the mammalian organism. The 
process of myogenesis is finely orchestrated by a series of changes in the 
expression of defined regulatory factors, as illustrated in Figure 4.1. In prenatal 
development, myogenesis starts when Pax3+Pax7+ myogenic progenitor cells 
initiate the expression of muscle determination factors (Myf5, MyoD, Mrf4, Mef2c) 
and commit to the myogenic lineage. The resulting cells, still undifferentiated, are 
known as myoblasts and eventually exit the cell cycle and fuse to each other 
forming syncytial myotubes. In such cells, which express Mhy1 and Myog, the 
multiple nuclei are aligned in the centralised position. Finally, the mature myofiber 
is characterised by the migration of the nuclei to the periphery of the cells [213-
215]. A very similar series of events takes place during postnatal growth and 
muscle regeneration after injury. In such scenarios, satellite cells – muscle specific 
stem cells that reside underneath the basal lamina adjacent to the myofiber and 
are normally quiescent – proliferate and differentiate into myoblasts which 
eventually fuse to and enlarge the existing myofibers in postnatal growth and are 
also able to form de novo fibers after injury [216, 217].  
Precisely the lack of cell division and the presence of various nuclei in a 
single cell, position the myofibers as a more challenging cell type to reprogram in 
comparison to the more commonly used fibroblasts or the primary hepatocytes 
discussed in Chapter III. While myoblasts have been reprogrammed to 
pluripotency in vitro by forced expression of Yamanaka factors, generating iPS cells 
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[218], there is to our knowledge no proof that such cell fate conversion can be 
achieved in fully differentiated myofibers.  
 
 
Figure 4. 1. Main cellular and gene expression events involved in myogenesis. During normal 
development (pre- or postnatal) or as a part of a regenerative response to injury in the adult, muscle 
progenitors proliferate to then commit to the myogenic lineage as myoblasts, which exit the cell cycle 
and fuse into multinucleated myotubes. In fully differentiated mature myofibers, nuclei migrate to the 
periphery of the cell, while the satellite cells relocate underneath the adjacent basal lamina. This 
process is finely orchestrated by changes in gene expression illustrated here. 
Overall, we attempted here to achieve in vivo reprogramming to 
pluripotency in a different tissue that, although favorable in terms of exogenous 
gene expression, may be biologically more challenging to induce to the pluripotent 
state.  
4.3. Materials and methods. 
4.3.1. Materials used in Chapter IV. 
4.3.1.1. Plasmid (pDNA) vectors.  
Reprogramming pDNA pCX-OKS-2A (OKS, encoding Oct3/4, Klf4, Sox2), pCX-cMyc 
(M, encoding cMyc) and pLenti-lll-EF1α-mYamanaka (OKSM, encoding Oct3/4, 
Klf4, Sox2, cMyc and eGFP) were used in this study. A more detailed description of 
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the cassettes is provided in Chapter III, Section 3.3.1.1. pDNA maps are 
illustrated in Figure S1. 
4.3.1.2. Mouse strains.  
Female mice were used in this work that entered the procedures at 7 weeks of age, 
unless otherwise specified. BALB/c mice were purchased from Harlan, UK. 
C57BL/6 mice were obtained from Charles-River, UK. For the muscle 
reprogramming experiments in juvenile mice, a pregnant C57BL/6 mouse was 
obtained from the in house breeding facility at the University of Manchester. 
Juvenile mice entered the procedure 2 weeks after birth.  
Sv129-Tg(Nanog-GFP) mice, which carry the eGFP reporter inserted into the 
Nanog locus [219], were a kind gift from the Wellcome Trust Centre for Stem Cell 
Research, University of Cambridge (UK) and bred and genotyped at the University 
of Manchester. This strain is also reported in the literature as TNG-A (Targeted 
Nanog GFP clone A), however for simplicity it will be referred to as Nanog-GFP in 
this thesis.   
CBA-Tg(Pax3-GFP), in which eGFP replaces the Pax3 coding sequence of exon 
1[220], were kindly provided by Professor Giulio Cossu at the Faculty of Medical 
and Human Sciences, University of Manchester (UK). They will be referred to as 
Pax3-GFP for simplicity. 
All experiments were performed with previous approval from the UK Home Office 
under a project license PPL 70/7763 and after allowing the mice to acclimatise to 
the facilities for one week. 
4.3.2. Methodology involved in Chapter IV. 
4.3.2.1. Intramuscular (i.m.) administration of reprogramming pDNA vectors. 
Mice were anesthetised with isofluorane and the left gastrocnemius (GA) muscle 
was i.m. injected with 50 µg OKSM, 50 µg OKS and 50 µg M, or 50 µg OKS alone in 
0.9% saline.  Since it has been reported that larger volumes of injection favour 
higher and less variable gene expression levels upon i.m. administration of pDNA 
[221], injection volume was fixed to 50 μl, which corresponds to the maximum 
recommended for i.m. administration in mice. The contralateral (right) GA muscle 
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was injected with 50 μl 0.9% saline solution alone and used as internal control. In 
the studies were the internal control received no injection (intact muscle), this has 
been clearly stated. Mice were culled at different time points, including 2, 4, 8, 12, 
24, 50 and 120 days after i.m. injection, as specified in each particular study. 
4.3.2.2. RNA extraction and real-time Reverse-Transcription quantitative 
Polymerase Chain Reaction (RT-qPCR) analysis.  
Aurum Fatty and Fibrous Kit (Bio-rad, UK) was used to isolate total RNA from 
whole GA muscles. RNA quantity and quality was assessed by UV 
spectrophotometry (BioPhotometer, Eppendorf, UK). cDNA synthesis from 1 µg of 
RNA sample was performed with iScript cDNA synthesis kit (Bio-Rad, UK) 
according to manufacturer’s instructions. 2 µl of cDNA sample were used for each 
real-time qPCR reaction, performed with iQ SYBR Green Supermix (Bio-Rad, UK). 
Experimental duplicates of each sample were included and run on CFX-96 Real 
Time System (Bio-Rad, UK) with the following protocol: 95°C for 3 min, 1 cycle; 
95°C for 10 sec, 60°C for 30 sec, – repeated for 40 cycles. β-actin was used as 
housekeeping gene and gene expression levels were normalised to saline-injected 
controls, unless otherwise specified. Livak’s method was followed to analyse the 
data and dCt values were utilized for statistical analysis. Primer sequences used in 
this Chapter are listed in Table S7.   
4.3.2.3. Preparation of muscle frozen sections for histological examinations. 
GA muscles were dissected from the hind limb and immediately immersed into 
isopentane, pre-cooled in liquid nitrogen, for 20 s. Frozen muscles were stored at -
80°C until further processing. 10 μm thick transverse sections were prepared on a 
Cryostat (Leica Microsystems, CM3050S) with the chamber temperature set at -
24°C. Muscle tissue sections were air-dried for 1 h at RT and stored at -80°C until 
H&E, IHC or Tunel staining were performed. 
4.3.2.4. Haematoxylin and Eosin (H&E) staining. 
10 μm thick frozen sections obtained as described in Section 4.3.2.3 were warmed 
at RT and H&E staining was performed following a standard protocol in an 
automated tissue stainer (Shandon Varistain 24-4). 
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4.3.2.5. Characterisation (IHC) of GFP+ cell clusters in Nanog-GFP and Pax3-
GFP muscle tissue sections.  
Nanog-GFP (n=3) and Pax3-GFP (n=2) mice were i.m. administered in the left GA 
with 50 μl OKS and 50 μl M in 50 μl 0.9% saline. The right GA muscle was 
administered with the same volume of 0.9% saline, as control. Mice were sacrificed 
2 or 4 days after injection and their GA muscles were processed as detailed in 
Section 4.3.2.3. To observe the GFP signal generated by Nanog or Pax3 expression, 
tissue sections were mounted with ProLong® Gold anti-fade DAPI containing 
mountant (Life Technologies, UK) after fixation with methanol (pre-cooled at -
20°C, 10 min) and imaged with 3D Histech Pannoramic 250 Flash slide scanner 
and Panoramic Viewer Software (100X). To investigate co-localisation of the GFP 
signal with the expression of different markers, tissue sections were processed for 
IHC.  In brief, muscle sections were post-fixed with methanol (pre-cooled at -20°C, 
10 min), air-dried for 15 min and finally washed twice with PBS for 5 min. Sections 
were then incubated for 1 h in blocking buffer (5% goat serum-0.1% Triton in PBS 
pH 7.3) at RT, followed by two washing steps with PBS (1 %BSA- 0.1% Triton, pH 
7.3) and overnight incubation at +4°C with the primary antibody: Rabbit pAb anti-
OCT4 (ab19857,3 µg/ml, Abcam, UK), rabbit pAb anti-NANOG (ab80892, 1 µg/ml, 
Abcam, UK), rabbit pAb anti-AP (ab95462, 1:200, Abcam, UK), mouse mAb anti-
SSEA1 (ab16285, 20 µg/ml, Abcam, UK), rabbit pAb anti-Pax7 (pab0435, 1:200, 
Covalab, France), and rabbit mAb anti-PDGFrβ (#3169, 1:100, Cell Signalling).  
Anti-PDGFrβ were a kind gift from Prof. Cossu’s lab (University of Manchester). 
The next day, sections were washed (2 min each) with PBS and incubated (1.5 h, 
RT) with the secondary antibody: goat pAb anti-rabbit IgG labeled with Cy3 or goat 
pAb anti-mouse IgG labeled with Cy5 (1/250, Jackson ImmunoResearch 
Laboratories). After two washes in PBS (5 min each), sections were mounted with 
ProLong® Gold anti-fade DAPI containing mountant (Life Technologies, UK). 100X 
images were obtained with a Leica TCS SP5 AOBS inverted confocal microscope.  
4.3.2.6. BrdU labelling and detection of proliferating cells. 
5-Bromo-2’-deoxyuridine (BrdU) assay was used to label proliferating cells in vivo, 
as previously described[222]. BALB/c mice (n=3) were intraperitoneally (i.p.) 
administered with 500mg/kg BrdU (B5002, Sigma, UK) in 1 ml 0.9% saline 18 h 
after i.m. injection with 50 μg OKSM or saline control. 6 h later, GA muscles were 
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dissected and processed for IHC as described in Section 4.3.2.5. Treatment with 2 
N HCl (10 min at 37°C) after fixation of the sections was included to denature the 
DNA. Mouse mAb anti-BrdU (B8434, 1:100, Sigma, UK) and goat pAb anti-mouse 
IgG labeled with Cy5 (1/250, Jackson ImmunoResearch Laboratories) were used. 
100X images were captured with a Leica TCS SP5 AOBS inverted confocal 
microscope. 
4.3.2.7. Histological and morphometric evaluation of muscle tissue after i.m. 
administration of reprogramming pDNA.  
The GA muscles of BALB/c mice (n=3) were dissected on days 2, 4, 8, 15, 50 and 
120 after i.m. injection with 50 μg OKSM or 50 μl 0.9% saline (control) and 
processed for H&E staining following the procedures in Sections 4.3.2.3 and 
4.3.2.4. Tissue sections were imaged with a 3D Histech Pannoramic 250 Flash 
slide scanner and representative images at 40X and 100X magnification were 
taken with Pannoramic Viewer software. The number of nuclei/mm2 was counted 
with Histoquant Software in 12 sections per muscle and we observed 3 muscles 
per condition and time point. The minimum myofiber diameter and number of 
myofibers/cross-sectional area were analysed from 5 sections per muscle (3 
muscles per condition and time point), with ImageJ 1.48 software. 
4.3.2.8. TUNEL staining.  
The GA muscles of BALB/c mice (n=3) were i.m. administered with 50 μg OKSM or 
50 μl 0.9% saline (control) and dissected 2, 4 and 8 days after injection. 10 µm 
thick frozen tissue sections were obtained as detailed in Section 4.3.2.3 and 
stained with DeadEnd Colorimetric TUNEL Assay kit (Promega, G7130, UK) 
according to manufacturer’s specifications. In brief, sections were fixed with 4% 
PFA for 15 min at RT and permeabilised with Proteinase K (20µg/ml, 15 min, 
37°C). Tissue sections were then incubated with TUNEL reaction mixture 
containing recombinant terminal deoxynucleotidyl transferase (rTdT) and 
biotinylated nucleotide (1 h, 37°C). After several washes in 20X SSC and PBS, slides 
were blocked with 0.3% hydrogen peroxide in PBS for 5 min and incubated with 
horseradish peroxidise-labelled streptavidin (Streptavidin-HRP) antibody diluted 
1:500 in PBS. Reaction with diaminobenzidine (DAB) was observed by light 
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microscopy (Leica, UK) and representative images were taken at 40X 
magnification. 
4.3.2.9. Desmin/laminin/DAPI staining.  
The GA muscles of BALB/c mice (n=3) were dissected on days 2, 4, 8, 15, 50 and 
120 after i.m. injection with 50 μg OKSM or 50 μl 0.9% saline (control) and 
processed for IHC staining following the procedures in Sections 4.3.2.3 and 
4.3.2.5. Rabbit pAb anti-laminin (ab11575, 1:200, Abcam, UK) and mouse mAb 
anti-desmin (ab6322, 1:200, Abcam, UK) were used as primary antibodies. Goat 
pAb anti-rabbit IgG labeled with Cy3 and goat pAb anti-mouse IgG labeled with Cy5 
(1/250, Jackson ImmunoResearch Laboratories Inc) were used as secondary 
antibodies. 40X images were obtained with a Zeiss Axio Observer epi-Fluorescence 
microscope. 
4.3.3. Statistical analysis. 
N numbers were specified for each particular study. Statistical analysis was 
performed first by Levene’s test to assess homogeneity of variance. When no 
significant differences were found in the variances of the different groups, 
statistical analysis was continued by one-way ANOVA and Tukey's post-hoc test. 
When variances were unequal, the analysis was followed with Welch ANOVA and 
Games-Howell’s post-hoc test. Probability values <0.05 were regarded as 








4.4.1. Gene expression in mouse skeletal muscle after i.m. administration of 
reprogramming pDNA. 
C57BL/6 mice were i.m. administered in the left GA muscle with either 50 
μg OKSM (Figure 4.2a) or 50 μg OKS and 50 μg M (Figure 4.3a) reprogramming 
pDNA. The contralateral GA muscle was injected with 0.9% saline alone, as internal 
control. It has been reported that larger volumes of injection favour higher and less 
variable transgene expression levels upon i.m. administration of pDNA [221]. 
Hence, injection volume was fixed to 50 μl in all the studies on adult mice in this 
Chapter, which corresponds to the maximum recommended for i.m. administration 
in mice. Gene expression was studied in GA muscles dissected 2 days after 
injection and similar results were obtained, regardless of the combination of 
reprogramming pDNA used. In brief, successful expression of the transgenes 
encoded in the reprogramming pDNA (Figures 4.2b and 4.3b) was accompanied 
by the upregulation of endogenous pluripotency markers (Figures 4.2c and 4.3c). 
Next, the expression of three markers, each of them related to a different stage 
during myogenesis, was investigated (Figures 4.2d and 4.3d). A 10-fold 
upregulation of Pax3 - which is distinctly expressed in myogenic progenitors but 
downregulated with differentiation [223] - was found in the groups i.m. 
administered with reprogramming pDNA, compared to the saline controls. On the 
contrary, the committed myoblast marker MyoD was downregulated upon 
injection of any of the reprogramming pDNA combinations. Finally, mRNA levels of 
Myh1, a marker of differentiated myofibers [213], did not show significant 





Figure 4. 2. Gene expression in C57BL/6 mouse skeletal muscle after i.m. administration of 
OKSM reprogramming pDNA.  (a) C57BL/6 mice were i.m. injected in the GA muscle with 50µg 
OKSM in 50 μl 0.9% saline or 50 μl 0.9% saline alone. GA muscles were dissected 2 days after injection 
and real-time RT-qPCR was performed to determine the relative gene expression of (b) 
reprogramming factors, (c) endogenous pluripotency markers and (d) genes involved in myogenesis. 
Gene expression levels were normalised to the saline-injected controls. **p<0.01 indicates statistically 
significant differences in gene expression between pDNA and saline-injected groups, assessed by one-
way ANOVA. Data are presented as mean ± SD, n=3. 
Overall - and similar to our observations in liver tissue - the expression of 
otherwise repressed pluripotency genes (Nanog, Ecat1, Rex1) and of a muscle early 
progenitor marker (Pax3), together with the downregulation of a marker 
characteristic of a later stage in myogenesis (MyoD), suggested the de-
differentiation of a subset of cells in the injected GA muscle. Interestingly, the same 
changes in gene expression were observed when the study was reproduced on a 
different WT mouse strain (BALB/c mice, Figure S3) confirming the 




Figure 4. 3. Gene expression in C57BL/6 mouse skeletal muscle after i.m. administration of OKS 
and M reprogramming pDNA. (a) C57BL/6 mice were i.m. injected with 50µg OKS and 50 μg M in 50 
μl 0.9% saline or 50 μl 0.9% saline alone. GA muscles were dissected 2 days after injection and real-
time RT-qPCR was performed to determine the relative gene expression of (b) reprogramming factors, 
(c) endogenous pluripotency markers and (d) genes involved in myogenesis. Gene expression levels 
were normalised to the saline-injected group. Data are presented as mean ± SD, n=3. 
Next, in order to interrogate whether the minor trauma provoked by the 
i.m. injection itself had any effect on the expression of the genes of interest, mRNA 
levels of pluripotency and myogenesis-related genes were compared in saline-
injected and uninjected GA muscles. Expression of the reprogramming factors 
encoded in the pDNA used in the study, Oct3/4, Sox2 and c-Myc, was also 
investigated because the endogenous genes have roles in pluripotency. Figure 4.4 
shows that no significant differences in the expression of such genes were 
observed between the two groups. This diverged from what we observed in the 
hepatocyte gene expression profile after HTV administration with saline solution, 
where both pluripotency and hepatocyte-specific markers appeared upregulated 
(Chapter III, Figure 3.7). These differences are most probably due to the fact that 
the injury caused upon HTV injection, albeit still mild, is more severe than that 
produced by i.m. administration; thus expected to trigger a more apparent 





Figure 4. 4. Effects of i.m. injection on the expression of reprogramming, pluripotency and 
myogenesis-related genes. (a) C57BL/6 mice were i.m. injected in the GA muscle with 50 µl 0.9% 
saline or left uninjected. GA muscles were dissected 2 days after injection and real-time RT-qPCR was 
performed to determine the relative gene expression of (b) reprogramming factors, (c) endogenous 
pluripotency genes and (d) genes involved in myogenesis. Gene expression levels were normalised to 
the uninjected (intact) group. Data are presented as mean ± SD, n=3. 
4.4.2. Gene expression in juvenile mouse skeletal muscle after i.m. 
administration of reprogramming pDNA. 
It was also of our interest to determine whether i.m. injection of 
reprogramming pDNA in younger animals would provide different outcomes at the 
gene expression level. We chose to repeat the study in 2-week-old C57BL/6 mice 
since at this post-natal stage highest levels of transgene expression after i.m. 
administration of naked pDNA have previously been achieved [224]. In addition, 
the observation that progenitor cells are more amenable to reprogramming than 
their differentiated counterparts – shown for several cell types [225-227], 
including muscle cells [228] - together with the fact that the percentage of such 
cells is significantly larger soon after birth [229], suggested that a higher 
reprogramming effect could be achieved in juvenile mice. We administered the 
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same doses as in previous experiments (50 μg) of either OKSM or OKS+M in the 
GA muscle of 2-week-old C57BL/6 mice, although injection volume was reduced in 
accordance to the smaller size of the hind limb muscles, and studied gene 
expression 2 days after injection. 
 
Figure 4. 5. Gene expression in juvenile mouse skeletal muscle after i.m. administration of 
OKSM reprogramming pDNA.  (a) 2-week-old C57BL/6 mice were i.m. injected in the GA muscle with 
50µg OKSM in 20 μl 0.9% saline or 20 μl 0.9% saline alone. 2 days after injection, real-time RT-qPCR 
was performed to determine the relative gene expression of reprogramming factors, pluripotency 
markers and genes involved in myogenesis in (b) GA and (c) biceps muscles. Gene expression levels 
were normalised to saline-injected controls. Data are presented as mean ± SD, n=3. 
When OKSM was administered, Oct3/4 and eGFP transgenes encoded in the 
vector were successfully expressed in the GA muscle (Figure 4.5b), however the 
mRNA levels were ca. 10-fold lower than those achieved in adult mice (Figure 
4.2b). In addition, although the same trend was observed in the expression of 
pluripotency and muscle-specific genes, we did not observe any enhancement in 
the upregulation of Nanog and Pax3, nor in the downregulation of MyoD compared 
to the adult counterparts. Similar results were obtained with the administration of 
OKS and M, although in this case we could not even confirm the upregulation of 




Figure 4. 6. Gene expression in juvenile mouse skeletal muscle after i.m. administration of OKS 
and M reprogramming pDNA.  (a) 2-week-old C57BL/6 mice were i.m. injected in the GA muscle 
with 50µg OKS and 50 μg M in 40 μl 0.9% saline or 40 μl 0.9% saline alone. 2 days after injection, real-
time RT-qPCR was performed to determine the relative gene expression of reprogramming factors, 
pluripotency markers and genes involved in myogenesis in (b) GA and (c) biceps muscles. Gene 
expression levels were normalised to saline-injected controls. Data are presented as mean ± SD, n=3. 
We then decided to analyse the expression of the same genes in the biceps 
muscle. We hypothesised that given the large injection volume for the small GA 
muscle of the juveniles, albeit reduced compared to that of our studies on adult 
mice, a significant part of the dose could have infused the biceps muscle instead. 
However, the expression of the transgenes encoded in the pDNA was even lower 
than that achieved in the GA muscle, especially 20μl OKSM were administered, and 
the levels of Nanog, Pax3 and MyoD did not show any significant differences with 
the saline injected-controls that resembled our previous observations in adult 
mice (Figures 4.5c and 4.6c). In conclusion and due to causes yet unidentified, 
our studies did not support previously published work that pointed at higher 
pDNA expression efficiencies in juvenile mice [224]. Consequently, we did not 
observe an enhancement in the efficiency of reprogramming. These observations 
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will merit ad hoc studies to determine the effects of age in the efficiency of pDNA 
expression and in vivo reprogramming. 
4.4.3. Gene expression in mouse skeletal muscle after i.m. administration of 
reprogramming pDNA in the absence of c-Myc. 
Given the oncogenic nature of c-Myc, we next investigated whether this 
reprogramming factor was strictly necessary to induce comparable changes in 
gene expression to those obtained with all four Yamanaka factors. To gather more 
information regarding the effects on myogenesis-related genes, expression of the 
myoblast marker Myf5 and of Myog, expressed by myotubes and mature myofibers, 
was also studied.  BALB/c mice were i.m. injected in the GA muscle with 50 μg OKS 
in 50 μl 0.9% saline or the same volume of 0.9% saline alone, as control (Figure 
4.7a). When the expression of endogenous pluripotency markers Nanog, Ecat1 and 
Rex1 was investigated 2 days after injection, ca. 10-fold upregulation was observed 
in the tissues administered with reprogramming pDNA compared to saline-
injected controls (Figure 4.7c). Regarding the expression of muscle-specific genes, 
Pax3 was also 10-fold upregulated, while the myoblast markers MyoD and Myf5 
appeared downregulated (Figure 4.7d). The expression of all such genes was 
therefore in the same order of magnitude as that observed when all four factors 
were administered, both in this (BALB/c, Figure S3) and a different mouse strain 
(C57BL/6, Figures 4.2 and 4.3). Only the markers associated to the myotube and 
mature myofiber – Myog and Myh1 - showed a marginal increase in their mRNA 
levels compared to the studies with the complete reprogramming cocktail. We did 
not find this result relevant, considering the expression of the rest of the genes 
investigated.  
These findings were even more encouraging than what we observed in liver 
tissue where, although we detected protein expression of pluripotency markers, 
we could not reproduce the same mRNA levels of pluripotency and hepatocyte-
specific genes in the absence of c-Myc (Figures 3.3 and 3.4). Although this might 
mean that such factor is dispensable to induce pluripotency in the skeletal muscle 
in vivo, we decided to maintain the complete reprogramming cocktail for the rest 
of our studies to ensure maximum reprogramming efficiency. However, the effects 
of Oct3/4, Sox2 and Klf4 alone should be further explored if in vivo reprogramming 




Figure 4. 7. Gene expression in mouse skeletal muscle after i.m. administration of OKS 
reprogramming pDNA (in the absence of c-Myc).  (a) BALB/c mice were i.m. injected in the GA 
muscle with 50µg OKS in 50 μl 0.9% saline or 50 μl 0.9% saline alone. GA muscles were dissected 2 
days after injection and real-time RT-qPCR was performed to determine the relative gene expression 
of (b) reprogramming factors, (c) endogenous pluripotency markers and (d) genes involved in 
myogenesis. Gene expression levels were normalised to saline-injected controls. **p<0.01 indicates 
statistically significant differences in Oct3/4 gene expression between pDNA and saline-injected 
groups, assessed by one-way ANOVA. Data are presented as mean ± SD, n=3. 
4.4.4. Gene and protein expression in Nanog-GFP and Pax3-GFP transgenic 
mice skeletal muscle after i.m. administration of reprogramming pDNA. 
Once the upregulation of genes characteristic of pluripotent and myogenic 
progenitor cells was confirmed in the skeletal muscle soon after the administration 
of reprogramming pDNA, we moved on to monitor changes in the mRNA levels of 
such markers at later time points, as well as their expression at the protein level. 
We performed this study on a Nanog-GFP transgenic mouse strain, which contains 
a GFP reporter inserted in the Nanog locus [230], under the hypothesis that the 
green fluorescence emitted by Nanog+ cells would facilitate the identification of the 




Nanog-GFP mice were i.m. administered with 50 μg OKS and 50 μg M in 50 
μl 0.9% saline or the same volume of saline solution alone in the GA muscle. Gene 
expression was analysed 2, 4 and 8 days after injection (Figure 4.8a). The 
expression of the reprogramming factors Oct3/4, Sox2 and c-Myc was at its highest 
on day 2 and gradually diminished over time (Figure 4.8b). The expression of 
endogenous pluripotency markers - including the GFP reporter controlled by the 
Nanog promoter – was also high 2 days after injection, but decreased to baseline 
levels after this time point (Figure 4.8c). These observations confirmed that the 
induction of pluripotency in skeletal muscle was fast and transient, as observed in 
liver tissue. The investigation of myogenesis-related genes reaffirmed the 
upregulation of the myogenic progenitor marker Pax3 in the mice treated with 
reprogramming pDNA, juxtaposed to the downregulation of markers relevant to 
any later stages in myogenesis. Particularly strong was the downregulation of 
MyoD 2 days after injection (Figure 4.8d). 
We also examined the mRNA levels of genes characteristically expressed in 
other cell types resident in the skeletal muscle. We chose to focus on satellite cells 
and pericytes given that they possess myogenic potential [217, 231]. Pax3 is 
mainly expressed by muscle progenitors during embryonic development but also 
by a subset of satellite cells in the adult organism [223, 232, 233]. Therefore, the 
study of other markers characteristic of such cell population was necessary to 
identify whether the increase in Pax3 mRNA levels was due to satellite cell 
proliferation or to genuine reprogramming to an embryonic-like phenotype. The 
analysis of markers specifically expressed in quiescent and/or activated satellite 
cells, identified in a previous work [234], evidenced a moderate but significant 
downregulation of all such transcripts in the pDNA treated group (Figure 4.8e), 
dismissing the hypothesis of satellite cell proliferation. Likewise, the investigation 
of pericyte-specific genes manifested the downregulation of such markers upon 
i.m. administration of reprogramming pDNA (Figure 4.8f). Overall, this data did 
not suggest the involvement of satellite cell and/or pericyte proliferation in the 







Figure 4. 8. Gene expression in Nanog-GFP transgenic mouse skeletal muscle after i.m. 
administration of reprogramming pDNA.  (a) Nanog-GFP transgenic mice were i.m. injected in the 
GA muscle with 50µg OKS and 50 μg M in 50 μl 0.9% saline or 50 μl 0.9% saline alone. GA muscles 
were dissected 2, 4 and 8 days after injection and real-time RT-qPCR was performed to determine the 
relative gene expression of (b) reprogramming factors, (c) endogenous pluripotency markers, (d) 
genes involved in myogenesis, (e) satellite cell markers and (f) pericyte markers. Gene expression was 
normalised to saline-injected controls. *p<0.05, **p<0.01 and ***p<0.001 indicate statistically 
significant differences in gene expression between pDNA and saline-injected groups, assessed by one-
way ANOVA when p≥0.05 in Levene’s test and by Welch ANOVA when p<0.05 in Levene’s test. Data are 




Protein expression - characterisation of clusters of in vivo reprogrammed 
cells 
Histological analysis of GA muscle tissue sections from the same study 
revealed the presence of clusters of GFP+ mononucleated cells. Such clusters were 
only found in tissues from mice administered with reprogramming pDNA, hence 
we identified them as Nanog expressing in vivo reprogrammed cells (Figure 4.9b). 
Green fluorescence was not detected any later than day 2 after injection (Figure 
S4), which again highlighted the transiency of the induction of pluripotency.  
The GFP signal triggered by Nanog upregulation co-localised with the 
expression of other pluripotency and ES cell specific markers - NANOG, OCT4, AP 
and SSEA1 - identified by IHC (Figure 4.9c). Positive cells for such markers that 
did not seem to express GFP – or exhibited very faint green fluorescence - were 
rarely but sometimes found within the clusters. This might be explained by the 
substitution strategy utilised to generate the transgenic strain, which involves that 
only heterozygous mice are viable and therefore GFP expression is monoallelic 
[219], but it might also be possible that a heterogeneous population of cells forms 
the clusters.  No immunoreactivity for any of the pluripotency markers tested was 
found in saline-injected controls, excluding AP, which is also expressed by 
pericytes (Figure S5c). We also found cells staining positively for satellite cell and 
other pericyte markers (PAX7 and PDGFrβ, respectively) in the tissues from pDNA-
injected mice (Figure S5b).  However, such cells were found in similar numbers as 
in saline-injected controls (Figure S5c) and were located in the vicinity of the 
clusters but not co-localising with the GFP+ cells within them. This finding 
reaffirmed our observations at the mRNA level (Figure 4.8) and indicated that the 
events triggered in the skeletal muscle upon in vivo reprogramming to 




Figure 4. 9. Characterisation of in vivo reprogrammed cell clusters in Nanog-GFP mouse 
skeletal muscle tissue. (a) Nanog-GFP transgenic mice were i.m. injected with 50µg OKS and 50 μg 
M or 50 μl 0.9% saline in the GA muscle. Tissues were dissected 2 days after injection and 10 μm-thick 
sections were obtained by cryotomy. (b) Number of GFP+ cell clusters per GA muscle. No GFP+ clusters 
were observed in saline-injected controls (n=3 mice, GA muscles were sectioned sequentially from 
tendon to tendon and 10 tissue sections/mouse were screened, representative of the different muscle 
areas). Data are presented as mean ± SD. (c) Clusters of reprogrammed cells in the GA muscle of the 
pDNA-injected group were identified by H&E and by the green fluorescence triggered by the 
expression of Nanog (100X, scale bar represents 50 μm). (c) IHC for the expression of pluripotency 
markers in GFP+ cell clusters and quantification (n=1). Images were taken with a confocal microscope 
(100X). Scale bar represents 50 μm. 
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The use of a Pax3-GFP transgenic mouse strain also allowed the 
identification of bright GFP+ cell clusters 2 days after injection of the same 
reprogramming pDNA combination, which were very similar to those observed in 
Nanog-GFP mouse tissues and did not appear in the saline-injected controls 
(Figures 4.10a-b). This observation agreed with our gene expression data that 
evidenced an upregulation of Nanog and Pax3 on day 2 after injection (Figure 4.8), 
but did not confirm whether both markers were co-expressed by the same cells. To 
answer such question, we performed anti-NANOG IHC on Pax3-GFP mouse skeletal 
muscle tissue sections and found precise co-localisation of both signals in cells 
within the clusters (Figure 4.10c). Such finding suggested that the cells that 
expressed NANOG expressed also PAX3.   
Overall, these observations suggested that in vivo reprogrammed cells 
which grow in clusters of mononucleated cells and express pluripotency and early 
myogenic progenitor markers, but not those characteristic to satellite cells or 
pericytes, are generated in the skeletal muscle tissue upon i.m. administration of 
reprogramming pDNA. While not all the cells within the clusters in Nanog-GFP and 
Pax3-GFP specimens expressed the green reporter, this heterogeneity might also 
be explained by the transiency of the reprogramming event, with some cells 
probably re-differentiating already at the time point investigated (day 2). 
4.4.5. Cell proliferation in mouse skeletal muscle after i.m. administration of 
reprogramming pDNA.  
Cell proliferation has been identified as a distinct and indispensable step in 
the somatic to pluripotent conversion [167, 235], hence we next aimed to 
investigate whether the clusters of in vivo reprogrammed cells showed signs of 
active division.  
To address this question, BALB/c mice were i.m. injected in the GA muscle 
with 50 μg OKSM – which encodes an eGFP reporter allowing the identification of 
transfected cells – or the same volume of vehicle alone. We planned to label the 
cells actively proliferating in the muscle 18 h after pDNA administration via i.p. 
injection of BrdU and to collect the tissues 6 h later for investigation (Figure 
4.11a). The signal of the eGFP reporter co-localised with that of an anti-BrdU 
antibody in GA muscle tissue sections from the pDNA-injected group. Importantly, 
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such co-localisation was found in clusters of mononucleated cells morphologically 
identical to those described in the previous section. This finding confirmed that 
cells transfected with reprogramming pDNA within the skeletal muscle tissue not 
only acquired an embryonic-like gene expression profile but also proliferated 
actively. No cell clusters, eGFP signal or BrdU incorporation were found in tissues 
from the saline-injected controls (Figure 4.11b).  
 
Figure 4. 10. Characterisation of in vivo reprogrammed cell clusters in Pax3-GFP mouse 
skeletal muscle tissue. (a) Pax3-GFP transgenic mice were i.m. injected with 50µg OKS and 50 μg M 
or 50 μl 0.9% saline in the GA muscle. Tissues were dissected 2 days after injection and 10 μm-thick 
sections were obtained by cryotomy. (b) Number of GFP+ cell clusters per GA muscle. No GFP+ clusters 
were observed in saline-injected controls (n=2 mice, GA muscles were sectioned sequentially from 
tendon to tendon and 10 tissue sections/mouse were screened, representative of the different muscle 
areas). Data are presented as mean ± SD. (c) Clusters of reprogrammed cells in the GA muscle were 
identified by H&E and by the green fluorescence triggered by Pax3 expression (100X, scale bar 
represents 50 μm). (d) IHC for the expression of the pluripotency marker NANOG in GFP+ clusters and 
quantification of PAX3+NANOG+ cell clusters (n=2). Images were taken with a confocal microscope 
(100X). Scale bar represents 50 μm. For number of PAX3+NANOG+ cell clusters, data are presented as 




Figure 4. 11. Cell proliferation in mouse skeletal muscle after i.m. administration of 
reprogramming pDNA. (a) BALB/c mice were i.m. injected in the GA muscle with 50µg OKSM in 50 μl 
0.9% saline or 50 μl 0.9% saline alone and 18 h later administered with 500mg/kg BrdU, i.p. GA 
muscles were dissected 24 h after pDNA injection. (b) 10 μm-thick tissue sections obtained by 
cryotomy were stained with anti-BrdU antibody. eGFP signal corresponds to the reporter encoded in 
OKSM pDNA. Images were captured with a confocal microscope (100X). Scale bar represents 50μm. 
(c) Number of GFP+BrdU+ cell clusters per GA muscle (n=3 mice, GA muscles were sectioned 
sequentially from tendon to tendon and at least 10 tissue sections/muscle were screened for the 
appearance of GFP+BrdU+ cell clusters, representative of all different muscle areas). Data are 
presented as mean ± SD. 
4.4.6. Short and long term histological outcomes of in vivo reprogramming to 
pluripotency in mouse skeletal muscle. 
The evolution of cell morphology, nuclear position and tissue architecture 
within and around the clusters of in vivo reprogrammed cells was monitored for an 
extended period of time. BALB/c mice were i.m. injected in the GA muscle with 50 
μg OKSM in 50 μl 0.9% saline or the same volume of saline alone. GA muscles were 
dissected 2, 4, 8, 15, 50 and 120 days after injection and processed for histological 
investigation (Figure 4.12a). 
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H&E staining confirmed the appearance soon after injection (day 2) of 
distinct and dense clusters of small mononucleated cells among the myofibers, 
which appeared only in the pDNA-injected group. On day 4, small calibre fibers 
with the nucleus in the centralised position and expressing desmin - both 
characteristics of the regenerating, immature myotube [213, 236] - appeared 
within such clusters. Only few desmin+ centronucleated myofibers were noted in 
the tissue on day 8 after injection and none at later time points. From day 15 
onwards, we did not observe any differences between the pDNA and saline-
injected tissues (Figures 4.12b and 4.13b). Such evolution in the organisation of 
the clusters, together with the fact that no teratomas were found even at the latest 
time point of the study (day 120), suggested that the reprogrammed cells could 
have committed to myogenesis and successfully integrated into the muscle tissue. 
Figure 4.12c provides higher magnification images of these findings. 
To further support this hypothesis and to address any concerns that the 
reprogrammed cells, exhibiting pluripotency features, would not be able to survive 
within an adult tissue microenvironment, TUNEL assay was performed to label any 
apoptotic nuclei (Figure 4.12d). TUNEL+ nuclei were only found at the earliest 
time points after injection and no differences were detected between the pDNA 
and saline-injected groups Therefore, their occurrence was attributed to marginal 
tissue damage along the needle track and not to reprogramming. 
Finally, changes in morphometric parameters in the tissue were studied in 
an attempt to indirectly follow the fate of the reprogrammed cells. First, the 
number of nuclei per mm2 was counted and found to be moderately but 
consistently higher in the muscles administered with reprogramming pDNA 
compared to saline controls (Figure 4.12e), which agreed with our findings in cell 
proliferation. In addition, the diameter of the myofibers was also larger in the 
pDNA group (Figure 4.12f), whereas the total number of myofibers per cross-
section remained invariable compared to saline controls (Figure 4.12g). These 
observations suggested that reprogrammed cells proliferated and fused to existing 
myofibers, enlarging their calibre, but did not form de novo fibers. Therefore, the 
events occurred in the skeletal muscle tissue upon in vivo reprogramming to 




Figure 4.12. Short and long-term outcomes of in vivo reprogramming to pluripotency in mouse 
skeletal muscle. (a) BALB/c mice were i.m. injected in the GA muscle with 50µg OKSM in 50 μl 0.9% 
saline or 50 μl 0.9% saline alone. GA muscles were dissected 2, 4, 8, 15, 50 and 120 days after pDNA 
injection and 10 μm-thick transverse tissue sections were obtained by cryotomy and stained with H&E. 
(b) Representative images at low magnification (40X, scale bar represents 100 μm). (c) 
Representative images at high magnification, focus on cell clusters that appear at the earliest time 
points after i.m. injection (100X, scale bar represents 50 μm). (d) TUNEL staining to label apoptotic 
nuclei was performed on days 2, 4 and 8 after injection. Representative images were obtained at 40X, 
scale bar represents 100 μm. The pattern in all stainings was faithfully recapitulated in pDNA-injected 
mice compared to saline controls, n=3. (e) Number of nuclei/mm2 (n=3 GA muscles per condition, 10-
12 sections per muscle). (f) Myofiber diameter (n=3 GA muscles per condition, 5 sections per muscle). 
(g) Myofiber number/cross-section (n=3 GA muscles per condition, 5 sections per muscle).  All data are 




Figure 4.13. Expression of desmin in mouse skeletal muscle after in vivo reprogramming to 
pluripotency. (a) BALB/c mice were i.m. injected in the GA muscle with 50µg OKSM in 50 μl 0.9% 
saline or 50 μl 0.9% saline alone. GA muscles were dissected 2, 4, 8, 15, 50 and 120 days after pDNA 
injection and 10 μm-thick transverse tissue sections were obtained by cryotomy. (b) IHC for the 
expression of desmin and laminin. Images were taken with an epi-fluorescence microscope (40X). Scale 
bar represents 50 μm. 
4.5. Discussion. 
In this Chapter, we aimed to verify the universality of the Yamanaka cocktail 
as a tool to induce somatic cells to pluripotency in vivo. We confirmed that adult 
cells can be reprogrammed to express pluripotency markers in the skeletal muscle, 
a tissue of entirely different developmental origin from that of the previously 
reprogrammed liver.  
Similar to the effects of HTV administration in liver, i.m. delivery of 
reprogramming pDNA and subsequent expression of Yamanaka factors led to 
transient de-differentiation of a subset of cells in the GA muscle. This was 
evidenced by the expression of pluripotency genes that are otherwise silenced in 
adult tissues (Figure 4.8c) and by the upregulation of Pax3, a transcription factor 
typically expressed in myogenic progenitors, but not in differentiated myotubes, 
nor in mature myofibers (Figure 4.8d). The same outcome was reproducibly 
found when the study was repeated in different mouse strains and with different 
reprogramming pDNA cassettes (Figures 4.2, 4.3 and S3). Notably, we did not 
find any significant differences in the gene expression levels of pluripotency and 
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early progenitor markers achieved in the absence of c-Myc (Figure 4.7), which 
could facilitate the prospective clinical translation of this approach.  
Gene expression profiles obtained from saline-injected and uninjected 
controls confirmed that the minor trauma derived from the i.m. injection did not 
have any input in the expression of pluripotency and muscle-specific genes 
(Figure 4.4). The contribution of satellite cell and pericyte proliferation, initially 
suspected from the increase in Pax3 mRNA levels, was disproved by a number of 
findings. First, we found that gene expression of several satellite cell and pericyte-
specific markers was downregulated in the pDNA-injected muscles compared to 
saline controls (Figures 4.8e-f). In addition, MyoD – which is rapidly upregulated 
upon satellite cell activation and highly expressed in their proliferating progeny 
[237] – was significantly downregulated in the reprogrammed group throughout 
our work (Figures 4.2, 4.3, 4.7, S4 and 4.8). Finally, no differences in the 
abundance of such cells between the pDNA and saline-injected tissues were 
observed in histological studies (Figure S5). 
Co-localisation studies on a Nanog-GFP transgenic mouse strain confirmed 
conversely that mononucleated cells growing in clusters among the myofibers 
expressed several pluripotency markers but not those characteristic of satellite 
cells or pericytes (Figures 4.9 and S5). Similar studies on a Pax3-GFP mouse 
strain confirmed that reprogrammed cells expressing Nanog, expressed also the 
myogenic progenitor marker Pax3 (Figure 4.10).  
The relatively rapid decrease in the expression of reprogramming factors 
after injection (Figure 4.8b) was interpreted as an indication of the proliferative 
status of the transfected cells. I.m. injection of pDNA is known to result instead in 
long-term transgene expression - at least 2 months, with peak levels reached 14 
days after injection as previously described [212] - given the post-mitotic status of 
the myofibers. Our observation can be explained if post-mitotic cells had re-
entered the cell cycle and divided actively upon in vivo reprogramming or if 
dividing cells had been transfected instead, in both cases resulting in the dilution of 
the pDNA. Importantly, BrdU labelling was able to confirm the proliferative status 
of the clusters of reprogrammed cells (Figure 4.11). Cells labelled with BrdU and 
expressing the eGFP reporter encoded in OKSM were found when the synthetic 
nucleoside was administered soon after (18 h) i.m. injection of reprogramming 
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factors. No incorporation of BrdU was detected in the saline-injected controls, 
which suggested that proliferation was a result of in vivo reprogramming. This 
observation was pivotal to support that reprogramming towards pluripotency 
occurred in vivo, given that active proliferation is known to be one of the 
indispensable initial stages in the pluripotent conversion [167].  
In addition, the evolution of the cell clusters over time suggested that the 
pluripotent-like proliferative state was only transient and reprogrammed cells 
eventually re-differentiated and were successfully integrated into the muscle 
tissue. Such conclusion was supported by the gradual disappearance of the 
mononucleated cell clusters (only prominent 2 days after injection), followed by 
the emergence of small calibre centronucleated muscle fibers expressing desmin 
from days 4 to 8 (characteristic of the regenerating or newly-formed immature 
myotube) and the fact that no differences were observed between tissues 
administered with pDNA or saline after this point (Figures 4.12b-c and 4.13b). 
These histological observations agreed with our findings at the mRNA level, in 
which significant upregulation of pluripotency markers was evident 2 days after 
injection, but not later (Figure 4.8). Likewise, no fluorescence originated from 
Nanog upregulation was observed in Nanog-GFP tissues after the same time point 
(Figure S4). The lack of significant apoptosis in the tissues administered with 
reprogramming pDNA and the morphometric information advocated also for the 
re-integration of the reprogrammed cells into the muscle tissue (Figures 4.12d-g). 
The latter suggested that in vivo reprogrammed cells behaved similarly to 
myogenic precursors such as satellite cells by fusing to neighbouring muscle cells 
but not forming de novo fibers. The final number of myofibers in the mouse 
skeletal muscle is fixed soon after birth, with little changes after postnatal day 14. 
During postnatal growth, satellite cell-derived myoblasts fuse to and enlarge the 
diameter of existing myofibers (hypertrophy) but no new fibers are formed 
(hyperplasia) [238]. In the reprogrammed tissue, we consistently observed a 
higher number of nuclei per mm2 compared to the saline control (Figure 4.12e), 
in agreement with our findings of cell division. In addition, the myofiber diameter 
increased (Figure 4.12f) but the number of myofibers per cross-sectional area 
remained invariable by the end of the study (day 120) (Figure 4.12g). In spite of 
the coherence of these observations, specific lineage tracing studies that could 
allow the permanent labelling of the in vivo reprogrammed cells will be required to 
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fully understand their fate in the tissue and further confirm the observations 
described here.  
A previous study has also reported successful integration of in vivo 
reprogrammed cells in the tissue after a proliferative phase. Ohnishi et al. similarly 
utilised BrdU labelling to identify proliferative cells upon in vivo reprogramming 
and follow their fate in a doxycycline-inducible reprogrammable mouse [196]. 
When the expression of reprogramming factors was sustained – via administration 
of the drug - for no more than 7 days, BrdU+ cells were successfully integrated into 
the respective tissues. In addition, BrdU+ cells producing insulin were observed 
within the pancreatic tissue of the treated animals, confirming that reprogrammed 
cells not only re-differentiated to the appropriate phenotype but were also able to 
accomplish their normal physiological function. The fact that under such 
conditions the reprogrammed cells did not progress to dysplasia, but they did 
when the drug was administered for longer periods of time [196], stressed again 
the importance of the transient expression of reprogramming factors for the 
successful re-integration of the reprogrammed cells into the tissue and the 
avoidance of tumourigenesis. The same conclusion transpired from our 
experiments in skeletal muscle, in which no teratoma formation was observed in 
any of the mice sacrificed at different time points over a period of 120 days 
(Figures 4.12b and 4.12c). This was again in accordance not only with Yilmazer’s 
findings in liver tissue [162] but also with the in vivo reprogramming reported in 
tadpole tail muscle [161].  
Many are indeed the common findings between the work presented in this 
Chapter and the Vivien et al. study using muscle tissue of pre-metamorphic 
tadpoles. The onset of reprogramming was also rapid in that model, with notable 
expression of endogenous pluripotency genes as early as 3 days after i.m. 
administration of OKS pDNA in the tail muscle.  Similar to our studies, the 
expression of the reprogramming factors encoded in the pDNA decreased 
significantly over time, and was not detected from day 14 onwards. Even more 
interesting were the similarities between the cell clusters that appeared among the 
myofibers after the administration of reprogramming pDNA in both models. 
Similar to what we have described in mouse skeletal muscle, the clusters observed 
by Vivien et al. in the tadpole tail were populated by proliferative mononucleated 
cells that expressed endogenous pluripotency markers. Finally, the pluripotent 
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conversion was also transient in the amphibian tissue, the cells within the clusters 
did not form teratomas but re-differentiated and integrated into the tissue.  
Vivien and colleagues were in addition able to isolate the in vivo 
reprogrammed cells from the tail muscle tissue and culture them in vitro, where 
they formed colonies able to differentiate towards the three developmental 
lineages. We also attempted to isolate such cells from the clusters present in the 
GA muscle. We based our efforts first on a protocol described to isolate satellite 
cells and other stem cells resident in skeletal muscle [239] and later on a method 
reported to isolate individual myofibers retaining their associated satellite cells 
[240]. While we were able to isolate and culture satellite cells and muscle cells that 
formed beating myotubes (data not shown), none of the protocols succeeded in the 
generation of i2PS cells from skeletal muscle tissue. We attribute this failure to the 
transiency with which the pluripotent-like cells exist in the tissue, which makes 
their isolation very challenging. Having already characterised the i2PS cells 
generated from liver tissue as a proof of concept that functional pluripotency can 
be achieved upon in vivo reprogramming, we preferred to focus our attention in 
the fate of the reprogrammed cells in vivo and their possible contribution to tissue 
regeneration as will be described in Chapter V.  
An interesting question that remains to be answered is the identity of the 
cells within the skeletal muscle that are reprogrammed towards pluripotency 
following this approach. We have not performed studies that identify the cell type 
or types transfected with reprogramming pDNA. Fully differentiated myofibers are 
known to spontaneously uptake naked pDNA [208], the reason why they are 
considered an advantageous target for gene delivery in vivo. Indeed, all of the early 
studies on direct i.m. administration of naked pDNA proved the expression of the 
relevant transgenes in mature myofibers, although they did not explore 
systematically the uptake in other cell populations [208, 209, 212, 224]. On the 
other hand, the feasibility to reprogram mammalian multinucleated and post-
mitotic myofibers into pluripotent mononucleated cells remains controversial due 
to the requirements of cell cycle re-entry and cell fission involved. While it has long 
been known that myofibers in urodele amphibians can re-enter the cell cycle and 
cleave into mononucleated progenitors [241], there is no proof of such an event in 
mammalian fully differentiated muscle cells. Recent studies have attempted to 
achieve mammalian myofiber de-differentiation and fission via ectopic expression 
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of transcription factors that mediate such processes in the amphibian organism 
[242-244] or simply via muscle injury [245, 246]. However, their results are 
questionable due to the lack of robust lineage tracing tools that confirm the origin 
of the resulting mononucleated cells.  
Myoblasts present in adult skeletal muscle have been successfully 
reprogrammed into iPS cells in vitro [228] and hence could have also been the 
targets of de-differentiation in our studies. We did not observe a reproducible 
downregulation of markers associated to fully differentiated myofibers, but we did 
consistently report the downregulation of the myoblast marker MyoD (Figures 
4.2, 4.3, 4.7, 4.8 and S4). The downregulation of this gene, mediated by the 
upregulation of the master regulator of pluripotency Oct4, has been determined as 
mandatory for the pluripotent conversion of myoblasts [218]. We also confirmed 
downregulation of markers specific to satellite cells, which are also amenable to 
reprogramming, as demonstrated in vitro, and with higher reprogramming 
efficiencies than other more committed cell types [228]. However, uptake of pDNA 
by satellite cells upon i.m. injection remains to be confirmed and, in fact, Vivien et 
al. demonstrated that such cell population was not transfected in their tadpole 
model [161]. We repeated our reprogramming studies using 2-week-old juvenile 
mice, under the hypothesis that if satellite cells were reprogrammed the 
significantly larger population of such cells in the juveniles compared to adult 
counterparts [229] would result in a higher reprogramming effect. Conversely, 
even the expression of transgenes encoded in the reprogramming pDNA was lower 
than that achieved in adult mice with the same dose of pDNA (Figures 4.5 and 
4.6), contradicting a previous study [224]. Hence, we currently have no 
experimental evidence to suggest that satellite cells are reprogrammed to 
pluripotency in vivo. Whether it is the fully differentiated myofibers and/or other 
cell types resident in the skeletal muscle, the population reprogrammed upon i.m. 
injection of reprogramming pDNA remains to be demonstrated and this question 
will have to be answered with the appropriate cell tracking strategies. 
Alternatively, incorporation of cell-specific promoters in the pDNA cassette might 
also help to address this question. Given the probably random incorporation of 
pDNA in a diversity of cells, it is conceivable that different interstitial cells 
(including satellite cells) were reprogrammed rather than a particular cell type; all 
down-regulating their specific markers.   
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In conclusion, the data presented in this Chapter showed that in vivo 
reprogramming towards pluripotency can be achieved in a different somatic tissue 
(mesoderm origin) from the previously reprogrammed liver (endoderm). Although 
tri-lineage contribution will have to be tested to confirm that complete 
reprogramming was achieved, i.m. administration of reprogramming pDNA 
induced a subset of cells within the tissue to execute an embryonic-like genetic 
program to then recapitulate features characteristic of normal myogenesis in 
terms of tissue morphometry and organisation. In light of these observations, we 
hypothesised that in vivo reprogramming towards pluripotency might enhance the 
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5.1. Scope of Chapter V. 
In Chapter III we demonstrated that the expression of reprogramming 
factors in vivo generates functionally pluripotent cells. In addition, we observed in 
Chapter IV that cells expressing pluripotency markers proliferated transiently in 
the skeletal muscle and then seemed to successfully re-integrate into the tissue, 
enlarging the diameter of existing myofibers, without forming teratomas. In the 
present Chapter, we aimed to investigate whether the induction of pluripotency 
within injured skeletal muscle would enhance the endogenous regenerative 
capacity of the tissue and accelerate rehabilitation at the histological and 
functional levels.   
5.2. Introduction. 
The skeletal muscle in some lower vertebrates - including urodele 
amphibians (newts and axolotls), anuran amphibians (Xenopus laevis tadpoles) and 
zebrafish larvae - has an outstanding capacity to regenerate after severe insults. 
Such phenomenon occurs either via de-differentiation of mature myofibers, 
activation of tissue resident stem cells or both mechanisms, and contributes to 
their ability to regrow amputated body structures [241, 247]. The regenerative 
capacity of the mammalian skeletal muscle is however less striking and relies 
mainly on the self-renewal and myogenic potential of resident stem cells, primarily 
satellite cells [248]. Such cells are normally quiescent but, in the event of an injury, 
proliferate and differentiate into myoblasts that fuse to existing myofibers or form 
new fibers to replenish the tissue [216, 217, 249]. The pool of satellite cells varies 
across species and dramatically decreases with age (from 30-35% in the neonate 
mouse to <5% in the adult; from 4.5% in the neonate human to <2% in the adult) 
[229, 250], hence it is normally sufficient to repair minor to moderate injuries but 
can be easily exhausted if the injury is severe [251]. In this scenario, various 
resident cell types differentiate into myofibroblasts that generate a collagen-based 
fibrotic scar unable to meet the contractile requirements of the tissue and that 
therefore prevents the complete functional rehabilitation of the injured muscle 
[137, 252]. Therefore, major injuries including severe lacerations, contusions and 
strains (significantly prevalent in sports medicine and traumatology) are often not 
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entirely resolved at the anatomical and functional levels, leading to a high 
frequency of relapse [5].  
Also important for the frequent lack of complete rehabilitation upon severe 
damage to the skeletal muscle is the fact that only conservative treatment is 
currently clinically available, which consists on the so-called RICE strategy (rest, 
ice, compression and elevation) at the earliest stages, followed by physical therapy 
aimed to recover the contractile function in the long term [5]. Anti-inflammatory 
therapy has additionally been proposed but recent studies have advised against it 
given the important role that inflammation plays at the earliest stages of the 
muscle degeneration-regeneration process [253, 254]. The surgical suturing of the 
defect has reported modest benefits, however it is very limited to particular types 
of injury [255]. Although other strategies - including the administration of anti-
fibrotic drugs [256-259], growth factors [260], replacement cells [261-263], 
miRNAs involved in muscle development [264] and combinations of these [265-
268] - are currently being extensively investigated, they are not devoid of 
limitations and have not yet reached routine clinical practice [5, 8]. 
We have previously hypothesised that the generation of pluripotent cells 
able to transiently proliferate and eventually re-differentiate to the appropriate 
phenotype within a damaged tissue might help to repopulate the injured site and 
therefore improve regeneration and functional rehabilitation [164]. This 
hypothesis became especially sound upon confirmation in Chapter IV that in vivo 
reprogramming to pluripotency in healthy skeletal muscle recapitulates events 
characteristic of mammalian post-natal myogenesis (fusion to existing myofibers) 
and possibly of the endogenous regeneration in certain organisms (de-
differentiation to an embryonic-like phenotype). 
In this Chapter, a chemically-induced (i.m. administration of cardiotoxin, 
CTX) and a physically-induced (surgical laceration) model of skeletal muscle injury 







5.3. Materials and methods. 
5.3.1. Materials used in Chapter V. 
5.3.1.1. Plasmid (pDNA) vectors.  
Reprogramming pDNA pCX-OKS-2A (OKS, encoding Oct3/4, Klf4, Sox2), pCX-cMyc 
(M, encoding cMyc) and pLenti-lll-EF1α-mYamanaka (OKSM, encoding Oct3/4, 
Klf4, Sox2, cMyc and eGFP) were used in this study. A more detailed description of 
the cassettes is provided in Chapter III, Section 3.3.1.1. pDNA maps are 
illustrated in Figure S1. 
5.3.1.2. Mouse strains.  
Female mice were used in this work that entered the procedures at 7 weeks of age. 
BALB/c mice were purchased from Harlan (UK) and C57BL/6 mice were obtained 
from Charles River (UK). All experiments were performed with previous approval 
from the UK Home Office under a project license PPL 70/7763 and after allowing 
the mice one week to acclimatise to the facilities. 
5.3.1.3. Myotoxic substances. 
Cardiotoxin (CTX), snake venom from Naja mossambica mossambica, was 
purchased from Sigma (C9759, UK) as a powder, and dissolved in PBS to a final 10 
μM concentration. 
5.3.2. Methods involved in Chapter V. 
5.3.2.1. Monitoring of endogenous regeneration after CTX injury in different 
mouse strains. 
BALB/c and C57BL/6 mice (n=3) were i.m. administered with 30 μl CTX (10μM) in 
the left GA muscle. The contralateral hind limb was left uninjected and used as 
control. Mice were sacrificed on days 3, 6 and 9 after injury and the progress of 
endogenous regeneration in the two strains was compared via macroscopic 




5.3.2.2. Monitoring of gene expression changes in skeletal muscle tissue over 
time after CTX administration. 
BALB/c mice (n=3) were i.m. administered with 30 μl CTX (10μM) in the left GA 
muscle. The contralateral hind limb was left uninjected and used as control. Mice 
were sacrificed on days 3, 6 9 and 15 after injury and the expression of 
inflammation, pluripotency and myogenesis-related genes in the injured muscles 
was compared to that of the intact controls. Gene expression levels were 
determined by real-time RT-qPCR, as described in Chapter IV, Section 4.3.2.2. 
Primer sequences used in this Chapter are listed in Table S8. 
5.3.2.3. CTX injury model and in vivo reprogramming to pluripotency. 
BALB/c mice (n=3-4, as specified in each study) were i.m. administered with 30 μl 
CTX (10μM) in the left GA. The time of injury was considered day 0 (d0). Two 
doses of 50 μg OKS and 50 μg M each were i.m. administered in the injured muscle 
on consecutive days, according to one of the following regimens: days 0 and 1 
(d0+1), 5 and 6 (d5+6) or 7 and 8 (d7+8) after injury. The injured (left) GA of the 
control group was administered with the equivalent volume (50 μl) of 0.9% saline. 
In both groups, the contralateral (right) GA was left intact (uninjured and 
uninjected) and used as internal control. Mice were sacrificed and GA muscles 
were dissected 2 and 7 days after the last administration of OKS+M or saline for 
further investigations. Schematic representations of the therapeutic regimens 
included in this study are provided in Figure 5.4. 
 5.3.2.4. Laceration of GA, soleus and plantaris muscles and in vivo 
reprogramming to pluripotency. 
BALB/c mice (n=3) were anesthetised with isoflurane and the left hind limb was 
shaved and prepared for surgery. 0.05 mg/kg buprenorphine were s.c. 
administered at the start of the procedure. A vertical skin incision (6 mm long) was 
made overlying the posterior compartment of the calf with a scalpel number 11 
and the fascia was exposed and incised with fine scissors at the level of mid GA to 
release the muscle belly. All the muscles in the posterior compartment of the calf – 
including lateral and medial GA, soleus and plantaris– were lacerated in the 
transverse plane, at their mid-point, through the 100% of their width and the 
100% of their depth (Figure 5.9a). The contralateral (right) hind limb was left 
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uninjured. The skin was sutured with 5 interrupted stitches (Vicryl 6-0 absorbable 
suture, Ethicon, UK) and the mice were allowed to recover in a warm chamber. 100 
μg OKSM or the equivalent volume (40 μl) of 0.9% saline (control) were i.m. 
administered in the injured (left) hind limb at the time of surgery (day 0), or 2 days 
after injury (day2). The contralateral (right) leg was left intact (uninjured and 
uninjected) and used as internal control. Mice were sacrificed and muscles were 
dissected 2 and 5 days after the administration of OKSM or saline for further 
investigations. Figure 5.9b provides schematic representations of such 
therapeutic regimens. 
5.3.2.5. Laceration of medial GA and in vivo reprogramming to pluripotency. 
BALB/c mice (n=3-4, as specified in each study) were operated as described above, 
however only the medial GA was blunt dissected and lacerated with a single 
incision in the transverse plane. The cut was performed at its mid-point, through 
the 100% of its width and the 100% of its depth (Figure 5.12a), preserving the 
lateral GA and all other muscles in the posterior compartment of the calf. The 
contralateral (right) hind limb was left uninjured. 100 μg OKSM or the equivalent 
volume (40 μl) of 0.9% saline (control) were i.m. administered in the injured (left) 
GA muscle at the time of surgery (day 0), or 5 or 7 days after injury. The 
contralateral (right) GA was left intact (uninjured and uninjected) and used as 
internal control. Figure 5.12b provides schematic representations of the 
therapeutic regimens included in this study. Mice were sacrificed and GA muscles 
were dissected 2 and 7 days after the administration of OKSM or saline for further 
investigations. The medial and lateral GA were processed separately for moist 
weight and gene expression studies.  
Record of muscle moist weight. 
Muscle moist weight was recorded straight after dissection on a precision balance 
PA114 Pioneer (Ohaus, UK). Changes in muscle weight were either expressed as 
the mean ± SD of each group or as the mean ± SD of the ratio injured/healthy hind 
limb of each treatment group.  
Analysis of gene expression. 
Relative gene expression of Oct3/4, Nanog and Pax3 2 days after the last 
administration of reprogramming pDNA or saline was analysed by real-time RT-
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qPCR as previously described (Chapter IV, Section 4.3.2.2). Livak’s method was 
followed to analyse the data and dCt values were utilized for statistical analysis. 
Primer sequences are listed in Table S8. 
Analysis of collagen deposition (picrosirius red/fast green staining).  
Muscles were dissected 2 and 7 days after the last administration of 
reprogramming pDNA or saline and fixed in 10% buffered formalin solution 
(Sigma, UK). After embedding the tissues in paraffin wax, 5 μm-thick transverse 
sections were obtained with a microtome (Leica RM2255) and left to dry overnight 
at 37°C prior to the staining procedure. De-paraffinization using a standard 
protocol was followed by 1 h incubation in picrosirius red/fast green staining 
solution (0.1% Sirius red, 0.1% fast green in a saturated aqueous solution of picric 
acid). Tissue sections were then quickly immersed in 0.5% acetic acid for 6 s and 
dehydrated in 100% ethanol and xylene to be finally mounted with DPX mountant 
(Sigma, UK). Sections were imaged on a 3D Histech Pannoramic 250 Flash slide 
scanner and 40X images were obtained with Pannoramic Viewer Software. The 
percentage of collagen+ areas around the site of injury was measured with ImageJ 
1.48 software in 3 to 5 randomly selected fields per section. The data for each GA 
muscle were calculated from 3 to 4 sections and we observed 2 to 4 GA muscles in 
each group. Precise n numbers are specified in each study. The measurements and 
calculations were performed in a blinded manner.   
Analysis of % of centronucleated myofibers.  
5 μm-thick transverse tissue sections were obtained as described above from 
muscles dissected 2 and 7 days after the last administration of reprogramming 
pDNA or saline. H&E staining was performed following a standard protocol. 40X 
images were obtained using a 3D Histech Pannoramic 250 Flash slide scanner and 
Pannoramic Viewer Software. The number of centronucleated myofibers and total 
number of fibers per cross-sectional area were quantified around the site of injury 
using ImageJ 1.48 software in 2 to 3 randomly selected fields per section. The data 
for each GA muscle were calculated from 3 sections, and we observed 2 to 4 GA 
muscles in each group, as specified in each study. Precise n numbers are specified 
in each study. The measurements and calculations were performed in a blinded 




The function of the GA muscle after injury (2 and 7 days after the last 
administration of reprogramming pDNA or saline) was assessed by recording the 
force produced under fast twitch and tetanus contraction triggered by direct 
stimulation of the sciatic nerve. Such measurements were performed with an 
Aurora 1300A myograph (Aurora Scientific Inc, Canada) that allowed the recording 
of muscle forces in terminally anaesthetized mice. In brief, mice were 
anaesthetised with isoflurane and the GA muscle was exposed and released from 
the fascia as previously described in Section 5.3.2.4. The GA muscle and sciatic 
nerve were blunt dissected. The femur’s head was prepared free from surrounded 
tissue and fixed to the platform clamp preventing movement of the leg upon 
stimulation.  The Achilles tendon was connected to the force transducer and an 
electrode was placed directly on the sciatic nerve. The nerve and muscle were kept 
moist with paraffin oil at 37°C throughout the measurements. A schematic 
representation of the setup is shown in Figure 5.1. Since we aimed to record 
isometric contractions, optimal muscle length was first determined by repeating 
twitch measurements with a fixed current of 5V while adjusting the length of the 
muscle. The maximum twitch force was then assessed by increasing the voltage of 
stimulation.  Finally, tetanus contractions were produced by repeated stimulation 
at optimal length and current (identified from the twitch measurements) with a 
150 Hz frequency. 1 and 5 minutes were allowed between twitch and tetany 
measurements, respectively, to avoid muscle fatigue that could influence the 
results. The percentage of recovered force was calculated as the ratio between the 
force produced by the left (injured) and right (intact) GA muscles and expressed as 
mean ± SE. n=4 mice per treatment group and time point. This protocol was 




Figure 5. 1. Recording of muscle force under twitch and tetanus contraction. (a) GA muscle and 
sciatic nerve were exposed under terminal anaesthesia and connected to a myograph. (b) In vivo 
myography setup. An electrode was placed on the sciatic nerve for direct stimulation while the Achilles 
tendon was tied to a force transducer. (c) Twitch contraction was produced by a single stimulation 
(red arrow) at the optimal muscle length and current (L= latent period, C= contraction, R=relaxation). 
(d) Tetanus contraction was produced by repeated stimulations (red arrows) with a frequency of 150 
Hz that did not allow the relaxation of the muscle between single contractions. 
5.3.3. Statistical analysis. 
N numbers were specified in each particular study. Statistical analysis was 
performed first by Levene’s test to assess homogeneity of variance. When no 
significant differences were found in the variances of the different groups, 
statistical analysis was continued by one-way ANOVA and Tukey's post-hoc test.  
When variances were unequal, the analysis was followed with Welch ANOVA and 
Games-Howell’s post-hoc test. Probability values <0.05 were regarded as 






5.4.1. Preparatory work: investigation of endogenous regeneration after 
skeletal muscle injury. 
We first relied on the simplest model of skeletal muscle damage (i.m. 
administration of CTX) to select the most appropriate mouse strain in which to 
perform the injury and regeneration studies and to design the treatment regimens, 
with a special focus on the time of administration of reprogramming pDNA. CTX is 
a venom produced by the snake Naja mossambica mossambica that causes 
myofiber necrosis [269] and hence has been widely used both to model muscle 
injury and to study the innate regenerative response triggered upon.  
5.4.1.1. Effects of CTX administration in skeletal muscle tissue of BALB/c and 
C57BL/6 mouse strains. 
Driven by studies reporting significant differences in the regeneration 
capacity of different mouse genetic backgrounds [270, 271], we first aimed to 
identify the strain that would provide a wider time interval between muscle injury 
and regeneration to assess the effect of in vivo reprogramming to pluripotency. 
Three days after the i.m. administration of 30 μl CTX in the GA muscle, an 
inflammatory infiltrate was obvious to the naked eye in the tissues dissected from 
BALB/c but not C57BL/6 mice (Figure 5.2b). Such observation, together with the 
significant increase in muscle weight compared to the contralateral (uninjured) 
hind limb also at day 3 (Figure 5.2c) and the incomplete clearance of necrotic 
fibers and restoration of normal tissue architecture 9 days after injury (Figure 
5.2d), illustrated the poorer and slower capacity of BALB/c skeletal muscle to 
regenerate compared to that of C57BL/6 mice. In light of these findings, the 





Figure 5. 2. Endogenous regeneration after i.m. injection of CTX in BALB/c and C57BL/6 mouse 
strains. (a) 30 μl CTX (10 μM) were i.m. administered in the left GA muscle of BALB/c and C57BL/ 6 
mice. The right GA was left uninjected and used as control. (b) Macroscopic appearance of GA muscles 
3 days after injection. (c) Muscle moist weight. *p<0.05 indicates statistically significant differences 
between the injured and healthy GA muscles, assessed by one-way ANOVA. Data are presented as mean 
± SD, n=3. (d) H&E staining of muscle tissue sections at different time points after CTX injection (30X, 
scale bar represents 100 μm). 
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5.4.1.2. Effects of the i.m. administration of CTX in the gene expression 
profile of the skeletal muscle over time. 
Changes in gene expression at different time points after the injection of 
CTX in the GA muscle were studied next. This information was particularly 
relevant to design the therapeutic regimens in accordance to the changes induced 
by the insult in the muscle tissue. Muscle injury progresses through three defined 
phases: degeneration, regeneration and muscle remodeling [216], regardless of the 
nature of the insult. The first phase (degeneration) is characterised by an 
inflammatory response that takes place promptly after injury [5]. The expression 
of monocyte/macrophage markers involved in such stage was at its highest 3 days 
after CTX administration (Figure 5.3b). Il-6, essential not only for macrophage 
infiltration but also for myoblast proliferation and hence for the success of 
regeneration [272], was highly upregulated on day 3 after injury, but its expression 
was significantly lower from day 6 onwards. The same trend was found for Mcp-1, 
while the upregulation of Cd11b and Ccr2 was sustained for a longer period after 
CTX injection and only decreased significantly after day 9. The T cell marker Cd3, 
also typically involved in muscle inflammation and regeneration [272-274], 
showed a consistent but not significant upregulation compared to the healthy 
muscle control up to day 9, suggesting a lower contribution of these cells in the 
infiltration of the injured site.  
The expression of the different myosin heavy chain (MyHC) isoforms is 
commonly used to monitor the progress of regeneration. While at the earliest 
stages of muscle degeneration embryonic and perinatal forms are highly 
upregulated, mRNA levels of adult isoforms plummet significantly. Such trend is 
progressively inverted as the tissue recovers [275]. We found that embryonic 
(Myh3) and perinatal (Myh8) isoforms were above 10-fold upregulated in the CTX-
injected group throughout the course of the study (Figure 5.3d), while the 
expression of adult isoforms (Myh2, Myh4 and Myh7) was strongly downregulated 
on day 3 after injury but increased significantly after that time point and reached 
comparable levels to the intact control by day 15. The greatest change in the 
expression of these genes took place from days 3 to 6 after CTX administration, 
which together with the data on muscle weight, histological investigation and 
expression of inflammation markers pointed at day 3 as the summit of the 




Figure 5. 3. Changes in gene expression in the GA muscle after i.m. administration of CTX. (a) 
BALB/c mice were i.m. administered with 30 μl CTX (10 μM) in the left GA. The right GA was left 
uninjected as control and real-time RT-qPCR was conducted to determine the relative gene expression 
of (b) inflammation markers (c) genes upregulated upon in vivo reprogramming to pluripotency in 
healthy skeletal muscle and (d) myosin heavy chain (MyHC) isoforms. Gene expression was normalised 
to that of uninjected (intact) muscle. *p<0.05, **p<0.01 and ***p<0.001 indicate statistically 
significant differences in gene expression among different time points after CTX injection. For Pax3 
expression, *p<0.05 indicates a statistically significant difference compared to the uninjected control 
Statistical significance was assessed by one-way ANOVA and Tukey’s test or Welch ANOVA and Games-






Finally, it was also of interest to investigate injury-induced changes in the 
expression of genes involved in in vivo reprogramming to pluripotency in healthy 
skeletal muscle. Nanog was upregulated on days 6 and 9 after injury, whereas Pax3 
was downregulated for the duration of the study but more prominently at the 
earliest time points after injury (Figure 5.3c). 
5.4.2. In vivo reprogramming to pluripotency in a chemically-induced model 
of skeletal muscle injury: i.m. administration of CTX. 
5.4.2.1. Administration of reprogramming pDNA at different time points after 
CTX injury: definition of “early intervention” and “late intervention” 
protocols. 
The potential of in vivo reprogramming to pluripotency to enhance 
regeneration was then first interrogated in the CTX injury model. The injection of 
30 μl CTX (10 μM) in the left GA was followed by the administration, in the same 
muscle, of two doses (on two consecutive days) of 50 μg OKS and 50 μg M each or 
the equivalent volume (50 μl) of  0.9% saline, as established in a previous work 
(data not shown). The contralateral hind limb was left uninjured and uninjected 
and used as internal control. In light of the previous observations, we classified the 
therapeutic regimens under two groups: “early intervention” protocols, when 
OKS+M or saline were administered prior to day 3 and thus during the bulk of the 
degeneration phase; and “late intervention” protocols, when the administration of 
reprogramming factors took place after day 3 and hence after the peak of such 
phase. One “early intervention” protocol - OKS+M or saline administered at the 
time of injury and one day later (d0+1) - and two “late intervention” regimens - 
OKS+M or saline administered on days 5 and 6 (d5+6) or on days 7 and 8 (d7+8) 
after CTX injection – were tested (Figure 5.4). Since the peak of reprogramming in 
healthy skeletal muscle was reached two days after the administration of 
reprogramming pDNA (Chapter IV, Figure 4.8), muscles were dissected at such 





Figure 5. 4. Administration of reprogramming pDNA at different time points after CTX 
injection. 30 μl CTX (10 μM) were i.m. administered in the BALB/c left GA at day 0. Two doses of 50 μg 
OKS and  50 μg M each or the equivalent volume (50 μl) of 0.9% saline were i.m. administered in the 
same muscle on (a) day 0 (immediately after CTX injection) and day 1 (b) days 5 and 6 or (c) days 7 
and 8 after CTX injection. The right hind limb was left uninjured and uninjected and used as internal 
control. Tissues were dissected 2 days after the last pDNA or saline administration for gene expression 
and muscle weight analysis, n=3. 
Macroscopic evaluation and changes in muscle weight. 
Macroscopic observation upon dissection revealed the presence of an 
inflammatory infiltrate in the specimens injected with CTX, which was very 
prominent for those collected 3 days after injury and was progressively reduced 
when the tissues were collected at later time points. No obvious differences 
between saline and OKS+M groups were observed (Figure 5.5a). We weighed the 
GA muscles upon dissection to investigate whether the administration of 
reprogramming factors would have any effect on the changes in muscle weight 
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produced by the injury. In agreement with our studies with CTX administration 
only (Figure 5.2), muscle weight increased in injured specimens compared to 
intact controls early after injury (day 3). At later time points, a significant decrease 
in muscle weight was consistently observed in CTX-injected muscles. However, no 
differences were observed at any time point between OKS+M and saline-treated 
GA muscles (Figure 5.5b).  
 
Figure 5. 5. Macroscopic evaluation and changes in muscle moist weight after CTX injury and 
i.m. administration of reprogramming pDNA. (a) GA muscles dissected 2 days after the last 
administration of OKS+M or saline (injured vs. contralateral intact control). (b) Muscle moist weight. 
*p<0.05 and **p<0.01 indicate statistically significant differences in muscle weight among groups, 
assessed by one-way ANOVA and Tukey’s test. Data are presented as mean ± SD, n=3. 
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Changes in gene expression. 
The expression of reprogramming factors and induction of pluripotency in 
the context of an injured microenvironment was then investigated. Oct3/4 mRNA 
levels 2 days after the last administration of OKS+M did not suggest differences in 
the efficiency of in vivo transfection when the reprogramming factors were 
administered at different time points after injury (Figure 5.6a). A different 
scenario was however found when the expression of Nanog was investigated. 
While the “early intervention” failed to induce the expression of the pluripotency 
marker, this gene was upregulated compared to the intact (Figure 5.6b) and 
saline-injured (Figure 5.6c) controls when reprogramming factors were 
administered on d5+6 after the onset of injury, and such upregulation was even 
higher when the administration took place on d7+8.  
Only with the latter intervention were we able to prove statistically 
significant differences in the expression of Nanog between the OKS+M and saline-
injured groups. These results suggested that the time of administration of 
reprogramming pDNA after injury could be important for the pluripotency 
outcomes. In addition, the administration of such reprogramming pDNA in the 
injured scenario failed to reproduce the upregulation of the myogenic progenitor 
marker Pax3, characteristically observed early upon in vivo reprogramming to 
pluripotency in healthy skeletal muscle (Figure 5.6d). On the contrary, and as 
reported after the administration of CTX alone (Figure 5.3c), this transcription 
factor was strongly downregulated in all injured groups, irrespective of the 
administration of saline or OKS+M, and for the entire duration of the study (15 
days after the injury). As a result, Pax3 expression could not be used as an 




Figure 5. 6. Changes in gene expression after CTX injury and i.m. administration of 
reprogramming pDNA. Real-time RT-qPCR was performed 2 days after the last administration of 
OKS+M or saline (3, 8 or 10 days after injury) to determine the relative gene expression of (a) the 
reprogramming factor Oct3/4 (b) the pluripotency marker Nanog (normalised to uninjured, 
uninjected controls), (c) the pluripotency marker Nanog (normalised to injured, saline-injected 
controls) and (d) the myogenic progenitor marker Pax3. Oct3/4 and Pax3 expression was normalised 
to that of intact muscle controls. *p<0.05 and ***p<0.001 indicate statistically significant differences 
between groups, assessed by one-way ANOVA and Tukey’s test or Welch ANOVA and Games-Howell’s 




5.4.2.2. Tissue regeneration upon i.m. administration of reprogramming 
pDNA on days 7 and 8 after CTX injury. 
We next fixed the administration of OKS+M or saline at d7+8 after CTX 
injection (“late intervention” protocol) on the grounds of the higher Nanong 
upregulation. We aimed to investigate the effects of the induction of pluripotency 
in vivo on the regeneration of the skeletal muscle by examining the tissues 2 and 7 
days after the last administration of OKS+M or saline (10 and 15 days after injury, 
Figure 5.7a). Regenerating myofibers are characterised by the centralized 
position of the nucleous, which migrates to the edges of the cell once they are fully 
differentiated and mature[216]. The number of centronucleated (regenerating) 
myofibers around the site of injury was counted on H&E stained tissue sections 
and expressed as a percentage of the total number of myofibers (mean ± SD, 
Figure 5.7b). No significant differences in the percentage of regenerating 
myofibers were observed between saline and OKS+M groups 10 days after the 
injection of CTX (59.4 ± 12.2 % saline, 63.2 ± 15.4 % OKS+M) and such numbers 
remained also invariable 15 days after injury (55.9 ± 21.5 % saline, 65.7 ± 11.1 % 
OKS+M).  
The generation of a collagen-based fibrotic scar is one of the most 
important factors precluding the complete functional rehabilitation of injured 
skeletal muscle tissue [5, 252]. Picrosirius red/fast green staining, which 
specifically dyes collagen in magenta and myofibers in green, revealed the 
existence of moderate collagen deposits in the site of injury (Figure 5.7c). 
However, no differences in the extension of such deposits, expressed as a 
percentage of the selected area (mean ± SD), were found between treatment 
groups or time points after injury (day 10: 0.6 ± 0.2 % intact, 9.4 ± 3.9 % saline, 





Figure 5. 7. Histological evaluation of skeletal muscle tissues after CTX injury (day 0) and i.m. 
administration of reprogramming pDNA (days 7 and 8). (a) 30 μl CTX (10 μM) were injected in 
the left BALB/c GA and two doses of 50 μg OKS and 50 μg M each or the equivalent volume (50 μl) of 
0.9% saline were administered on days 7 and 8 after injury. The right GA was left uninjured and 
uninjected and used as control. Tissues were dissected 2 and 7 days after the last pDNA administration 
(10 and 15 days after injury) and analysed histologically. (b) H&E staining (40X, scale bar represents 
100 μm) and quantification of % of centronucleated myofibers (n=2-4 GA muscles per condition, 3 
sections per muscle, 2 random fields per section; data are presented as mean ± SD). (c) Picrosirius 
red/fast green staining for collagen and H&E staining of the same cross-section (40X, scale bar 
represents 100 μm). (d) Quantification of collagen deposition. ***p<0.001 indicates statistically 
significant differences between the intact control and the injured groups, analysed by Welch ANOVA 
and Games-Howell’s test, (n=2-4 GA muscles per condition, 4 sections per muscle, 3 random fields per 
section; data are presented as mean ± SD). 
5.4.2.3. Investigation of functional rehabilitation upon i.m. administration of 
reprogramming pDNA on days 7 and 8 after CTX injury. 
Our final goal was to investigate whether reprogramming the skeletal 
muscle to pluripotency after injury would improve its functional recovery. Muscle 
function was investigated in terminally anaesthetised mice by directly stimulating 
the sciatic nerve and recording the muscle force produced under twitch and 
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tetanus contraction, as detailed in the Materials and Methods section of this 
Chapter (Section 5.3.2.5, Figure 5.1). 83.3 ± 15.9 % of the twitch and 72.7 ± 14.5 
% of the tetanus force of the contralateral (intact) GA, expressed as mean ± SE, had 
already been recovered in the OKS+M group by day 10 after injury (Figure 5.8), 
only 2 days after the administration of reprogramming factors. However a very 
similar result was observed in the saline control (82.6 ± 15.7 % twitch, 68.2 ± 7.6 
% tetanus).  Even 15 days after CTX injury, 7 days after the last OKS+M 
administration, such intervention did not generate any significant difference in the 
recovered force compared to saline-injected controls (OKS+M: 67.3 ± 9.5 % twitch, 
57.4 ± 10.6 % tetanus; saline: 100.7 ± 22.1 % twitch, 60.4 ± 20.5 % tetanus).  
 
Figure 5. 8. Investigation of functional rehabilitation after CTX injury (day 0) and i.m. 
administration of reprogramming pDNA (days 7 and 8). (a) 30 μl CTX (10 μM) were injected in 
the left BALB/c GA and two consecutive doses of 50 μg OKS and 50 μg M each or the equivalent 
volume (50 μl) of 0.9% saline were administered at days 7 and 8 after injury. The right GA was left 
uninjured and uninjected and used as control. Muscle function was assessed 2 and 7 days after the last 
pDNA administration (10 and 15 days after injury). (b) Recovered forces of the injured GA under 
twitch and tetanus contraction are expressed as a percentage of the contralateral (uninjured) GA 
force. Data are presented as mean ± SE, n=4. 
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5.4.3. In vivo reprogramming to pluripotency in a physically-induced model 
of skeletal muscle injury: laceration of GA, soleus and plantaris muscles. 
We next sought to explore the therapeutic potential of in vivo 
reprogramming to pluripotency in a more anatomically localised and clinically 
relevant injury model. The left GA, soleus and plantaris muscles of BALB/c mice 
were surgically lacerated in the transverse plane as represented in Figure 5.9a. 
The right hind limb was left uninjured and used as an intact control. 
5.4.3.1. Administration of reprogramming pDNA at different time points after 
laceration of GA, soleus and plantaris muscles. 
A single dose of 100 µg OKSM or the equivalent volume (40 μl) of 0.9% 
saline was i.m. administered in the injured (left) hind limb at the time of injury 
(day 0) or 2 days later (day 2). The uninjured (right) hind limb was left uninjected. 
Tissues were collected at different time points including 2, 4 and 7 days after 
injury (2 and 5 days after OKSM or saline administration), as indicated in Figure 
5.9b. 
Changes in muscle weight. 
When muscles were dissected at different time points after injury, a similar 
trend was observed for the saline and OKSM-injected specimens, without 
significant differences between the two treatment groups. Overall, the ratio 
injured/intact was high early after injury but decreased over time and was <1 by 
day 7 (Figure 5.9c), which agreed with the observations in the CTX model. 
Changes in gene expression. 
The lack of Oct3/4 expression when OKSM was administered at the time of 
injury (Figure 5.10a) confirmed the technical limitations encountered during the 
surgical procedure (i.e. impossibility to retain the pDNA solution in the tissue). On 
the contrary, the administration of reprogramming factors 2 days later resulted in 
Oct3/4 mRNA levels comparable to those obtained in the CTX injury model. 
As predicted from the above observations, we could not detect a significant 
upregulation of Nanog compared to the intact control when OKSM was 
administered on day 0. More unexpectedly, the administration of reprogramming 
factors 2 days later also failed to trigger the expression of Nanog above the levels 
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observed in the saline control, hence most probably attributed to the initiation of 
the endogenous regenerative response. All such mRNA levels were in fact only 
marginally higher than those of the intact controls (Figure 5.10b).  Pax3 was 
strongly downregulated early after injury in both treatment groups (Figure 
5.10c). Only 7 days after injury were we able to detect significantly higher mRNA 
levels of such gene in the OKSM group compared to the saline control, however, 
the absence of clear Nanog upregulation rested importance to this finding.  
 
5.4.3.2. Tissue regeneration upon i.m. administration of reprogramming 
pDNA 2 days after laceration of GA, soleus and plantaris muscles.  
Histological investigation of the above muscles 7 days after injury (5 days 
after the administration of OKSM or saline, Figure 5.11a) reported no differences 
in the percentage of centronucleated (regenerating) myofibers between treatment 
groups (47.5 ± 20.8 % saline, 47.3 ± 14.6 % OKSM) as illustrated in Figure 5.11b. 
The establishment of severe muscle damage was evidenced by a remarkable 
inflammatory infiltrate in the injured site and the deposition of collagen, 
considerably more prominent than in the chemically-induced model (Figure 
5.11c). Collagen accumulation was quantitatively similar in all injured specimens 
(Figure 5.11d), regardless of the treatment group (2.1 ± 1.2 % intact, 28.8 ± 8.1 % 
saline, 21.3 ± 9.0 % OKSM).  
Only “early intervention” protocols were investigated in this particular 
injury model. The severity of the damage precluded further investigations and 





Figure 5. 9. Laceration of GA, soleus and plantaris muscles and i.m. administration or 
reprogramming pDNA. (a) The left GA, soleus and plantaris muscles of BALB/c mice were surgically 
lacerated in the transverse plane. The cut was performed at its mid-point and through the 100% of 
their width and depth. (b) 100 μg OKSM or the equivalent volume (40 μl) of 0.9% saline were 
administered at the time of injury or 2 days later (c) Muscle weight was recorded 2, 4 and 7 days after 
laceration (2 and 5 days after pDNA or saline administration) and expressed as a ratio injured/intact. 
**p<0.01 indicates statistically significant differences in the injured/intact ratio of the saline group 
between days 2 and 7 after injury, analysed by one-way ANOVA and Tukey’s test. Data are presented 




Figure 5. 10. Changes in gene expression after laceration of GA, soleus and plantaris muscles 
and i.m. administration of reprogramming pDNA. Real-time RT-qPCR was performed 2 and 5 days 
after the administration of reprogramming pDNA or saline control (2, 4 and 7 days after laceration) 
to analyse the relative gene expression of (a) the reprogramming factor Oct3/4 (b) the pluripotency 
marker Nanog (c) the myogenic progenitor marker Pax3. Gene expression was normalised to the 
intact muscle control. *p<0.05 indicates statistically significant differences in gene expression between 




Figure 5. 11. Histological evaluation after laceration of GA, soleus and plantaris muscles (day 
0) and i.m. administration of reprogramming pDNA (day 2). (a) The left GA, soleus and plantaris 
muscles of BALB/c mice were surgically lacerated and 100 μg OKSM or the equivalent volume (40 μl) 
of 0.9% saline were i.m. administered 2 days after injury. The right hind limb was left uninjured and 
uninjected and used as control. Tissues were dissected 7 days after laceration for histological 
investigation. (b) H&E staining (40X, scale bar represents 100 μm) and quantification of % of 
centronucleated myofibers (n=3 GA muscles per condition, 3 sections per muscle, 3 random fields per 
section). Data are presented as mean ± SD. (c) Picrosirius red/fast green staining for collagen and 
H&E staining of the same cross-section (40X, scale bar represents 100 μm). (d) Quantification of 
collagen deposition. ***p<0.001 indicates statistically significant differences between the intact 
control and the injured groups, analysed by Welch ANOVA and Games-Howell’s test (n=3 GA muscles 





5.4.4. In vivo reprogramming to pluripotency in a physically-induced model 
of skeletal muscle injury: laceration of medial GA. 
Aiming to establish an equally clinically relevant and anatomically localised 
but more moderate injury model, we transversely lacerated the medial GA in the 
left BALB/c hind limb, preserving the lateral GA, soleus and plantaris and leaving 
the contralateral (right) hind limb uninjured as intact control. An illustration of the 
anatomical localisation and dimensions of the defect is provided in Figure 5.12a.  
5.4.4.1. Administration of reprogramming pDNA at different time points after 
laceration of medial GA. 
A single dose of 100 µg OKSM or the equivalent volume (40 μl) of 0.9% 
saline was i.m. administered in the injured GA at the time of injury (day 0, “early 
intervention”) or 5 or 7 days later (“late intervention” protocols). The contralateral 
(right) hind limb was left intact (uninjured and uninjected) and GA muscles were 
dissected 2 days after the administration of OKSM or saline (2, 7 and 9 days after 
laceration, respectively, Figure 5.12b). The medial and lateral GA were then 
processed separately for muscle weight and gene expression studies.  
Macroscopic evaluation. 
Macroscopic observation of the GA muscles harvested at different time 
points after injury suggested the progressive retraction of the medial head, 
however no obvious differences were confirmed between saline and OKSM-
injected groups (Figure 5.13a). 
Changes in muscle weight. 
A significant increase in the moist weight of the whole GA was observed 
soon after laceration which, in agreement with the findings in previous injury 
models, decreased at later time points. By day 9 after laceration, the ratio 
injured/intact was < 1 (Figure 5.13b). The separate analysis of the medial and 
lateral heads confirmed that the progressive loss of mass took place specifically in 
the directly injured tissue (medial head, Figure 5.13c) and was very significant by 
day 9 after injury. Conversely, the initial increase in muscle weight was almost 
exclusively due to the increase in the lateral GA mass (Figure 5.13d). Such 




Figure 5. 12. Laceration of medial GA and i.m. administration of reprogramming pDNA. (a) The 
medial head of the left GA muscle of BALB/c mice was surgically lacerated in the transverse plane. The 
cut was performed at its mid-point and through the 100% of its width and depth. (b) 100 μg OKSM or 
the equivalent volume (40 μl) of 0.9% saline were administered at the time of injury (day 0) or 5 of 7 
days later. The right hind limb was left uninjured and uninjected and used as an internal control. 
Muscles were dissected 2 days after the administration of reprogramming pDNA or saline (2, 7 or 9 





Figure 5. 13. Macroscopic evaluation and changes in muscle moist weight after laceration of 
medial GA and i.m. administration of reprogramming pDNA. (a) GA muscles dissected 2 days after 
pDNA or saline administration (injured vs. contralateral intact control). Muscle moist weight was 
expressed as an injured/intact ratio for the (b) whole GA muscle, (c) medial GA and (d) lateral GA. 
*p<0.05 and **p<0.01 indicate statistically significant differences in muscle weight between the 




Changes in gene expression. 
In agreement to the more severe laceration of GA, soleus and plantaris, the 
delivery and expression of reprogramming pDNA was technically hindered when 
the administration took place at the time of injury, which inevitably resulted in the 
lack of Nanog upregulation (Figures 5.14a-b). The expression of Oct3/4 when 
OKSM was administered 7 days after injury was restricted to the lateral GA, 
possibly due to the excessive retraction and loss of muscle mass in the medial head 
that even complicated its dissection.  More importantly, and similar to the CTX 
injury model, the upregulation of Nanog compared to the intact control increased 
with increasing time interval between injury and OKSM administration (Figure 
5.14b). The difference in upregulation between OKSM- and saline-injected injured 
groups was calculated in order to correct for the endogenous upregulation of the 
pluripotency marker resulting from innate regeneration. Importantly, such 
difference increased significantly with the increasing time lapse between injury 
and therapeutic intervention (Figure 5.14c). 
 The downregulation of Pax3, although persisted throughout the course of 
the study and showed no significant differences between treatment groups, was 





Figure 5. 14. Changes in gene expression after laceration of medial GA and i.m. administration 
of reprogramming pDNA. Real-time RT-qPCR was performed 2 days after the administration of 
pDNA or saline (2, 7 and 9 days after laceration, respectively) to analyse the relative gene expression 
of (a) the reprogramming factor Oct3/4 (b) the pluripotency marker Nanog (normalised to uninjured, 
uninjected controls), (c) the pluripotency marker Nanog (normalised to injured, saline-injected 
controls, lateral head) and (d) the myogenic progenitor marker Pax3. For Oct3/4 and Pax3, gene 
expression was normalised to intact muscle controls. *p<0.05 and **p<0.01 indicate statistically 
significant differences between groups, assessed by Welch ANOVA and Games-Howell’s test. Data are 





5.4.4.2. Tissue regeneration upon i.m. administration of reprogramming 
pDNA 7 days after laceration of the medial GA. 
As in the CTX-induced injury model, the administration of reprogramming 
pDNA was fixed on day 7 after injury to take advantage of the higher Nanog 
upregulation. Tissues were collected 2 and 7 days after OKSM or saline 
administration (9 and 14 days after injury) and analysed histologically (Figure 
5.15a). 2 days after injection (9 days after injury), a significantly higher 
percentage of the myofibers surrounding the injured site were regenerating in the 
OKSM group (56.0 ± 23.4 %) – as evidenced by the centralised position of the 
nuclei – compared to the saline control (33.9 ± 12.9 %). While in the saline-
injected group this figure continued to increase 7 days after the injection (14 days 
after injury, 45.6 ± 14.6 %), the percentage of fibers still regenerating in the OKSM 
group significantly dropped (18.2 ± 7.7 %). Representative images are shown in 
Figure 5.15b. 
H&E staining confirmed the presence of necrotic fibers and inflammatory 
infiltrate in the vicinity of the injured site, which was very prominent in both 
groups 9 days after laceration, but diminished considerably by day 14 in the OKSM 
group (Figure 5.15c). Picrosirious red/fast green staining of the same cross-
sections evidenced that collagen deposition on day 9 was moderately more 
extensive in the tissues from saline control animals and that this difference was 
even more pronounced on day 14. While the percentage of collagen+ areas in the 
vicinity of the injury remained practically invariable in the OKSM group (12.3 ± 
5.1%, to 15.5 ± 6.5%), it raised from 15.4 ± 5.2% on day 9 to 22.6 ± 6.7% on day 14 




Figure 5. 15. Histological evaluation after laceration of medial GA (day 0) and i.m. 
administration of reprogramming pDNA (day 7). (a) The medial head of the left GA muscle of 
BALB/c mice (n=4) was surgically lacerated and 100 μg OKSM pDNA or the equivalent volume (40 μl) 
of 0.9% saline were administered 7 days after the injury. The right hind limb was left uninjured and 
uninjected for control. Tissues were dissected 2 and 7 days after pDNA/saline administration (9 and 
14 days after injury) and analysed histologically. (b) H&E staining (40X, scale bars represent 100 μm) 
and quantification of % of centronucleated myofibers. **p<0.01 and ***p<0.001 indicate statistically 
significant differences between groups analysed by Welch ANOVA and Games-Howell’s test (n=2-4 GA 
muscles per condition, 3 sections per muscle, 2 random fields per section). Data are presented as mean 
± SD. (c) Picrosirius red/fast green staining for collagen and H&E staining of the same cross-section 
(40X, scale bars represent 100 μm). (d) Quantification of collagen deposition. *p<0.05 and ***p<0.001 
indicate statistically significant differences between groups, analysed by Welch ANOVA and Games-
Howell’s test (n=2-4 GA muscles per condition, 4 sections per muscle, 5 random fields per section). 





5.4.4.3. Investigation of functional rehabilitation upon i.m. administration of 
reprogramming pDNA 7 days after laceration of the medial GA. 
Finally, functional recovery was investigated 2 and 7 days after OKSM or 
saline administration (9 and 14 days after laceration) by myography as previously 
described (Figure 5.16). 2 days after the administration of OKSM or saline, the 
percentage of recovered force under twitch and tetanus contraction was low 
compared to the measurements in the CTX model and no differences were 
observed between treatment groups (twitch: 57.8 ± 11.8 % saline, 57.9 ± 11.6 % 
OKSM, tetanus:  47.8 ± 5.5 % saline, 41.5 ± 19.0 % OKSM). On the contrary, the 
analysis on day 7 suggested that OKSM-treated animals recovered a higher 
percentage of the force of the contralateral (intact) GA, compared to the saline-
injected controls, when both fast twitch (50.4 ± 12.3% saline, 80.2 ± 18.2% OKSM) 
and tetanus contractions (49.9 ± 19.2% saline, 56.6 ± 20.9% OKSM) were induced. 
However, the number of animals thata entered the procedure was low (n=4) and 
these results were not supported by statistical significance. Hence, albeit 
promising, these observations will have to be confirmed in future studies. 
 
Figure 5. 16. Investigation of functional rehabilitation after laceration of medial GA (day 0) 
and i.m. administration of reprogramming pDNA (day 7). (a) The medial head of the left BALB/c 
GA was surgically lacerated and 100 μg OKSM or the equivalent volume (40 μl) of 0.9% saline were 
administered 7 days after injury. The right medial GA was left uninjured and uninjected and used as an 
internal control. Muscle function was assessed 2 and 7 days after pDNA or saline administration (9 
and 14 days after injury). (b) Recovered forces of the injured muscles under twitch and tetanus 
contractions are expressed as a percentage of the contralateral (uninjured) hind limb force. Data are 




In this Chapter we provide first time evidence of the therapeutic potential of 
in vivo cell reprogramming to pluripotency in a model of skeletal muscle injury. 
Administration of reprogramming pDNA one week after surgical laceration of the 
medial GA enhanced myofiber regeneration, prevented fibrosis and modestly 
improved the recovery of muscle force. 
Most of the recent experimental efforts in the treatment of major skeletal 
muscle injuries have however been directed to the search of appropriate cell 
sources to replenish the injured muscle. Bone marrow mesenchymal stromal cells 
(BMMSCs) [261], CD133+ human peripheral blood cells [262], adipose tissue-
derived regenerative cells (ADRCs) [263] and adipose tissue-derived stem cells 
(ADSCs) [266, 267] have been tested in laceration injury models similar to the ones 
presented here. However, the improvement in muscle regeneration reported in 
such studies very rarely correlated with the number of transplanted cells that 
successfully integrated into the host’s tissue – which was generally very low – and 
was often attributed to paracrine effects. Only Shi et al. were able to demonstrate 
integration, survival and differentiation of CD133+ human peripheral blood cells to 
the myogenic and endothelial lineages [262]. Mori et al. could only confirm 
differentiation of very limited numbers of ADRCs [263] while Natsu et al. observed 
that BMMSCs did not differentiate or fuse to the host’s fibers at all [261]. Even 
myoblast transplantation, theoretically favoured by their natural commitment to 
the myogenic lineage, was hampered by extremely poor graft survival [276]. 
Although immune responses against the transplanted cells might have played a 
role in their poor tissue integration, the use of immunosuppressive drugs or 
immunodeficient animal models improved graft survival in some [262] but not all 
the above studies [261, 263]. Therefore, other factors limiting the contribution of 
the transplanted cells towards the replenishment of the tissue should be 
investigated. In fact, cell therapy strategies for the treatment of muscle injuries 
have not always been able to show therapeutic efficacy on their own. A study by 
Hwang et al. required co-administration of growth factors to achieve sufficient 
engraftment and differentiation of transplanted ADSCs [267]. Although muscle 
regeneration modestly improved even when such factors were administered on 
their own [260], their clinical use suffers from their rapid clearance and, in some 
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cases, controversial mitogen status. Gene therapy strategies are being explored in 
order to optimise their delivery and expression [265, 277].  
We have proposed here a novel strategy that combines gene and cell 
therapy in the in vivo setup and may overcome some of the hurdles faced by 
traditional cell therapy thanks to the generation of host-specific replacement cells 
in situ.  
Administration of reprogramming pDNA 7 days after surgical laceration of 
the medial GA resulted in a significant increase in the percentage of regenerating 
fibers 2 days after the induction of pluripotency. This finding suggested that 
regeneration was accelerated compared to saline-treated controls (Figure 5.15b). 
One week later, immature regenerating fibers were still abundant in the saline-
injected tissues, indicating that the regeneration process was still ongoing, while 
the number of fibers in such state had significantly decreased in the 
reprogrammed group. In addition, a modest – albeit not statistically significant – 
improvement in recovered muscle force in comparison to saline controls was 
detected one week after the administration of reprogramming pDNA, but not 
earlier (Figure 5.16).  The timing of these events agreed with our observations in 
healthy skeletal muscle, in which centronucleated myofibers appeared soon after 
the administration of reprogramming pDNA and only seemed to mature and 
integrate into the normal tissue architecture approximately one week after 
injection (Chapter IV, Figures 4.12 and 4.13). However, cell tracking strategies 
that indelibly label the in vivo reprogrammed cells will be required to fully confirm 
whether the recovery of muscle force is a direct cause of their re-differentiation to 
the myogenic lineage and integration in the injured muscle tissue.  
The deposition of collagen that ultimately generates a fibrotic scar is 
normally initiated one week after injury and can continue to accumulate for weeks 
thereafter, depending on the severity of the damage [252]. As expected, collagen 
deposition significantly increased in the control group between days 2 and 7 after 
saline administration (days 9 and 14 after injury, Figure 5.15d). However, it 
remained invariable between these two time points in the reprogrammed group, 
suggesting that in vivo reprogramming to pluripotency was able to prevent 
fibrosis. Further studies will however be necessary to determine the mechanisms 
behind this effect. Myofibroblasts originate from the differentiation of various 
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resident cell types [252], hence we could speculate that reprogramming to 
pluripotency antagonises such cell fate conversion in a subset of cells. In addition, 
the reprogrammed cells replenishing the injured site may be able to repress 
myofibroblast proliferation via paracrine mechanisms, as it has been 
demonstrated upon MS cell transplantation in other tissues [278].  
Regardless of the mechanism, we hypothetise that the attenuation of 
collagen deposition may act as one of the main contributors to the improved 
functional rehabilitation in the reprogrammed muscles (Figure 5.16). The 
relevance of the inhibition of fibrosis has also been highlighted by others [256-259, 
265, 266, 268, 279] based on the facts that (a) the establishment of a fibrotic scar 
acts in detriment of the contractile capabilities of the muscle [5, 252] and (b) the 
inhibition of the TGF-β signaling pathway and subsequent reduction of fibrosis 
benefits the integration of transplanted cells [266]. In agreement, a study by Lee et 
al. evidenced that the combination of cell and growth factor therapy was not able 
to fully restore muscle function in the absence of anti-fibrotic substances [265]. 
Importantly, we have achieved here enhancement of myofiber regeneration and 
prevention of fibrosis without co-administration of growth factors or anti-fibrotic 
agents. Nonetheless, future investigation of synergistic effects will be of interest. 
A different strategy also in the crossroads between gene and cell therapy 
was published by Nakasa et al. in a muscle laceration model similar to ours [264]. 
A cocktail of three miRNAs involved in muscle development and homeostasis were 
i.m. administered in the rat tibialis anterior immediately after laceration. Their 
findings one week after administration were very similar to those observed in our 
medial GA laceration model, including increased number of centronucleated fibers, 
attenuation of fibrosis and improved recovery of muscle force. However, the 
proposed mechanism behind such findings does not involve reprogramming to 
pluripotency but conversely the enhancement of myoblast proliferation and 
differentiation. Promoting differentiation towards the myogenic lineage 
constitutes a more direct approach to repopulate injured muscle, avoiding 
pluripotent or pluripotent-like intermediates. However, it relies on the presence of 
sufficient numbers of muscle progenitors, which cannot be taken for granted 
depending on the pathological condition of the muscle. Muscle progenitors are 
known to be depleted as a consequence of ageing [250] and in some conditions 
such as muscular dystrophy, where muscle mass is progressively replaced by 
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fibrotic and adipose tissue [280]. Therefore, it is conceivable that this approach 
may not be effective depending on the type of injury. Conversely, we suggest that 
thanks to the universality of the Yamanaka factors to reprogram different starting 
cell types, in vivo reprogramming towards pluripotency might be a more versatile 
strategy not only effective in muscle lacerations such as the ones explored here but 
also in other types of ailments. 
Although also limited by the requirements of not only particular cell types 
but also specific reprogramming cocktails, in vivo transdifferentiation strategies 
have shown encouraging results in the post-injury recovery of a different muscle, 
the heart, via in situ conversion of cardiac fibroblasts into CMs [147-151]. This 
suggests that similar strategies could also enhance regeneration after skeletal 
muscle injury. To this respect, the transcription factor MyoD stands out as a 
potential candidate, thanks to its capacity to transdifferentiate fibroblasts to 
myoblasts in the culture dish. However, the in vivo overexpression of MyoD with 
therapeutic purposes is still largely unexplored [146, 281] and has not yet been 
investigated in skeletal muscle injury models.  
 We could not reproduce the encouraging histological and modest 
functional rehabilitation results obtained after medial GA laceration when a similar 
protocol was implemented in the CTX injury model. In the laceration model, we 
had absolute control of the anatomical localisation and dimensions of the injury 
and were able to direct the administration of reprogramming pDNA to the 
periphery of the defect. CTX administration produced a less severe insult – 
evidenced by the lower percentage of collagen deposition (Figure 5.7d) and the 
less deteriorated muscle function (Figure 5.8b) – but it was difficult to control the 
extension and exact localisation of the injured site within the muscle volume. As a 
result, we could not control whether the reprogramming pDNAs were 
administered directly in the injured site or in the periphery of it and suspect that a 
considerable fraction of the pDNA may have been internalised by cells in the 
damaged tissue. Since the feasibility to reprogram cells undergoing stress 
situations is yet to be explored, we speculate that they may be less amenable to the 
pluripotent-like conversion. In fact, Oct3/4 mRNA levels were slightly higher in the 
CTX model while the upregulation of Nanog was lower compared to the medial GA 
laceration model (Figures 5.6 and 5.14). Therefore, the reprogramming effect 
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achieved might have not been enough to enhance significantly the regeneration of 
the tissue. 
Our observations that gene expression in healthy and injured muscle was 
significantly different might also explain why healthy and injured cells responded 
differently to reprogramming. The expression of Nanog and Pax3, 
characteristically upregulated upon in in vivo reprogramming to pluripotency in 
healthy skeletal muscle, was affected in a temporal manner by the induction of 
tissue damage. Nanog was modestly upregulated after the administration of  CTX 
alone (Figure 5.3) as expected from its role in the process of regeneration after 
injury, unveiled in a previous report [184] and confirmed by our HTV 
administration experiments in mouse liver tissue (Chapter III, Figure 3.7). Pax3 
was conversely downregulated upon injury (Figure 5.3c), possibly due to its role 
as survival factor and its negative regulation in apoptotic mechanisms [282, 283]. 
Pax3 mRNA levels were more prominently depleted soon after injury and in 
directly injured tissue (i.e. medial GA vs. lateral GA, in the model in which the latter 
was preserved, Figure 5.14d), which confirmed the links between muscle injury 
and the downregulation of this gene.  
In fact we have identified the timing of the administration of 
reprogramming pDNA as a critical factor that affects the success of the induction of 
pluripotency in injured tissue. Lack of reprogramming when OKSM was 
administered at the time of injury in surgically-induced injury models was 
explained by technical limitations (Figures 5.10 and 5.14). However, successful 
expression of Oct3/4 when reprogramming pDNAs were administered at such time 
point in the CTX model failed as well to upregulate Nanog (Figure 5.6). When 
reprogramming pDNA was administered after the summit of the 
inflammation/degeneration phase, following what we denominated “late 
intervention” protocols, the upregulation of Nanog increased with the increased 
time lapse between injury and therapeutic intervention (Figures 5.6 and 5.14). 
This observation was consistent in CTX and laceration models and would be 
explained by our hypothesis that injured cells do not respond to the 
reprogramming stimulus as well as their healthy counterparts. Rather than this 
being a limitation in our study, we propose that the fact that optimal 
reprogramming effect was achieved when reprogramming pDNA was 
administered after the bulk of the inflammation phase, but before muscle 
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remodeling was established, constitutes and advantage over other approaches in 
the treatment of skeletal muscle injuries. The cell therapy strategies discussed here 
and the miRNA study by Nakasa et al. relied on the administration of replacement 
cells or miRNAs at the time of injury. The absence of data to support the efficacy of 
the treatment when administered at later time points questions the clinical 
relevance of these studies, especially given the extended culturing – sometimes 
close to 4 weeks – required to achieve enough numbers of replacement cells [261, 
262, 266, 267]. Very importantly, the strategy we propose here circumvents the 
need for rapid post-injury intervention, which may facilitate its potential clinical 
translation.  
Overall, we can affirm that a balance was found in the administration of 
reprogramming pDNA avoiding the peak of the degeneration phase but prior to the 
establishment of muscle remodeling in a localised and clinically-relevant model of 
skeletal muscle injury (laceration of medial GA). In such model, the induction of 
pluripotency has proved to accelerate muscle regeneration, prevent fibrosis and 
modestly improve functional recovery without the need for rapid intervention or 
co-administration of growth factors, anti-fibrotic agents or other substances. In 
addition, this strategy avoids some of the hurdles faced by traditional cell therapies 
(in vitro culture, challenges of cell delivery and engraftment) and in vivo 
transdifferentiation (requirement for specific cell types and reprogramming 
cocktails). The results presented here are therefore promising for the treatment of 
major skeletal muscle injuries, although further studies will be necessary to 
confirm the mechanisms behind the enhancement of regeneration described here 
(i.e. contribution of reprogrammed cells to the regenerated tissue) and functional 
rehabilitaton will have to be confirmed with higher animal numbers and longer 
term studies. In addition, in vivo reprogramming to pluripotency may also have a 
place in the treatment of other ailments thanks to the versatile character of the 

















Overall, the studies presented in this thesis confirm that adult somatic cells 
can be transiently reprogrammed to a functionally pluripotent state in vivo in the 
absence of teratomas and that the induction of pluripotency can enhance 
regeneration and, albeit modestly, functional rehabilitation of injured tissue. Below 
are the major findings in this work and their implications for the future directions 
of the field: 
 In vivo reprogramming towards pluripotency can be achieved in different 
somatic tissues via ectopic expression of Yamanaka factors. In vivo cell 
reprogramming to a pluripotent or pluripotent-like state has been achieved in 
two adult tissues of different developmental origin, liver and skeletal muscle. 
Hence, the versatile character of the Yamanaka factors, able to reverse the 
differentiated status of a variety of cell types in vitro [51, 60], has been 
validated in the in vivo setting. Such attribute constitutes a remarkable 
advantage over transdifferentiation strategies, which conversely require 
extensive work towards the identification of specific reprogramming factors 
for each particular cell fate conversion [49, 144, 147, 158, 159]. Future work 
will have to address whether complete reprogramming to pluripotency was 
achieved in the skeletal muscle, as demonstrated upon liver reprogramming. It 
will also involve the investigation of in vivo reprogramming to pluripotency in 
other tissues as well as studies to determine the specific cell types within the 
tissue that are reprogrammed to pluripotency. 
 Transient reprogramming to pluripotency in vivo does not generate 
teratomas. Our observations in liver [162, 163] and skeletal muscle tissue, 
together with those produced by others [161, 195, 196], pointed at the 
transiency of the expression of reprogramming factors and of the pluripotent 
conversion in the tissues as a key factor to avoid the generation of teratomas. 
Notably, the expression of reprogramming factors was not sustained (only 
minor signs of integration of the pDNA were observed), we were not able to 
find cells expressing pluripotency markers in the tissues any later than 4 days 
after the administration of reprogramming pDNA and no signs of dysplasia 
were found in the liver or the skeletal muscle for the duration of our studies 
(120 days). However, future work will necessarily require ad hoc toxicity 
studies to confirm the safety of the approach. 
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 In vivo reprogrammed liver cells and i2PS cells are bona fide pluripotent 
cells.  The functional pluripotency of in vivo reprogrammed cells directly 
extracted from liver tissue was confirmed through the generation of teratomas 
in nude mice. Additionally, i2PS cells were able to contribute widespread to the 
adult tissues of chimeric mice upon blastocyst injection [185]. While the gene 
expression and differentiation potential of i2PS cells did not suggest 
reminiscence of major signatures from the tissue of origin,  further studies will 
have to confirm the absolute absence of epigenetic memory in the in vivo 
reprogrammed and i2PS cells.  In vitro generated iPS cell clones have shown 
heterogeneity depending on many factors including the starting cell type, 
choice of reprogramming technology and even the laboratory where they were 
produced [284]. Hence, it will be interesting to compare epigenetic signatures 
between in vivo reprogrammed cells directly isolated from different tissues to 
investigate the influence of the tissue of origin. 
 In vivo reprogrammed cells proliferate transiently to then re-
differentiate and integrate into the tissue. We have confirmed that cells in 
vivo transfected with reprogramming pDNA divided actively but transiently. 
After this proliferative stage, the absence of cells expressing pluripotency 
markers together with morphometric analysis of the tissue indicated that the 
reprogrammed cells re-differentiated and successfully re-integrated in the 
tissue without significant apoptosis or any tissue abnormalities. Similar 
findings have been described by others [161, 196]. While we speculate that the 
successful re-differentiation of the pluripotent-like intermediates is governed 
by specific biochemical and mechanical cues in the microenvironment, further 
studies will be required to address the role of such factors. In addition, lineage 
tracing strategies able to indelibly label the reprogrammed cells will be 
necessary to fully confirm these findings.  
 In vivo reprogramming towards pluripotency can enhance the 
regenerative capacity of injured tissues. Induction of pluripotency one 
week after surgical laceration of the medial GA muscle was proved able to 
accelerate myofiber regeneration, prevent fibrosis and modestly improve 
muscle function. However, the exact mechanism behind this beneficial effect 
remains to be explained and cell tracking strategies will be necessary to follow 
the reprogrammed cells and confirm their re-differentiation and integration in 
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the injury site. In addition, and in light of the different results obtained in 
different injury models, further work will need to clarify under which exact 
conditions is this strategy able to enhance regeneration and especially, 
whether damaged cells are responsive to reprogramming or not.  
The above findings support our hypothesis that in vivo reprogramming 
to pluripotency may combine the opportunities offered by both in vitro iPS cell 
generation and in vivo transdifferentiation while overcoming some of their 
respective limitations (i.e. taking advantage of the versatile character of 
Yamanaka factors while avoiding limitations associated to in vitro culture and 
benefiting from the role of the microenvironment). Although they should be 
interpreted in the context of very preliminary research, the observations in 
this thesis indicate that in vivo cell reprogramming to pluripotency holds 
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Figure S 1. Maps of the DNA plasmids employed in the study. (a) pCX-OKS-2A (OKS pDNA), (b) 






Figure S 2. Isolation of MEFs and preparation of feeder layers for the culture of pluripotent stem 
cells. MEFs were isolated from E12.5-14.5 CD1 mouse embryos after removal of internal organs and 
cell dissociation. (a) MEFs were cultured as monolayers in tissue culture vessels and mitotically 
inactivated with mitomycin C. The morphology E14TG2A cell colonies was compared when cultured on 
(b) MEFs feeder layers and (c) gelatin-coated surfaces. Images were acquired with an optical 




Figure S 3. Gene expression in BALB/c mouse skeletal muscle after i.m. administration of OKSM 
reprogramming pDNA.  (a) BALB/c mice were i.m. injected in the GA muscle with 50µg OKSM in 50 
μl 0.9% saline or 50 μl 0.9% saline alone. GA muscles were dissected 2 days after injection and real-
time RT-qPCR was performed to determine the relative gene expression of (b) reprogramming factors, 
(c) endogenous pluripotency markers and (d) genes involved in myogenesis. Gene expression levels 
were normalised to the saline-injected group. *p<0.05 and ***p<0.001 indicate statistically significant 
differences in gene expression between pDNA and saline-injected groups, assessed by one-way ANOVA. 





Figure S 4. Characterisation of GFP+ cell clusters in the GA muscle of Nanog-GFP mice. (a) 
Nanog-GFP transgenic mice were i.m. injected with 50µg OKS and 50 μg M or 50 μl 0.9% saline in the 
GA muscle. Tissues were dissected 2 and 4 days after injection. (b) 10 μm-thick tissue sections were 
obtained by cryotomy and the green fluorescence resulting from the expression of Nanog was observed 
with an epi-fluorescence microscope. Representative images were taken at 100X, scale bar represents 





Figure S 5.  Characterisation of in vivo reprogrammed cell clusters in the GA muscle of Nanog-
GFP mice. (a) Nanog-GFP transgenic mice were i.m. injected with 50µg OKS and 50 μg M or 50 μl 
0.9% saline (control) in the GA muscle. Tissues were dissected 2 days after injection and 10 μm-thick 
tissue sections were obtained by cryotomy. (b) IHC for the expression of a satellite cell (PAX7) and a 
perycite (PDGFrβ) marker in Nanog+ cell clusters. (c) IHC for the expression of pluripotency, satellite 
cell and perycite markers in saline-injected controls.. Images were taken with a confocal microscope 






Starting cell Induced cell 
Reprogramming 
factors 
Vector Administration Outcomes Ref. 




(Insulin and glucagon 
producing cells) 
Pdx1 Adenovirus Intravenous Endocrine and exocrine pancreatic 
markers  
Insulin production 




Liver None Hepatocyte 
Cholangiocyte 








N/A Endocrine and exocrine pancreatic 
markers  
Liver dysmorphogenesis and 
jaundice 
[140] 
Liver Diabetes Liver (cell type 
not 
determined) 
Induced β-islet NeuroD, β-cellulin Adenovirus Intravenous Appearance of β-islet like 
structures in liver 
Long term amelioration of diabetes 
[141] 








Adenovirus Intravenous Insulin production in liver 
Amelioration of hyperglycaemia 
[142] 
Pancreas Diabetes α-cell Induced β-cell Pdx1, Ngn3, MafA Adenovirus Intrapancreatic Generation of induced β-cells that 
secrete insulin in response to 
glucose. Long term alleviation of 
diabetes. 
[49] 
Liver Diabetes Hepatic 
progenitor/ova







Intravenous Transdetermination of hepatic 
progenitors 
No hepatocyte transdifferentiation 
Amelioration of diabetes 
[143] 
Liver Diabetes Sox9+ cell Insulin-secreting duct Pdx1, Ngn3, MafA Adenovirus Intravenous Generation of long-lasting insulin 
secreting ducts in liver.  
Long term alleviation of diabetes. 
[144] 






Starting cell Induced cell 
Reprogramming 
factors 










Cardiomyocyte Gata4, Mef2c, Tbx5 Retrovirus Intramyocardial 
Decreased infarct size. Significant 





Cardiomyocyte Gata4, Mef2c, Tbx5 Retrovirus Intramyocardial 
Cardiomyocyte-like cells in fibrotic 
area 









Decreased infarct size. Significant 






microRNAs 1, 133, 
208 and 499 
Lentivirus Intramyocardial 
Fibroblast to cardiomyocyte 
conversion in the infarct area 










Pacemaker cell- induced 
sinoatrial node (iSAN) cell 
Tbx18 Adenovirus Intramyocardial 
Establishment of a biological 








Pacemaker cell- induced 




Establishment of a biological 
pacemaker Correction of 
bradycardia 
[153] 






Starting cell Induced cell 
Reprogramming 
factors 










Transduced in vitro 
Doxycycline in 
drinking water 
iNs in tissue [154] 
Brain None Astrocyte 
Induced adult 
neuroblast (iANB) 
Sox2 Lentivirus Stereotactic (brain) 
iANBs in tissue 










Induced neuron (iN) NeuroD1 Retrovirus Stereotactic (brain) 
Mature iN in tissue 














Changes in morphology, gene and 
protein expression (until P3) 
Changes in axon connectivity 
(until E17.5) 
[159] 





Changes in morphology, gene and 














iANBs in tissue 
Mature neurons (+VPA) 
Synapses with resident neurons 
No functional data 
[158] 




Nomenclature Composition (for 50 ml medium) Use 
DMEM/LIF medium 
DMEM........................................42 ml 
FBS (15%)...............................7.5 ml 
NEAAs (1%)...........................0.5 ml 
2-mercaptoethanol...............50 µl 
LIF...................................................5 µl 
 Culture of E14TG2a cells. 
 Culture of i2PS cells. 
 Generation of i2PS cells from 
primary hepatocytes (add 





KO DMEM.............................35.5 ml 
KSR.............................................7.5 ml 







 Culture of E14TG2a cells. 





FBS (15%)...............................7.5 ml 




 Isolation of primary MEFs. 






FBS (15%)..............................7.5 ml 
NEAAs (1%)..........................0.5 ml 









FBS (20%)...............................10 ml 
NEAAs (1%)..........................0.5 ml 
2-mercaptoethanol..............50 µl 
 
 EB generation. 
 Differentiation of cells from 
EBs. 
Table S 4. Composition of cell culture media used in this thesis.
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Group Gene Forward primer Reverse primer 
Housekeeping gene β-Actin GACCTCTATGCCAACACAGT AGTACTTGCGCTCAGGAGGA 
Reporter gene eGFP GACGGCGACGTAAACGGCCA CAGCTTGCCGGTGGTGCAGA 
Reprogramming factors 
Oct3/4 TGAGAACCTTCAGGAGATATGCAA CTCAATGCTAGTTCGCTTTCTCTTC 
Sox2 GGTTACCTCTTCCTCCCACTCCAG TCACATGTGCGACAGGGGCAG 
c-Myc CAGAGGAGGAACGAGCTGAAGCGC TTATGCACCAGAGTTTCGAAGCTGTTCG 
Pluripotency markers 
Nanog CAGAAAAACCAGTGGTTGAAGACTAG GCAATGGATGCTGGGATACTC 
Ecat1 TGTGGGGCCCTGAAAGGCGAGCTGAGAT ATGGGCCGCCATACGACGACGCTCAACT 
Rex1 ACGAGTGGCAGTTTCTTCTTGGGA TATGACTCACTTCCAGGGGGCACT 
Cripto ATGGACGCAACTGTGAACATGATGTTCGCA CTTTGAGGTCCTGGTCCATCACGTGACCAT 
Gdf3 GTTCCAACCTGTGCCTCGCGTCTT AGCGAGGCATGGAGAGAGCGGAGCAG 
Endo-Oct3/4 TCTTTCCACCAGGCCCCCGGCTC TGCGGGCGGACATGGGGAGATCC 
Endo-Sox2 TAGAGCTAGACTCCGGGCGATGA TTGCCTTAAACAAGACCACGAAA 
Endo-Klf4 GCGAACTCACACAGGCGAGAA ACC TCGCTTCCTCTTCCTCCGACACA 
Hepatocyte markers 
Alb GTTCGCTACACCCAGAAAGC CCACACAAGGCAGTCTCTGA 
Aat CAGAGGAGGCCAAGAAAGTG ATGGACAGTCTGGGGAAGTG 
Trf ACCATGTTGTGGTCTCACGA ACAGAAGGTCCTTGGTGGTG 
Early differentiation markers 
Afp AGCGAAATGTAGCAGGAGGA AAACATCCCACTTCCAGCAC 
Fgf-5 AGTCAATGGCTCCCACGAAG TGACGGTGAAGGAAAGTTCC 
Brachyury CATGTACTCTTTCTTGCTGG GGTCTCGGGAAAGCAGTGGC 
Chimerism studies 
H2Kb GTGATCTCTGGCTGTGAAGTG GTCGCGTTCCCGTTCTT 
H2Kd GTTCCAGCGGATGTTC TAGGTAGGCCCTGTAATA 
D19Mit59 CTCTAACTATCCTCTGACCTTCACA TTTTAAGCAGAACATTGAGGACC 
Table S 5. Primer sequences used for the characterisation of in vivo reprogrammed liver tissue and i2PS cells (Chapter III).
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Group Region Forward primer Reverse primer 
Primers for PCR-based 
integration study 
O-1 CGGAATTCAAGGAGCTAGAACAGTTTGCC CTGAAGGTTCTCATTGTTGTCG 
O-2 GATCACTCACATCGCCAATC CTG GGAAAGGTGTCCTGTAGCC 
K GCGGGAAGGGAGAAGACACTGCGTC TAGGAGGGCCGGGTTGTTACTGCT 





1 AGGTGCAGGCTGCCTATC TTAGCCAGAAGTCAGATGCTC 
2 CTGGATCCGCTGCATTAATGA CCGAGCGCAGCGAGTCA 
3 GAAAAGTGCCACCTGGTCGACATT GGGCCATTTACCGTAAGTTATGTA 
4 TATCATATGCCAAGTACGC TAGATGTACTGCCAAGTAGGAA 
5 TCTGACTGACCGCGTTACT AGAAAAGAAACGAGCCGTCATT 
6 GCGAGCCGCAGCCATTGCCTTTTA CCCAGATTTCGGCTCCGCCAGAT 
Primers for Southern 
blot probes 
Transgene Forward primer Reverse primer 
Oct3/4 AAGTTGGCGTGGAGAC CTGAAGGTTCTCATTGTTGTCG 
Sox2 GGAGTGGAAACTTTTGTCC TTGACCACAGAGCCCATGGA 
Klf4 GCGGGAAGGGAGAAGACACTGCGTC GCCCGAGGGGCTCACGTCATTGATG 
c-Myc GCTCGCCCAAATCCTGTACCTCGTCCGA GCAACGCAATTAATGTGAGTTAG 
Table S 6. Primer sequences used in genomic integration studies (Chapter III).
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Group Gene Forward primer Reverse primer 
Housekeeping gene β-Actin GACCTCTATGCCAACACAGT AGTACTTGCGCTCAGGAGGA 
Reporter gene eGFP GACGGCGACGTAAACGGCCA CAGCTTGCCGGTGGTGCAGA 
Reprogramming 
factors 
Oct3/4 TGAGAACCTTCAGGAGATATGCAA CTCAATGCTAGTTCGCTTTCTCTTC 
Sox2 GGTTACCTCTTCCTCCCACTCCAG TCACATGTGCGACAGGGGCAG 
c-Myc CAGAGGAGGAACGAGCTGAAGCGC TTATGCACCAGAGTTTCGAAGCTGTTCG 
Pluripotency markers 
Nanog CAGAAAAACCAGTGGTTGAAGACTAG GCAATGGATGCTGGGATACTC 
Ecat1 TGTGGGGCCCTGAAAGGCGAGCTGAGAT ATGGGCCGCCATACGACGACGCTCAACT 
Rex1 ACGAGTGGCAGTTTCTTCTTGGGA TATGACTCACTTCCAGGGGGCACT 
Myogenesis markers 
Pax3 GGGAACTGGAGGCATGTTTA GTTTTCCGTCCCAGCAATTA 
MyoD AGCACTACAGTGGCGACTCA GCTCCACTATGCTGGACAGG 
Myf5 GAGCTGCTGAGGGAACAGGTGG GTTCTTTCGGGACCAGACAGGG 
Myh1 CAGGTCAACAAGCTGCGGGTG GATCTTCACATTTTGCTCATC 
Myog TGTTTGTAAAGCTGCCGTCTGAC AAAAATTGGCAAAACCACACAATGC 
Satellite-cell markers 
Pax7 GACGACGAGGAAGGAGACAA CGGGTTCTGATTCCACATCT 
Caveolin-1 AGCAAAAGTTGTAGCGCCAG TGGGCTTGTAGATGTTGCCC 
Integrin a 7 CAATCTGGATGTGATGGGTG CTCAGGGGACAAGCAAAGAG 
Jagged-1 AGCTCACTTATTGCTGCGGT CCGCTTCCTTACACACCAGT 
Pericyte markers 
TN-AP GTGGATACACCCCCCGGGGC GGTCAAGGTTGGCCCCAATGCA 
PdgfrB AAGTTTAAGCACACCCATGACAAG ATTAAATAACCCTGCCCACACTCT 
Rgs5 GCTTTGACTTGGCCCAGAAA CCTGACCAGATGACTACTTGATTAGC 





Group Gene Forward primer Reverse primer 
Housekeeping gene β-Actin GACCTCTATGCCAACACAGT AGTACTTGCGCTCAGGAGGA 
Reprogramming factor Oct3/4 TGAGAACCTTCAGGAGATATGCAA CTCAATGCTAGTTCGCTTTCTCTTC 
Pluripotency marker Nanog CAGAAAAACCAGTGGTTGAAGACTAG GCAATGGATGCTGGGATACTC 
Myogenesis marker Pax3 GGGAACTGGAGGCATGTTTA GTTTTCCGTCCCAGCAATTA 
Inflammation markers 
Il-6 ATGGATGCTACCAAACTGGA CCTCTTGGTTGAAGATATGA 
Cd11b TGTCCTAGGGAATGGAGGCA ACCACAGAACATGCCCATCC 
Mcp-1 CATGCTTCTGGGCCTGCTGTTC CCTGCTGCTGGTGATCCTCTTGTAG 
Ccr2 TCCTGTAAAGACCTCAGCCCAA AGTTTCCTGCAGAAAGAGAAGG 
Cd3 AGGGTGATTAGGATGGTGGGA ACAATTGGGCTCCTCCTGAC 
Myosin heavy chain 
isoforms 
Myh3 AGAGGCAGGCTGAGGAGGCT CCGGCTAGAGGTGAAGTCACGGG 
Myh8 ACACATCTTGCAGAGGAAGG TAAACCCAGAGAGGCAAGTG 
Myh2 AAGCGAAGAGTAAGGCTGTC GTGATTGCTTGCAAAGGAAC 
Myh4 ACAAGCTGCGGGTGAAGAGC CAGGACAGTGACAAAGAACG 
Myh7 CCAAGGGCCTGAATGAGGAG GCAAAGGCTCCAGGTCTGAG 
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